Pharma & CDMOKOSPI 128940Orphan Drug475 approvals193 trials

Hanmi Pharm. Co., Ltd.

KOSPI-listed pharmaceutical company behind the combination drugs Amosartan (hypertension) and Rosuzet (dyslipidemia).

As of 2026-10-10, Hanmi Pharm. Co., Ltd. has 5 Korean MFDS device approvals, 466 Korean MFDS drug approvals, 213 PubMed-indexed papers on record (counted by the MAA Company Index from its own matching of public databases).

Price

Change

Market cap

Business overview

Source: DART corporate disclosure

Founded and listed on the KOSPI in 2010, Hanmi Pharm is a pharmaceutical manufacturing and sales company. It sells the combination antihypertensive Amosartan, the combination dyslipidemia drug Rosuzet, the GERD treatment Esomezol, the BPH treatment Hanmi Tamsulosin Capsule, and the erectile dysfunction drug Palpal Tab., while operating the raw-material API subsidiary Hanmi Fine Chemical Co. and the overseas subsidiary Beijing Hanmi Pharmaceutical Co. Hanmi Fine Chemical passed a 2006 FDA inspection of its sterile API division and, after completing a new API synthesis plant in 2007, obtained cGMP certifications from the US FDA, Germany's BSG, Australia's TGA, and Japan's PMDA, exporting to more than 40 countries; Beijing Hanmi sells around 20 products including the children's digestive aid Mamiai and the cough syrup Yitanjing, and launched the combination antihypertensive Meiyaping (marketed in Korea as Amosartan) in 2022.

Products & technology

AmosartanCombination antihypertensive
RosuzetCombination dyslipidemia treatment
EsomezolGERD treatment
Hanmi Tamsulosin CapsuleBPH treatment
Palpal Tab.Erectile dysfunction treatment
MamiaiChildren's digestive aid (sold in China)
YitanjingCough and phlegm remedy (sold in China)
MeiyapingCombination antihypertensive sold in China (marketed in Korea as Amosartan)

Regulatory approvals

data.go.kr

4 Orphan Drug designations · 2018–2025 / 466 Korean MFDS drug approvals · 1980–2026 / 5 Korean MFDS device approvals · 2012–2016

OrphanHM15421/GC1134A(피하주사제)2025-01-15
Orphan Drug designation · in development20240176136
OrphanHM15912(주사제)2019-06-24
Orphan Drug designation · in development20190050457
OrphanHM43239(경구제)2019-02-15
Orphan Drug designation · in development20190000054
OrphanHM15136(주사제)2018-11-12
Orphan Drug designation · in development20180279514
MFDS drugAzel-Clean Cream2026-09-08
Drug · OTC · Notification202602668
MFDS drugRolontis Auto-Injector Inj.2026-04-14
Drug · Prescription · Approval202601086
MFDS drug.2026-04-10
Drug · OTC · Notification202601034
MFDS drugEnzaron Soft Cap. 40mg2026-03-18
Drug · Prescription · Approval202600792
MFDS drugHanmi Pentosan Cap.2026-03-17
Drug · Prescription · Approval202600777
MFDS drugSulmum Chewable Tab.2026-02-27
Drug · OTC · Notification202600604
MFDS drugOlotadine Eye Drop 0.2%2026-01-28
Drug · Prescription · Approval202600249
MFDS drugAmosartan XQ Tab. 5/50/2.5/10mg2025-09-22
Drug · Prescription · Approval202502506

Show 68 more

MFDS drugAmosartan XQ Tab. 5/100/2.5/10mg2025-09-22
Drug · Prescription · Approval202502507
MFDS drugMaxibupen Cold Soft Cap.2025-08-06
Drug · OTC · Notification202502043
MFDS drugMaxibupen Cough Soft Cap.2025-08-06
Drug · OTC · Notification202502046
MFDS drugEmpalon Duo SR Tab. 5/1000mg2025-07-24
Drug · Prescription · Approval202501902
MFDS drugEmpalon Duo SR Tab. 12.5/1000mg2025-07-24
Drug · Prescription · Approval202501903
MFDS drugMaxibupen Nose Soft Cap.2025-07-22
Drug · OTC · Notification202501849
MFDS drugSuspen Kids Syrup2025-07-17
Drug · OTC · Notification202501821
MFDS drugEmpalon Duo SR tab. 25/1000mg2025-07-11
Drug · Prescription · Approval202501759
MFDS drugEmpalon Duo SR tab. 10/1000mg2025-07-11
Drug · Prescription · Approval202501760
MFDS drugAmoprel Tab. 1.67/16.67/4.17mg(Amlodipine, Losartan, Chlorthalidone)2025-05-30
Drug · Prescription · Approval202501344
MFDS drugCal MD Tab.2025-05-28
Drug · OTC · Notification202501318
MFDS drugHanmi Peramivir inj.2025-03-31
Drug · Prescription · Approval202500751
MFDS drugMujonal Max Solution2025-03-10
Drug · OTC · Approval202500523
MFDS drugHanmi Ginkgo Tablet 80mg2025-02-27
Drug · OTC · Notification202500437
MFDS drugMagne B Speed Solution2024-12-19
Drug · OTC · Notification202403017
MFDS drugHanmi Ginkgo Tablet 240mg2024-09-12
Drug · OTC · Notification202402238
MFDS drugCo and Cool S Nasal Spray2024-05-14
Drug · OTC · Notification202401177
MFDS drugNunenCool Eye Drop 0.6%2024-03-29
Drug · OTC · Notification202400682
MFDS drugRelaxdam Tab.2024-02-19
Drug · OTC · Notification202400351
MFDS drugAbiterone Duo Tab. 500/2.5mg(Abiraterone, Prednisolone)2024-02-14
Drug · Prescription · Approval202400316
MFDS drugLinaglomet XR Tab. 5/1000mg(Linagliptin,Metformin)2024-01-24
Drug · Prescription · Approval202400188
MFDS drugLinaglomet XR Tab. 2.5/1000mg(Linagliptin,Metformin)2024-01-24
Drug · Prescription · Approval202400189
MFDS drugRaspirin Cap. 100/5mg(Aspirin, Rabeprazole)2023-10-30
Drug · Prescription · Approval202303032
MFDS drugOmest Soft Capsule 5/1000mg2023-08-30
Drug · Prescription · Approval202302554
MFDS drugOmest Soft Capsule 10/1000mg2023-08-30
Drug · Prescription · Approval202302555
MFDS drugNunenQ Eye Drop2023-08-22
Drug · OTC · Notification202302477
MFDS drugAbiteron Tab. 500mg(Abiraterone Acetate(micronized))2023-06-14
Drug · Prescription · Approval202301839
MFDS drugSildapa M SR Tab. 5/50/1000mg2023-05-22
Drug · Prescription · Approval202301623
MFDS drugSildapa M SR Tab. 5/50/500mg2023-05-22
Drug · Prescription · Approval202301624
MFDS drugSildapa M SR Tab. 5/50/750mg2023-05-22
Drug · Prescription · Approval202301625
MFDS drugClosartan Tab. 50/6.25mg(Losartan Potassium/Chlorthalidone)2023-04-28
Drug · Prescription · Approval202301412
MFDS drugEdoxban Tab. 30mg2023-04-12
Drug · Prescription · Approval202301209
MFDS drugEdoxban Tab. 15mg2023-04-12
Drug · Prescription · Approval202301210
MFDS drugNocotine Tab. 1mg2023-03-31
Drug · Prescription · Approval202301089
MFDS drugNocotine Tab. 0.5mg2023-03-31
Drug · Prescription · Approval202301090
MFDS drugSpeedpain Easy Soft Cap.2023-02-09
Drug · OTC · Notification202300495
MFDS drugNicegoline tab. 10mg2023-01-31
Drug · Prescription · Approval202300405
MFDS drugNicegoline tab. 30mg2023-01-31
Drug · Prescription · Approval202300406
MFDS drugLevoxacin Eye Drops 1.5%2023-01-25
Drug · Prescription · Approval202300326
MFDS drugEdoxban Tab. 60mg2022-12-05
Drug · Prescription · Approval202204362
MFDS drugSildapa Tab. 10/100mg2022-11-04
Drug · Prescription · Approval202204006
MFDS drugEsomezol DR SR Cap. 10mg(Esomeprazole magnesium trihydrate)2022-09-30
Drug · Prescription · Approval202203716
MFDS drugHanmi Bromfenac Sodium Hydrate Eye Drops(Single-use)(tentatively named)2022-09-07
Drug · Prescription · Approval202203503
MFDS drugDapalon Duo SR tab. 5/500mg2022-06-15
Drug · Prescription · Approval202202497
MFDS drugDapalon Duo SR tab. 5/1000mg2022-06-15
Drug · Prescription · Approval202202498
MFDS drugDapalon Duo SR tab. 10/500mg2022-06-15
Drug · Prescription · Approval202202499
MFDS drugDapalon Duo SR tab. 10/1000mg2022-06-15
Drug · Prescription · Approval202202500
MFDS drugClosartan Tab. 100/12.5mg2022-05-31
Drug · Prescription · Approval202202296
MFDS drugClosartan Tab. 50/12.5mg2022-05-31
Drug · Prescription · Approval202202297
MFDS drugEsomezol plus Tab. 20/350mg2022-03-21
Drug · Prescription · Approval202201119
MFDS drugEsomezol plus Tab. 40/350mg2021-10-22
Drug · Prescription · Approval202107076
MFDS drugRosuzet Tab. 10/2.5mg2021-09-24
Drug · Prescription · Approval202106637
MFDS drugSuvast Tab. 2.5mg2021-08-17
Drug · Prescription · Approval202105987
MFDS drugEmpalon Tab. 25mg2021-08-11
Drug · Prescription · Approval202105848
MFDS drugEmpalon Tab. 10mg2021-08-11
Drug · Prescription · Approval202105849
MFDS drugVildaglemet Tab. 50/500mg2021-07-13
Drug · Prescription · Approval202105309
MFDS drugVildaglemet Tab. 50/1000mg2021-07-13
Drug · Prescription · Approval202105310
MFDS drugVildaglemet Tab. 50/850mg2021-07-13
Drug · Prescription · Approval202105311
MFDS drugGliterol Inhalation Cap. 110/50mcgRevoked2021-06-08
Drug · Prescription · Approval202104446
MFDS drugRolontis Prefilled Syringe Inj.2021-03-18
Drug · Prescription · Approval202102429
MFDS drugVildagle Tab. 50mg2021-02-10
Drug · Prescription · Approval202101225
MFDS drugMujonal Power Spray SolutionRevoked2020-11-19
Drug · OTC · Notification202008020
MFDS drugAmosartan XQ Tab. 5/50/5/10mg2020-11-09
Drug · Prescription · Approval202007691
MFDS drugAmosartan XQ Tab. 5/50/20/10mg2020-11-09
Drug · Prescription · Approval202007692
MFDS drugAmosartan XQ Tab. 5/50/10/10mg2020-11-09
Drug · Prescription · Approval202007693
MFDS drugAmosartan XQ Tab. 5/100/5/10mg2020-11-09
Drug · Prescription · Approval202007694
MFDS drugAmosartan XQ Tab. 5/100/20/10mg2020-11-09
Drug · Prescription · Approval202007695
MFDS drugAmosartan XQ Tab. 5/100/10/10mg2020-11-09
Drug · Prescription · Approval202007696

Showing the 80 most recent of 475 records.

Clinical trials

data.go.kr

193 MFDS clinical trial authorisations · 2012–2026 (Phase 1 92 · Bioequivalence 49 · Phase 3 34 · Phase 2 17 · Phase 1/2 1)

Phase 3HIP26022026-08-31
1 trial site
BioequivalenceHGP26012026-08-26
2 trial sites
BioequivalenceHGP26012026-08-26
2 trial sites
Phase 3HCP1803-42026-05-29
11 trial sites
BioequivalenceHCP1004-A2026-04-21
2 trial sites
BioequivalenceHCP1004-A2026-04-20
2 trial sites
Phase 1HIP24042026-01-26
2 trial sites
Phase 3HM11260C2026-01-21
14 trial sites
Phase 2HM95573정2026-01-05
13 trial sites
Phase 1HIP25032025-12-03
1 trial site
BioequivalenceHGP25012025-09-10
2 trial sites
Phase 1HCP23052025-06-11
1 trial site

Show 68 more

BioequivalenceHGP24032024-12-26
2 trial sites
BioequivalenceHGP24072024-12-10
2 trial sites
Phase 1HM163902024-11-07
5 trial sites
Phase 3HCP1004-A2024-08-09
29 trial sites
Phase 1HCP23052024-07-02
1 trial site
Phase 2HM151362024-04-24
2 trial sites
Phase 1HCP23032024-03-20
2 trial sites
Phase 1HCP23032024-03-19
2 trial sites
Phase 3HCP1803-42024-02-05
10 trial sites
Phase 3HM11260C2023-10-23
22 trial sites
Phase 1BH31202023-08-18
5 trial sites
Phase 3HGP23042023-03-16
54 trial sites
Phase 1HCP22032023-03-08
1 trial site
Phase 1HCP22012023-02-07
1 trial site
Phase 1HCP1803-42023-01-26
1 trial site
BioequivalenceHGP22062022-12-19
2 trial sites
Phase 3HIP06122022-10-31
55 trial sites
BioequivalenceHGP07062022-10-05
2 trial sites
BioequivalenceHGP22032022-09-06
2 trial sites
Phase 1HCP22022022-09-06
1 trial site
Phase 1HCP22022022-08-31
1 trial site
Phase 1HM976622022-08-30
5 trial sites
Phase 1HCP22022022-07-14
4 trial sites
Phase 1HCP19042022-05-20
1 trial site
Phase 3HCP21022022-04-25
55 trial sites
BioequivalenceHGP21012021-12-21
1 trial site
Phase 3HCP1803-42021-11-30
13 trial sites
BioequivalenceHGP21022021-10-28
1 trial site
Phase 2HM159122021-10-08
1 trial site
Phase 1HCP20012021-08-23
1 trial site
Phase 2HM152112021-08-12
12 trial sites
Phase 3HCP19042021-08-10
18 trial sites
Phase 3HIP21012021-07-27
44 trial sites
Phase 1HIP21052021-06-29
2 trial sites
Phase 1HCP19022021-04-12
2 trial sites
Phase 1HIP21012021-03-30
1 trial site
Phase 2FLX475정2021-02-08
10 trial sites
Phase 1HCP19042021-01-27
1 trial site
Phase 2HCP1803-42021-01-11
11 trial sites
Phase 1HIP20012020-10-08
1 trial site
Phase 1HCP19032020-09-04
2 trial sites
Phase 3HCP19042020-08-11
17 trial sites
Phase 3HCP19042020-08-04
18 trial sites
Phase 3HCP19032020-03-30
31 trial sites
Phase 1HIP18022020-02-19
2 trial sites
Phase 1HIP16012019-12-17
2 trial sites
BioequivalenceHGP14072019-09-30
2 trial sites
Phase 1HM159122019-07-08
1 trial site
Phase 1HCP17042019-05-20
2 trial sites
Phase 3HIP16012019-04-16
15 trial sites
Phase 2포지오티닙정(포지오티닙염산염)2019-04-04
5 trial sites
BioequivalenceHGP17012019-01-25
2 trial sites
Phase 1HGP16022019-01-23
1 trial site
Phase 1HIP16012019-01-23
2 trial sites
Phase 1HCP18012019-01-04
1 trial site
Phase 3HCP17012019-01-02
13 trial sites
Phase 2HCP1803-42018-12-14
9 trial sites
BioequivalenceHGP17012018-12-11
2 trial sites
Phase 1HIP18012018-11-27
1 trial site
Phase 1HIP17012018-10-15
1 trial site
Phase 1HCP17042018-10-15
1 trial site
Phase 3HIP16012018-09-04
20 trial sites
Phase 1HM151362018-09-04
1 trial site
Phase 3HCP11022018-08-31
15 trial sites
Phase 1HCP17012018-08-24
1 trial site
Phase 1HCP17032018-08-16
1 trial site
Phase 1HCP14022018-06-01
1 trial site
Bioequivalence아섹정(아세클로페낙)2018-03-29
2 trial sites

Showing the 80 most recent of 193 records.

Global clinical trials

ClinicalTrials.gov · sponsor-matched

A Study to Evaluate Efficacy and Safety of HCP1803-4 in Patients With Essential Hypertension
Phase 3 · Not yet recruiting · 2026-07 · NCT07660796
Study to Evaluate HM15275 in Subjects With Type 2 Diabetes Mellitus
Phase 2 · Recruiting · 2026-05 · NCT07527650
A Study to Evaluate Efficacy and Safety of HM11260C in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Metformin and Dapagliflozin
Phase 3 · Recruiting · 2026-04 · NCT07379333
Effectiveness and Safety of Sequential Triple Combination Therapy (Amlodipine/Losartan/Chlorthalidone) in Korean Patients With Hypertension
Recruiting · 2026-03 · NCT07784296
Belvarafenib in Combination With Cobimetinib in Patients With Locally Advanced or Metastatic NRAS-Mutant Melanoma
Phase 2 · Recruiting · 2026-02 · NCT07449754
A Study to Evaluate the Pharmacokinetics and Safety Between HIP2503 and HCP1306 in Healthy Volunteers
Phase 1 · Not yet recruiting · 2025-12 · NCT07297693
Study to Evaluate HM15275 in Obese or Overweight Subjects Without Diabetes Mellitus
Phase 2 · Active not recruiting · 2025-12 · NCT07205900
A Single and Multiple Ascending Dose Study of HM17321 in Healthy and Obese Participants
Phase 1 · Recruiting · 2025-11 · NCT07219589
Dose Escalation and Expansion Study of HM16390 Alone or With Pembrolizumab in Advanced or Metastatic Solid Tumors
Phase 1 · Recruiting · 2024-12 · NCT06724016
A Study to Evaluate the Efficacy and Safety of HCP1004 in Chronic Low-Back Pain Patients
Phase 3 · Completed · 2024-11 · NCT06595004

Show 179 more trials

A Study to Evaluate the Drug-drug Interaction and Safety Between HCP1306, RLD2302 and RLD2102 in Healthy Volunteers
Phase 1 · Completed · 2024-09 · NCT06518122
A Phase 1 Study to Assess HM15275 in Healthy and Obese Subjects.
Phase 1 · Completed · 2024-05 · NCT06481098
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions
Phase 1 · Completed · 2024-05 · NCT06357910
A Study to Evaluate Efficacy and Safety of HGP2304 in Essential Hypertension Patients
Phase 3 · Completed · 2024-05 · NCT06174766
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2303 and Co-administration of Each Component in Healthy Volunteers
Phase 1 · Completed · 2024-05 · NCT06346184
A Study to Evaluate Efficacy and Safety of HCP1803 Compared to RLD2001-1 in Patients with Essential Hypertension
Phase 3 · Completed · 2024-03 · NCT06438172
A Study to Evaluate Efficacy and Safety of HM11260C in Adult Obesity Patients Without Diabetes Mellitus
Phase 3 · Completed · 2024-01 · NCT06174779
Dose Escalation and Expansion Study of BH3120 Alone or With Pembrolizuamb in Advanced or Metastatic Solid Tumors
Phase 1 · Recruiting · 2023-12 · NCT06234397
A Study to Evaluate the Drug-drug Interaction and Safety of RLD2301 and RLD2007 in Healthy Volunteers
Phase 1 · Completed · 2023-04 · NCT05862090
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2201 and Co-administration of Each Component in Healty Male Volunteers
Phase 1 · Completed · 2023-03 · NCT05737082
A Study to Evaluate the Effiacy and Safety of HIP0612 in Patients With Gastric Ulcer
Phase 3 · Completed · 2023-03 · NCT05656092
A Study to Evaluate the PK, Safety and Tolerability of HCP1803.
Phase 1 · Completed · 2023-02 · NCT05723549
Dose Escalation and Expansion Study of HM97662 in Advanced or Metastatic Solid Tumors
Phase 1 · Active not recruiting · 2023-01 · NCT05598151
Phase 1 Study of PK and Safety of HM15912 (Sonefpeglutide) in Subjects With Normal and Severe Kidney Function
Phase 1 · Completed · 2022-12 · NCT05711381
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers Under Fed Conditions
Phase 1 · Completed · 2022-10 · NCT05548543
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2202 and Co-administration of Each Component in Healthy Volunteers
Phase 1 · Completed · 2022-09 · NCT05548387
A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients
Phase 3 · Completed · 2022-09 · NCT05450601
A Study to Evaluate Pharmacokinetic/Pharmacodynamic Drug-drug Interaction and Safety/Tolerability Between RLD2202 and RLD2203
Phase 1 · Completed · 2022-08 · NCT05481307
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1904 in Healthy Male Volunteers.
Phase 1 · Completed · 2022-06 · NCT05407220
A Study to Evaluate Efficacy and Safety of HCP1803 in Patients With Essential Hypertension
Phase 3 · Completed · 2022-05 · NCT05362110
HM15136 (Efpegerglucagon) Treatment for 8 Weeks in Subjects Aged ≥2 Years With Congenital Hyperinsulinism (CHI)
Phase 2 · Active not recruiting · 2022-05 · NCT04732416
Phase 2 Study to Assess the Safety, PK, and PD of Sonefpeglutide (HM15912) in SBS-IF Subjects
Phase 2 · Recruiting · 2022-03 · NCT04775706
Clinical Efficacy and Safety Evaluation of HCP1904-3 in Essential Hypertension Patients
Phase 3 · Completed · 2021-11 · NCT05199129
A Study to Evaluate the Pharmacokinetics and Safety Between HCP2001 and Co-administration of Each Component in Healthy Volunteers
Phase 1 · Completed · 2021-09 · NCT05155995
Study to Evaluate the Efficacy and Safety of HIP2101 in Patients With Acute or Chronic Gastritis
Phase 3 · Completed · 2021-08 · NCT05024721
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination of HCP1904 and Co-Administration of RLD2001-2 and RLD2006 Tablets in Healthy Subjects.
Phase 1 · Completed · 2021-07 · NCT05191563
Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP2105 to RLD2104 in Healthy Volunteers
Phase 1 · Completed · 2021-07 · NCT04975711
A Study to Evaluate the Pharmacokinetics and Safety Between HCP1902 and Co-administration of RLD2007, RLD2008
Phase 1 · Completed · 2021-06 · NCT04946903
FLX475 Combined With Pembrolizumab in Patients With Advanced or Metastatic Gastric Cancer
Phase 2 · Completed · 2021-05 · NCT04768686
Study to Evaluate the Safety and Pharmacodynamic/Pharmacokinetic Characteristics of HIP2101 in Healthy Volunteers
Phase 1 · Completed · 2021-05 · NCT04967014
A Phase 2 Study to Explore the Dose of HCP1803 in Patients With Essential Hypertension
Phase 2 · Completed · 2021-04 · NCT04959305
The Pharmacokinetic Characteristics and Safety Between HIP2001 and HGP2001 in Healthy Volunteers
Phase 1 · Completed · 2021-01 · NCT04764201
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1903
Phase 1 · Completed · 2020-11 · NCT04762407
Clinical Efficacy and Safety Evaluation of HCP1904-2 in Essential Hypertension Patients
Phase 3 · Completed · 2020-10 · NCT04830449
Clinical Efficacy and Safety Evaluation of HCP1904-1 in Essential Hypertension Patients
Phase 3 · Completed · 2020-10 · NCT04820907
Efocipegtrutide (HM15211) in Adults With Biopsy-Confirmed Nonalcoholic Steatohepatitis (NASH)
Phase 2 · Completed · 2020-07 · NCT04505436
Efficacy and Safety of HGP1910 and HCP1903 in Patients With Primary Hypercholesterolemia
Phase 3 · Completed · 2020-07 · NCT04652349
Study to Compare the Safety, Pharmacokinetics and Pharmacodynamics of HIP1802 to HGP1705 in Healthy Volunteers
Phase 1 · Completed · 2020-04 · NCT04324905
An Observational Study to Evaluate the Treatment of Newvast® Tab(Atorvastatin) in Korean Patients With Dyslipidemia
Completed · 2020-01 · NCT05555238
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Subjects
Phase 1 · Completed · 2020-01 · NCT04204629
Single Ascending Dose Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15912(Sonefpeglutide) in Healthy Korean Subjects
Phase 1 · Completed · 2019-10 · NCT04076293
Study for Multiple Doses of HM15136(Efpegerglucagon) in Obese or Overweight Subjects With Comorbidities
Phase 1 · Completed · 2019-08 · NCT04167553
Poziotinib in Patients With NSCLC Having EGFR or HER2 Exon 20 Insertion Mutation
Phase 2 · Terminated · 2019-07 · NCT04044170
A Phase 3 Study to Compare the Efficacy and Safety of Co-administered HGP0608, HGP0904 and HCP1306 Versus HCP1701 in Patients With Hypertension and Dyslipidemia
Phase 3 · Completed · 2019-07 · NCT04074551
An Observational Study of Tamsulosin in Patients With Benign Prostatic Hyperplasia
Completed · 2019-07 · NCT05422677
Safety to Evaluate the Efficacy and Safety of HIP1601 in Patients With Non Erosive Reflux Disease
Phase 3 · Completed · 2019-06 · NCT04325620
A Study to Evaluate the Pharmacokinetics and Safety of HCP1704 in Healthy Subjects
Phase 1 · Completed · 2019-06 · NCT04081857
An Observational Study to Evaluate the Incidence of MACCE According to Time Interval of Taking Medication in Patients With Acute Coronary Syndrome or Cerebral Infarction Who Received DAPT for the Secondary Prevention and Esomezol Cap for the Prevention of Gastrointestinal Bleeding
Completed · 2019-04 · NCT05487560
Food-effect on PK and PD of Single Oral Dose of HIP1601 in Healthy Male Subjects
Phase 1 · Completed · 2019-04 · NCT03882112
A Phase 2 Study to Assess Dose-response Relationship of HCP1803 in Patients With Essential Hypertension
Phase 2 · Completed · 2019-03 · NCT03897868
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HGP1602 in Healthy Subjects
Phase 1 · Completed · 2019-03 · NCT04084184
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HCP1801 in Healthy Subjects
Phase 1 · Completed · 2019-02 · NCT03826641
A Study to Compare the Pharmacokinetics, Safety and Tolerability Between Fixed-Dose Combination and Co-Administration of HGP0904, HGP0608 and HCP1306 Tablets in Healthy Male Subjects.
Phase 1 · Completed · 2018-12 · NCT04322266
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of HIP1801 in Healthy Male Subjects.
Phase 1 · Completed · 2018-12 · NCT04084197
Clinical Trial to Assess the Efficacy and Safety of MUCOLASE Tablet(Streptokinase • Streptodornase)
Phase 4 · Unknown · 2018-11 · NCT04252963
A Study of Multiple Doses of HM15211(Efocipegtrutide) in Obese Subjects With NAFLD
Phase 1 · Completed · 2018-11 · NCT03744182
Efficacy and Safety of HIP1601 Capsule
Phase 3 · Completed · 2018-10 · NCT04080726
A Study to Evaluate the Pharmacokinetics and Safety of HIP1701 in Healthy Subjects
Phase 1 · Completed · 2018-10 · NCT04087525
Efficacy and Safety of HCP1102 Capsule in Patients With Perennial Allergic Rhinitis
Phase 3 · Completed · 2018-10 · NCT04324918
Study to Evaluate the Effect on Improvement of LVH by the Control of BP in Hypertension Patients With AV Disease
Phase 4 · Completed · 2018-10 · NCT03666351
A First-in-Human, Study to Assess Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HM15136(Efpegerglucagon) in Healthy Subjects
Phase 1 · Completed · 2018-10 · NCT04032782
A Study to Evaluate the Pharmacokinetic and Pharmacodynamic Interactions Between HGP0904, HGP0608, and HCP1306 in Healthy Male Subjects.
Phase 1 · Completed · 2018-05 · NCT04081844
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Q Tablet
Completed · 2018-04 · NCT05450575
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM15211(Efocipegtrutide)
Phase 1 · Completed · 2018-04 · NCT03374241
Olmutinib 600 mg QD in Patients With T790M-positive NSCLC After Treatment With an EGFR-TKI
Phase 1 · Terminated · 2018-03 · NCT04510415
An Observational Study to Evaluate Effectiveness and Safety of Amosartan Plus Tablet
Completed · 2018-02 · NCT05462535
Safety, Pharmacokinetics and Pharmacodynamics of the Two Esomeprazole Formulations
Phase 1 · Unknown · 2018-02 · NCT03372850
Efficacy and Safety of Efpeglenatide Versus Placebo in Patients With Type 2 Diabetes Mellitus Inadequately Controlled With Diet and Exercise
Phase 3 · Completed · 2017-12 · NCT03353350
Observational Study to Evaluate Therapeutic Effectiveness and Safety of Monterizine Cap.
Completed · 2017-11 · NCT04654702
An Observational Study Assessing Effects in Patients With Combination Therapy With Raloxifene/Cholecalciferol
Completed · 2017-11 · NCT04788290
Multiple Ascending Dose Study of HM12460A in Type 2 Diabetes Mellitus
Phase 1 · Terminated · 2017-10 · NCT03332836
Molar Potency Study of HM12460A in Healthy Subjects
Phase 1 · Completed · 2017-10 · NCT03330314
PK and Safety Study of HCP1102, HGP0813 and HGP1408
Phase 1 · Completed · 2017-07 · NCT03371849
HM95573 in Combination With Either Cobimetinib or Cetuximab in Patients With Locally Advanced or Metastatic Solid Tumors
Phase 1 · Unknown · 2017-05 · NCT03284502
Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers
Phase 1 · Completed · 2017-05 · NCT03118817
Pharmacokinetic Drug Interactions Between HGP1607 and HGP1501
Phase 1 · Completed · 2017-03 · NCT03089112
Clinical Efficacy and Safety Evaluation of HCP1202 in COPD Patients
Phase 3 · Unknown · 2016-10 · NCT02941679
Statin Monotherapy and Rosuzet Tab.(Rosuvastatin/Ezetimibe) Administration in Patients With Dyslipidemia in Korea
Completed · 2016-06 · NCT04829149
Pharmacokinetics and Safety of HCP1105 and Co-administration of HGP0918, HGP0816 in Healthy Male Volunteers
Phase 1 · Completed · 2016-06 · NCT02941796
Safety and Pharmacokinetic Characteristics After Administration of HIP1503 and HGP1103 in Healthy Male Volunteers
Phase 1 · Completed · 2016-03 · NCT02940314
Evaluation the Effect of Acetyl-L-carnitine in Patients With Mild Cognitive Impairment Accompanied With Chronic Cerebrovascular Disease
Phase 4 · Unknown · 2016-01 · NCT04346862
Clinical Trial on Education Method of Fluterol® Inhalation Inhaler for Asthma Control
Phase 4 · Completed · 2015-10 · NCT03110874
PK and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 Under Fed Condition in Healthy Male Volunteers
Phase 1 · Completed · 2015-10 · NCT02715401
Investigating the Pharmacokinetic Characteristics of HIP1402 in Healthy Male Volunteers
Phase 1 · Completed · 2015-09 · NCT02529800
Phase II Trial of HM61713 for the Treatment of ≥2nd Line T790M Mutation Positive Adenocarcinoma of the Lung
Phase 2 · Terminated · 2015-08 · NCT02485652
Pharmacokinetics of HCP1401 and Co-administration of HCP0605, HGP1405 in Healthy Male Volunteers
Phase 1 · Completed · 2015-08 · NCT04252872
Evaluating the Bioequivalence of HIP1302, HGP1406
Phase 1 · Completed · 2015-08 · NCT02545829
Multiple Ascending Dose Study of HM12470 in Type 1 and Type 2 Diabetes Mellitus
Phase 1 · Unknown · 2015-07 · NCT03332849
Pharmacokinetics and Safety of HCP1303 and Co-administration of HGP1201, HIP1402 in Healthy Male Volunteers
Phase 1 · Completed · 2015-07 · NCT02712411
Evaluating a Pharmacokinetic Drug Interaction Between HGP0918 and HGP0816
Phase 1 · Completed · 2015-07 · NCT02554136
Evaluating the Bioequivalence of HIP1403, HGP0919
Phase 1 · Completed · 2015-04 · NCT02473900
Evaluating the Bioequivalence of HIP1403 and HGP0919 Suspensions
Phase 1 · Completed · 2015-04 · NCT02941731
Poziotinib in Patients With HER2+ Recurrent Stage IV BC Who Have Received at Least 2 Prior HER2-directed Regimens
Phase 2 · Completed · 2015-04 · NCT02418689
A Study to Evaluate Efficacy and Safety of HCP1401 for Stage 2 Hypertension Patients Not Controlled by HCP0605
Phase 3 · Completed · 2015-04 · NCT02916602
Molar Potency Study of HM12470 in Healthy Subjects
Phase 1 · Completed · 2015-03 · NCT03330327
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HCP1303 Capsules
Phase 3 · Completed · 2015-03 · NCT02667938
Phase II Trial to Evaluate the Efficacy and Safety of HM61713 as the 1st-line NSCLC Anticancer Therapy
Phase 2 · Completed · 2015-03 · NCT02444819
Pharmacokinetics of HCP1305 and Co-administration of HCP0605, HGP0816 in Healthy Male Volunteers
Phase 1 · Completed · 2015-02 · NCT04039724
Clinical Trial to Evaluate Safety, Tolerability and Pharmacokinetics and Anti-tumor Activity of HM95573
Phase 1 · Completed · 2015-01 · NCT02405065
Study to Evaluate the Non-inferiority of Cavir in HBeAg(+)Chronic Hepatitis B Patients Treated With Baraclude
Phase 4 · Unknown · 2015-01 · NCT02523547
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12470
Phase 1 · Completed · 2015-01 · NCT02302443
Evaluate the Pharmacokinetics and Safety of HCP1306 and Co-administration of HGP0816, HGP1404 in Healthy Male Volunteers
Phase 1 · Completed · 2014-11 · NCT02941848
A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With BPH
Phase 3 · Completed · 2014-10 · NCT02390882
Evaluating the Efficacy and Safety of HCP1105 in Combined Hyperlipidemic Patients With High Risk for CHD
Phase 3 · Unknown · 2014-10 · NCT02551172
Investigating the Pharmacokinetic Drug Interactions Between HGP1201 and HGP0904
Phase 1 · Completed · 2014-09 · NCT02243319
Trial to Evaluate the Efficacy and Safety of HCP1302
Phase 3 · Completed · 2014-09 · NCT02587988
Efficacy and Safety of HCP1102 Capsule
Phase 3 · Completed · 2014-09 · NCT02552667
Pharmacokinetic Interaction Between HGP0904, HGP0608 and HGP1405
Phase 1 · Completed · 2014-08 · NCT02387554
Clinical Efficacy and Safety Evaluation of Co-administered HGP0904, HGP0608 and HGP0816 in Patients With Hypertension and Dyslipidemia
Phase 3 · Completed · 2014-07 · NCT02899455
Investigating the Pharmacokinetic Drug Interactions Between Rosuvastatin and Ezetimibe
Phase 1 · Completed · 2014-06 · NCT02127320
Efficacy/Safety of HCP1306 Tablet Versus HGP0816 Tablet in Patients With Primary Hypercholesterolemia
Phase 3 · Completed · 2014-06 · NCT02205606
Evaluating a Pharmacokinetic Drug Interaction Between Tadalafil and Tamsulosin
Phase 1 · Completed · 2014-03 · NCT02239484
Glycaemic Control of Monthly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Phase 2 · Completed · 2014-02 · NCT02081118
Evaluating a Pharmacokinetic Drug Interaction Between Amlodipine/Losartan and Rosuvastatin
Phase 1 · Unknown · 2014-02 · NCT02140489
Effect of LAPS-Exendin on Body Weight in Obese Population
Phase 2 · Completed · 2014-02 · NCT02075281
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
Phase 2 · Completed · 2014-01 · NCT02057172
Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 10mg
Phase 1 · Completed · 2013-12 · NCT02026817
A Phase 1b Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
Phase 1 · Unknown · 2013-12 · NCT02059564
Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 500mg and Rosuvastatin 10mg
Phase 1 · Completed · 2013-10 · NCT02011633
Safety and Efficacy Study of HGP1207 in Patients With Pulmonary Hypertension
Phase 3 · Unknown · 2013-09 · NCT01913847
Study to Evaluate a Pharmacokinetic of HM61713 in Healthy Male Subjects
Phase 1 · Completed · 2013-09 · NCT01894399
Partial Replicated Crossover Clinical Study to Compare Pharmacokinectic Characteristics of Eperisone Hydrochloride and Aceclofenac With HCP1104 Treatment to Those of Co-administration of Eperisone Hydrochloride 50mg Tablet and Aceclofenac 100mg Tablet in Healthy Adult Male Volunteers
Phase 1 · Completed · 2013-08 · NCT01869985
Safety,Tolerability and Pharmacokinetic Study of Recombinant Human Interferon Alfa 2B in Chronic Hepatitis C Patients (HM10660A)
Phase 1/2 · Unknown · 2013-07 · NCT02057887
Single-dose, 2-way Crossover Open Study to Evaluate the Food Effect on the PK of HCP1201 in Healthy Volunteers
Phase 1 · Completed · 2013-06 · NCT01901757
Comparison of PK After Administration of HCP1201 and Co-administration of Metformin SR 750mg and Rosuvastatin 20mg
Phase 1 · Completed · 2013-06 · NCT01929512
Efficacy and Safety Study of ALS-L1023 in Patients With Abdominal Obesity of Metabolic Syndrome
Phase 3 · Terminated · 2013-05 · NCT01872182
To Compare the Pharmacokinetics of Traclear 62.5 mg Tablets and HGP1206 125mg 1 Tablet in Healthy Male Volunteers
Phase 1 · Completed · 2013-04 · NCT01864863
A Pilot Study to Evaluate the Pharmacokinetics of Omega-3 Between Rosuvastatin and Omega-3 Coadministration and HCP1007
Phase 1 · Completed · 2013-02 · NCT01929070
Comparing Efficacy and Safety Between Eperisone a BID and a TID Regimen in Acute Low Back Pain Patients
Phase 2 · Completed · 2013-02 · NCT01806818
Evaluating a Pharmacokinetic Drug Interaction Between Metformin Hydrochloride and Rosuvastatin Calcium
Phase 1 · Completed · 2013-01 · NCT01775579
Safety,PK/PD, Food Effect Study of Orally Administered HM71224 in Healthy Adult Male Volunteers
Phase 1 · Completed · 2013-01 · NCT01765478
A First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HM12460A
Phase 1 · Completed · 2012-12 · NCT01724814
A Study of KX2-391 With Paclitaxel in Patients With Solid Tumors
Phase 1/2 · Unknown · 2012-12 · NCT01764087
A Phase I-II Study of HM781-36B Combined With Paclitaxel and Trastuzumab in HER-2 Positive Advanced Gastric Cancer
Phase 1/2 · Completed · 2012-11 · NCT01746771
Study to Evaluate and Compare Safety and Pharmacokinetics of the HCP1004 and VIMOVO 500/20mg in Healthy Korean Male
Completed · 2012-10 · NCT01688193
Study to Evaluate a Pharmacokinetic Drug Interaction Between Eperisone Hydrochloride and Aceclofenac in Healthy Male Subjects
Completed · 2012-08 · NCT01638286
Study to Evaluate the Pharmacokinetics and Safety of Singulair and Xyzal in Free Combination and Fixed-dose Combination
Phase 1 · Completed · 2012-07 · NCT01651481
Efficacy and Safety of Concomitant Montelukast Sodium and Levocetirizine Dihydrochloride in Perennial Allergic Rhinitis (PAR) Patients
Phase 3 · Completed · 2012-06 · NCT01640535
Clinical Trial to Evaluate the Effect on the Pharmacokinetic Characteristics of HCP1007 Capsule
Phase 1 · Completed · 2012-03 · NCT01548157
Phase I/II Trial to Evaluate Safety, Tolerability and Pharmacokinetic Profile of HM61713 in NSCLC Patients
Phase 1/2 · Completed · 2012-03 · NCT01588145
Therapeutic Equivalence Study of HCP0910 250/50 Mcg to Seretide 250 Diskus in Asthmatic Patients
Phase 1 · Completed · 2012-02 · NCT01521455
Clinical Trial to Evaluate the Effect of Food on the Pharmacokinetic Characteristics of HIP0901 Capsule
Phase 1 · Completed · 2012-02 · NCT01555398
A Drug-Drug Interaction Study of Ambroxol and Levodropropizine
Phase 1 · Completed · 2012-02 · NCT01573663
Pharmacokinetics of Sildenafil Following Administration of an Chewable Tablet of Sildenafil Relative to Viagra® Conventional Oral Tablet in Healthy Volunteers
Phase 1 · Completed · 2011-12 · NCT01514903
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
Phase 2 · Completed · 2011-12 · NCT01452451
A Bioequivalence Study Comparing HIP0901 Capsule With Lipidilsupra Tablet
Phase 1 · Completed · 2011-11 · NCT01509196
A Drug Interaction Study of Montelukast and Levocetirizine
Phase 1 · Completed · 2011-11 · NCT01491503
Safety and Efficacy Study of Recombinant Human Growth Hormone in Adult Growth Hormone Deficiency Patients
Phase 2 · Completed · 2011-10 · NCT01822340
A Bioequivalence Study Comparing Irbesartan/Atorvastatin Combination Tablet With Coadministration of Irbesartan and Atorvastatin
Phase 1 · Completed · 2011-09 · NCT01447797
A Bioequivalence Study Comparing Clopidogrel/Aspirin Combination Tablet With Coadministration of Clopidogrel and Aspirin
Phase 1 · Completed · 2011-07 · NCT01448330
Clinical Trial to Determine the MTD of HM781-36B in Patients With Advanced Solid Tumors
Phase 1 · Completed · 2011-06 · NCT01455584
Efficacy and Safety of Irbesartan and Atorvastatin in Hypertension and Hyperlipidemia
Phase 3 · Completed · 2011-05 · NCT01442987
Exploratory Clinical Study to Evaluate the Optimal Dosage of Mosapride and Probiotics in Irritable Bowel Syndrome Without Predominant Diarrhea
Phase 2 · Completed · 2011-05 · NCT01505777
Efficacy/Safety of Pseudoephedrine Plus Levocetirizine Versus Placebo in Patients With Vasomotor Rhinitis
Phase 3 · Completed · 2011-05 · NCT01509209
Safety, Pharmacokinetic, Pharmacodynamic Study of LAPS-IFNa in Healthy Adult Subjects
Phase 1 · Completed · 2011-03 · NCT01504581
Phase I of OratecanTM in Combination With Capecitabine in Patients With Advanced Solid Malignancies
Phase 1 · Completed · 2010-12 · NCT01463982
Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia
Phase 4 · Unknown · 2010-12 · NCT01564875
A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
Phase 1 · Completed · 2010-09 · NCT01197014
The Efficacy and Safety Study of Anti-hypertension Combination Drug in Patients Uncontrolled With Monotherapy.
Phase 4 · Completed · 2010-08 · NCT01828359
A Bioequivalence Study of Amlodipine Plus Losartan Versus Amlodipine and Losartan
Phase 1 · Completed · 2010-08 · NCT01197001
A Study of HM10560A in Healthy Male Subject
Phase 1 · Completed · 2010-03 · NCT01093742
A Study of HM11260C in Healthy Male Subject
Phase 1 · Completed · 2010-02 · NCT01093729
Safety and PK of HM10460A (HNK460) in Healthy Adult Japanese and Caucasian Subjects
Phase 1 · Completed · 2009-11 · NCT01037543
Phase I Study to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of HM781-36B in Patients With Advanced Solid Tumors
Phase 1 · Completed · 2009-11 · NCT01455571
A Study of HM10760A (Long-acting Erythropoietin (EPO)) in Healthy Korean Subjects
Phase 1 · Completed · 2009-11 · NCT01013064
A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects
Phase 1 · Completed · 2009-10 · NCT01030315
Assess the Safety, Tolerability, and Pharmacokinetic (PK) Characteristics of HM10460A (HNK460) in Healthy Adult Korean Subjects
Phase 1 · Completed · 2009-10 · NCT00998283
Duration of P-glycoprotein Inhibition After Oral Administration of HM30181AK Tablet
Phase 1 · Completed · 2009-06 · NCT00954304
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Stage 2 Hypertension
Phase 3 · Completed · 2009-05 · NCT01127217
A Study of Oraxol® in Gastric Cancer Patients
Phase 1/2 · Unknown · 2009-05 · NCT01491217
Comparison of Effect & Safety of Clopidogrel Napadisilate With Clopidogrel Bisulfate in Coronary Artery Disease Patients
Phase 4 · Completed · 2009-03 · NCT01830491
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies
Phase 1 · Completed · 2008-07 · NCT00979563
Clinical Trial to Evaluate Safety and Tolerability of OratecanTM in Patients With Advanced Solid Malignancies (Oratecan-102)
Phase 1 · Completed · 2008-06 · NCT00986843
Efficacy/Safety of Amlodipine Plus Losartan Versus Amlodipine in Patients With Essential Hypertension
Phase 3 · Completed · 2008-05 · NCT00940667
Efficacy/Safety of Amlodipine Plus Losartan Versus Losartan in Patients With Essential Hypertension
Phase 3 · Completed · 2008-04 · NCT00940680
Efficacy and Safety of Morning Versus Evening Intake of Simvast Controlled Release (CR) Tablet in Patients With Hyperlipidemia
Phase 3 · Completed · 2007-11 · NCT00973115
Diurnal Variation in Hypertensive Stroke Patients
Phase 4 · Completed · 2007-08 · NCT01830517
Efficacy and Safety of Amlodipine and Losartan in Patients With Essential Hypertension
Phase 2 · Completed · 2007-05 · NCT00942344
Clinical Trial to Determine the Maximum Tolerated Dose and to Assess the Safety and Pharmacokinetic Profile of Oral Paclitaxel in Patients With Advanced Solid Cancer
Phase 1 · Completed · 2006-08 · NCT01491204

Key disclosures

KRX KIND via OpenDART

Management투자판단관련주요경영사항 (에페오토인젝터주(에페글레나타이드) 식품의약품안전처 품목허가 승인)2026-10-07
Management투자판단관련주요경영사항2026-09-29
Contract[기재정정]투자판단관련주요경영사항 (급성골수성백혈병(AML) 치료 항암신약 HM43239 기술이전 계약 체결)2026-08-26
Management투자판단관련주요경영사항2026-08-24
Management[기재정정]투자판단관련주요경영사항2026-08-21
Management[기재정정]투자판단관련주요경영사항2026-08-21
Contract투자판단관련주요경영사항 (소네페글루타이드 (Sonefpeglutide; LAPS GLP2 agonist; HM15912) 기술이전 계약 체결)2026-06-01
Management투자판단관련주요경영사항 (HCP18034 개발을 위한 식약처(MFDS) 제3상 임상시험 계획 승인)2026-05-29
Contract단일판매ㆍ공급계약체결2026-05-21
Management투자판단관련주요경영사항2026-02-19

Show 14 more events

Publications

PubMed · affiliation-matched

Long-term average atherogenic index of plasma and cardiovascular mortality in 8.9 million Korean adults: A nationwide cohort study.
Atherosclerosis · 2026-10 · Kang HH, Bae Y, Kim H 외 1
Cardiovascular Risk Associated With General and Abdominal Obesity in Young Adults Without Traditional Risk Factors: A Korean Nationwide Cohort Study.
Journal of lipid and atherosclerosis · 2026-09 · Lee JH, Kim M, Kim H 외 5
Ezetimibe Treatment Is Associated with Lower Risk of Incident Cancer: A Nationwide Population-Based Cohort Study.
Endocrinology and metabolism (Seoul, Korea) · 2026-09 · Cho Y, Park HS, Park MA 외 5
Clopidogrel Vs Aspirin Monotherapy for Secondary Prevention After Percutaneous Coronary Intervention: A Nationwide Cohort Study.
JACC. Asia · 2026-08 · Cho JH, Chan You S, Kim H 외 11
DoE-guided comparison of SNEDDS, solid dispersion, and polymeric nanoparticles for enhancing apparent epithelial transport and oral exposure of sorafenib.
Journal of pharmaceutical sciences · 2026-08 · Kwon TK, Park CH, Im HT 외 1
Sex differences of clinical outcomes in patients undergoing percutaneous coronary intervention: a nationwide cohort study.
Coronary artery disease · 2026-07 · Kim HL, Bae Y, Kim M 외 6
Higher cardiovascular risk observed with beta-blockers in CKD patients without prior cardiovascular disease.
Clinical kidney journal · 2026-07 · Han SH, Kim M, Lee J 외 1
Clinical Outcomes of Contemporary Bariatric Surgical Procedures: A Nationwide Cohort Study.
Journal of obesity & metabolic syndrome · 2026-06 · Kim J, Choi HS, Kim M 외 3
Temporal Trend of Cardiovascular Disease Burden Among Cancer Patients Between 2005 and 2022: Nationwide Population-Based Cohort Study in South Korea.
Korean circulation journal · 2026-05 · Cho I, Lee S, Cho J 외 18
Systemic cancer risk profile in neovascular age-related macular degeneration: insights into shared aging-related mechanisms from a nationwide population-based study.
Aging · 2026-05 · Kim HM, Bae Y, Kim M 외 2

Show 203 more publications

Dental caries risk in patients with chronic airway diseases using dry powder inhalers: a retrospective cohort study.
BMC oral health · 2026-05 · Ha J, Ahn JH, Jang JG 외 6
Risk factors and mortality for amputations in the diabetic foot: a nationwide cohort study.
Diabetes research and clinical practice · 2026-04 · Shim DW, Lee W, Park KH 외 5
Asthma prevalence and risk factors in early-onset atopic dermatitis using Korean National Health Insurance Service data.
Scientific reports · 2026-04 · Kim J, Jung M, Lee JY 외 5
Combined Pre-Hypertension, Pre-Diabetes, and Pre-Hyperlipidemia and Long-Term Cardiovascular Risk in Young Adults: A Nationwide Cohort Study.
European journal of preventive cardiology · 2026-04 · Lee YJ, Lee JH, Kim M 외 6
Age-related differences in adherence to inhaled corticosteroids among adult patients with asthma: a national cohort study in South Korea.
BMC pulmonary medicine · 2026-04 · Park HS, Lee J, Kim H 외 1
Association between dental implantation and dementia: a nationwide population-based study.
BMC geriatrics · 2026-04 · Kim YS, Lee YJ, Lee EH 외 4
Cancer risk in patients with systemic lupus erythematosus: a population-based cohort study in the Republic of Korea 2004-2021.
Scandinavian journal of rheumatology · 2026-03 · Choi SJ, Lee S, Park S 외 3
Association of statin therapy on acute ischemic stroke patients with atrial fibrillation: insights from a nationwide cohort study.
Scientific reports · 2026-02 · Kim H, Min SH, Kim JM 외 6
Impact of gastrectomy on the risk of alcohol-associated liver disease in patients with gastric cancer.
Scientific reports · 2026-02 · Moon SY, Baek YH, Kang D 외 6
Prognosis of Infective Endocarditis According to Clinical Characteristics, Economic Status, and Center Experience.
Yonsei medical journal · 2026-02 · Kim WD, Seo J, Lee S 외 7
The Long-Term Rate of Reoperation After Midurethral Sling Insertion Among Women With Urinary Incontinence: A Population-Based Study.
International urogynecology journal · 2026-02 · Park IW, Cho J, Kim M 외 3
Exposure-driven tolerance modeling of efpeglenatide-induced nausea or vomiting using repeated time-to-event analysis: implications for dose-escalation strategies.
Frontiers in pharmacology · 2026-01 · Seo J, Choi S, Kim N 외 2
Comparative risk of dementia between direct oral anticoagulants and warfarin after atrial fibrillation related ischemic stroke.
Frontiers in aging neuroscience · 2026-01 · Choi S, Park S, Jung YH 외 4
Association of combined mobility and cognitive impairments with adverse health outcomes in adults aged 66 years: a nationwide cohort study.
Journal of Yeungnam medical science · 2026-01 · Ryu SY, Park S, Yun J
Heart Failure Statistics 2025 Update: A Report From the Korean Society of Heart Failure.
International journal of heart failure · 2026-01 · Lee CJ, Lee H, Ko KY 외 10
Impact of a History of COVID-19 Infection on Postoperative Complications in Spinal Surgery: A Nationwide Cohort Study.
Journal of clinical medicine · 2026-01 · Kim N, Seo J, Park M 외 8
Impact of dose and compliance of antidementia medications on long-term outcomes in Alzheimer's disease: a nationwide real-world study.
Alzheimer's research & therapy · 2026-01 · Kim T, Hong YJ, Kim M 외 7
Risk of cardiovascular disease associated with use of tumor necrosis factor inhibitors in ankylosing spondylitis.
Journal of rheumatic diseases · 2026-01 · Kim JW, Yoon JS, Park S 외 6
Temporal Trends and Outcomes of Amyloidosis in Korea: A 14-Year Nationwide Cohort Study.
Journal of clinical medicine · 2025-12 · Jung MH, Jung HO, Lee SY 외 4
Cardiovascular outcomes associated with incident diabetes during statin therapy: a nationwide propensity-matched cohort study.
Cardiovascular diabetology · 2025-12 · Sung KC, Kang D, Lee J 외 5
Effects of Osteoporosis Medication Use on Reprocedure Rates Following Vertebral Augmentation: A Nationwide Cohort Study.
Clinics in orthopedic surgery · 2025-12 · Park SR, Lee BH, Suk KS 외 7
Association of the triglyceride-glucose index with cardiovascular outcomes across cardiovascular-kidney-metabolic syndrome stages.
The Korean journal of internal medicine · 2025-11 · Kim BS, Kim HJ, Moon S 외 3
Risk of colorectal cancer in kidney transplant recipients and patients with end-stage renal disease undergoing hemodialysis.
The Korean journal of internal medicine · 2025-11 · Ahn Y, Yu H, Bae Y 외 2
Long-term clinical outcome and risk stratification across stages of cardiovascular-kidney-metabolic syndrome in a nationwide cohort.
The Korean journal of internal medicine · 2025-11 · Kim HJ, Kim BS, Kim H 외 5
All-Cause Mortality and Bleeding Risks Associated With Serotonin Reuptake Inhibitors in Patients With End-Stage Kidney Disease and Depression: A Nationwide Cohort Study.
Psychiatry investigation · 2025-10 · Lee J, Park M, Shin DH 외 7
A comprehensive analysis of antihypertensive medications and their impact on lung cancer incidence and all-cause mortality: a population-based study in South Korea.
Journal of thoracic disease · 2025-10 · Choi J, Lee S, Kang D 외 5
Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021.
Scientific reports · 2025-10 · So H, Choi SJ, Park S 외 2
Procedural and clinical risk factors of infective endocarditis - A nationwide case-control study in South Korea.
Journal of infection and public health · 2025-10 · Lee HJ, Kim WD, Ha KE 외 10
Medical travel patterns for hepatocellular carcinoma treatment in South Korea: National Health Insurance data from 2013 to 2021.
World journal of gastrointestinal oncology · 2025-09 · Kim S, Kim N, Lee HS 외 3
Cardiorenal outcomes and safety of SGLT2 inhibitors in patients with diabetes secondary to disorders of the exocrine pancreas: a nationwide population-based study.
Diabetes & metabolism · 2025-09 · Ha KH, Park M, Lee Y 외 2
Risk of Hematologic Malignancies in Patients With Acute Myocardial Infarction: A Nationwide Population-Based Cohort Study.
JACC. CardioOncology · 2025-08 · Yoon SY, Kim M, Kim H 외 10
Trends in Epidemiology, Clinical Characteristics, and Outcomes of Infective Endocarditis: A 16-Year Nationwide Cohort Study in Korea.
Journal of Korean medical science · 2025-08 · Ha KE, Kim WD, Ko KY 외 9
Does Surgical Treatment With Uvulopalatopharyngoplasty for Obstructive Sleep Apnea Prevent Future Arrhythmic Events?
Pacing and clinical electrophysiology : PACE · 2025-08 · Jung LY, Kim S, Kim Y 외 4
Real-world data on long-term outcomes in patients with T-cell lymphomas: a nationwide study of Korea.
Blood research · 2025-08 · Baek DW, Lee JM, Jang Y 외 6
Combined impact of prediabetes and fatty liver index on cardiometabolic outcomes and mortality in middle aged adults: a nationwide cohort study.
Cardiovascular diabetology · 2025-07 · Lyu YS, Park M, Kim HK 외 10
Longitudinal Changes in Cardiovascular-Kidney-Metabolic Syndrome Stages and Their Impact on Outcomes: A Nationwide Cohort Study.
Journal of clinical medicine · 2025-06 · Kim BS, Kim HJ, Kim H 외 3
Hepatic Steatosis in Cardiovascular-Kidney-Metabolic Syndrome: Fatty Liver Index as a Predictor of Cardiovascular Outcomes.
European journal of preventive cardiology · 2025-06 · Kim BS, Kim HJ, Kim H 외 4
A nationwide retrospective cohort study of the association between acupuncture exposure and clinical outcomes of idiopathic Parkinson's disease using health insurance claim data in South Korea.
Integrative medicine research · 2025-06 · Hwang YC, Lee J, Kang D 외 9
HG043, a potent thienopyrimidine GPR119 agonist, demonstrates enhanced anti-diabetic and anti-obesity effects in preclinical models.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2025-06 · Lee S, Kim H, Choi I 외 2
Prevalence and Incidence of Ethambutol-Induced Optic Neuropathy and Its Risk Factors in Korea: A Nationwide Population-Based Study.
Journal of Korean medical science · 2025-05 · Lee S, Ryu WY, Kang D 외 1
Advanced QbD-Based Process Optimization of Clopidogrel Tablets with Insights into Industrial Manufacturing Design.
Pharmaceutics · 2025-05 · Bak YW, Woo MR, Cho HJ 외 4
Increased risk of depression and anxiety in patients with chronic back pain following COVID-19 infection based on a nationwide population-based study.
Scientific reports · 2025-04 · Seo J, Kim N, Suk KS 외 9
Mortality Trends in Patients Undergoing Hemodialysis, 2003-2021: Data from National Health Insurance Service in Korea.
Journal of clinical medicine · 2025-04 · Kim KW, Bae Y, Lee JY 외 2
Adherence to Antidiabetic Medication and Cardiovascular Outcomes in Cancer Patients: A Nationwide Population-Based Cohort Study.
Cancers · 2025-03 · Jung MH, Jung MK, Kim ES 외 10
Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.
Journal of hospice and palliative care · 2025-03 · Kim M, Kim Y, Park JM
Increased Mortality Associated with Amiodarone Compared to Other Antiarrhythmic Drugs in New-Onset Atrial Fibrillation.
Journal of clinical medicine · 2025-02 · Kim YG, Lee HS, Kim H 외 6
Effects of SGLT2 Inhibitors on Cardiovascular and Lower Limb Events in Patients with Type 2 Diabetes: A Nationwide Population-Based Study.
Diabetes, metabolic syndrome and obesity : targets and therapy · 2025-01 · Lee MJ, Bae JH, Khang AR 외 11
Correction: The role of ambulatory blood pressure monitoring in enhancing medication adherence among patients with newly diagnosed hypertension: an analysis of the National Health Insurance cohort database.
Clinical hypertension · 2025-01 · Kim HL, Park SJ, Bae YJ 외 3
The association of fatty liver index and metabolic syndrome with cardiovascular outcomes, liver-related mortality, and all-cause mortality: a nationwide cohort study.
Internal and emergency medicine · 2025-01 · Park SH, Park J, Kim H 외 7
Risk of cardiovascular disease associated with long-term use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis.
Rheumatology (Oxford, England) · 2025-01 · Kim JW, Yoon JS, Park S 외 6
Impact of blood pressure and medication adherence on clinical outcomes in patients with hypertension.
Frontiers in medicine · 2025-01 · Kim HJ, Kim BS, Kim H 외 3
Sex Differences in the Risk of Bladder Cancer among Kidney Transplant Recipients and Patients with Kidney Failure Receiving Hemodialysis: A Nationwide Cohort Study.
American journal of nephrology · 2025-01 · Yu H, Kim SJ, Bae Y 외 2
Population pharmacokinetics of efpeglenatide in individuals with obesity and with type 2 diabetes.
Frontiers in pharmacology · 2025-01 · Choi S, Seo J, Park S 외 3
The effect of SGLT2 inhibitor in patients with type 2 diabetes and atrial fibrillation.
PloS one · 2025-01 · Cho Y, Shin SH, Park MA 외 5
Structure-activity relationship studies of Imidazo[1',2':1,6]pyrido[2,3-d]pyrimidine derivatives to develop selective FGFR inhibitors as anticancer agents for FGF19-overexpressed hepatocellular carcinoma.
European journal of medicinal chemistry · 2025-01 · Kim J, Jung SH, Lee JC 외 4
Comparative analysis of real-world data on the efficacy and safety of and adherence to ICS/LABA combinations in asthma management.
Respiratory research · 2025-01 · Park HS, Lee J, Kim H 외 1
Safety of High-Dose Intravenous Iron in Hemodialysis Patients: Results from the National Health Insurance Service (2019-2020) in South Korea.
Journal of clinical medicine · 2024-12 · Cho A, Bae Y, Kim M 외 3
Increased Risk of Superficial Fungal Infections Among Psoriasis Patients Receiving Systemic Treatment: A Nationwide Retrospective Population-Based Cohort Study.
Annals of dermatology · 2024-12 · Seo JI, Kim H, Lee JK 외 3
Combined impact of prediabetes and hepatic steatosis on cardiometabolic outcomes in young adults.
Cardiovascular diabetology · 2024-11 · Choi W, Park M, Park S 외 7
Efficacy and diabetes risk of moderate-intensity statin plus ezetimibe versus high-intensity statin after percutaneous coronary intervention.
Cardiovascular diabetology · 2024-11 · Choo EH, Moon D, Choi IJ 외 9
Smoking Cessation and Incident Cardiovascular Disease.
JAMA network open · 2024-11 · Cho JH, Shin SY, Kim H 외 7
Comparison of Statin With Ezetimibe Combination Therapy Versus Statin Monotherapy for Primary Prevention in Middle-Aged Adults.
Korean circulation journal · 2024-09 · Cha JJ, Hong SJ, Lim S 외 16
Long-term outcomes of high bleeding risk patients undergoing percutaneous coronary intervention: a Korean nationwide registry.
European heart journal · 2024-09 · Kang J, Yun J, Park KW 외 10
Reply: The Association of Bradycardic Event Risk With Antiarrhythmic Drugs for Atrial Fibrillation.
Journal of the American College of Cardiology · 2024-09 · Kim YG, Lee HS, Kim H 외 1
The association between inflammatory bowel disease and risk of prostate cancer: a population-based retrospective study based on Korean National Health Insurance Service database.
Prostate international · 2024-09 · Jung G, Song B, Kim JK 외 3
Increased risk of epilepsy after transient global amnesia: A population-based study in South Korea.
Clinical neurology and neurosurgery · 2024-08 · Lee SJ, Lee TK, Bae YJ 외 1
Insurance Types and All-Cause Mortality in Korean Cancer Patients: A Nationwide Population-Based Cohort Study.
Journal of personalized medicine · 2024-08 · Shin J, Bae YJ, Kang HT
Incidence of atrial fibrillation in patients with renal infarction: A retrospective cohort analysis of the Korean national health insurance registry.
International journal of cardiology · 2024-07 · Moon I, Park SY, Kim D 외 10
Risk of cardiovascular disease with high-dose versus low-dose use of non-steroidal anti-inflammatory drugs in ankylosing spondylitis.
Annals of the rheumatic diseases · 2024-07 · Kim JW, Yoon JS, Park S 외 3
One-Pot Biocatalytic Route from Alkanes to α,ω-Diamines by Whole-Cell Consortia of Engineered Yarrowia lipolytica and Escherichia coli.
ACS synthetic biology · 2024-07 · Kim YC, Yoo HW, Park BG 외 4
Thiazide-associated hyponatremia in arterial hypertension patients: A nationwide population-based cohort study.
Journal of evidence-based medicine · 2024-06 · Kwon S, Kim H, Lee J 외 3
Exploring Molecular Genetic Alterations and RAF Fusions in Melanoma: A Belvarafenib Expanded Access Program in Patients with RAS/RAF-Mutant Melanoma.
The oncologist · 2024-06 · Kim KH, Cho S, Jeong Y 외 11
Association between depression, antidepressant use, and the incidence of atherosclerotic cardiovascular diseases.
Journal of affective disorders · 2024-05 · Kim H, Lee YB, Lee J 외 6
Prognosis of amyotrophic lateral sclerosis patients after tracheostomy invasive ventilation in Korea.
Amyotrophic lateral sclerosis & frontotemporal degeneration · 2024-05 · Kim JS, Park M, Park S 외 5
Selective estrogen receptor modulators (SERMs) with vitamin D composite agent can prevent fracture better than SERMs treatment: based on the National Health Claims Database 2017-2019.
Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA · 2024-05 · Byun SE, Kim H, Lee SY 외 1
Body mass index is associated with clinical outcomes in idiopathic pulmonary fibrosis.
Scientific reports · 2024-05 · Yoon HY, Kim H, Bae Y 외 1
Pregnancy related complications in women with hypertrophic cardiomyopathy: a nationwide population-based cohort study.
BMC cardiovascular disorders · 2024-05 · Choi WY, Park KT, Kim HM 외 5
Heart Failure Statistics 2024 Update: A Report From the Korean Society of Heart Failure.
International journal of heart failure · 2024-04 · Lee CJ, Lee H, Yoon M 외 11
Effects of risk factors on the development and mortality of early- and late-onset dementia: an 11-year longitudinal nationwide population-based cohort study in South Korea.
Alzheimer's research & therapy · 2024-04 · Chun MY, Chae W, Seo SW 외 9
Smoking status and clinical outcome in idiopathic pulmonary fibrosis: a nationwide study.
Respiratory research · 2024-04 · Yoon HY, Kim H, Bae Y 외 1
The Long-Term Impact of 5-alpha Reductase Inhibitors on the Development of Bladder Cancer and the Need for Radical Cystectomy: A Nationwide Observational Study.
The world journal of men's health · 2024-04 · Pyun JH, Son NH, Ko YH 외 3
Association of Antiarrhythmic Drug Therapy With Syncope and Pacemaker Implantation in Patients With Atrial Fibrillation.
Journal of the American College of Cardiology · 2024-03 · Kim YG, Lee HS, Kim H 외 6
The role of ambulatory blood pressure monitoring in enhancing medication adherence among patients with newly diagnosed hypertension: an analysis of the National Health Insurance cohort database.
Clinical hypertension · 2024-03 · Kim HL, Park SJ, Bae YJ 외 3
Association between age at diagnosis of type 2 diabetes and cardiovascular morbidity and mortality risks: A nationwide population-based study.
Diabetes research and clinical practice · 2024-02 · Seo DH, Kim M, Suh YJ 외 4
Balloon-Expandable Versus Self-Expandable Valve in Transcatheter Aortic Valve Replacement: A Nation-Wide Study.
The American journal of cardiology · 2024-02 · Sa YK, Choi IJ, Chang K 외 13
Bipolar disorder and the risk of cardiometabolic diseases, heart failure, and all-cause mortality: a population-based matched cohort study in South Korea.
Scientific reports · 2024-01 · Lee YB, Kim H, Lee J 외 6
Impact of multiple infections on risk of incident dementia according to subjective cognitive decline status: a nationwide population-based cohort study.
Frontiers in aging neuroscience · 2024-01 · Lee JW, Kim M, Kim H 외 6
Impact of COVID-19 pandemic on the incidence and severity of myasthenia gravis in Korea: using National Health Insurance Service database.
Frontiers in neurology · 2024-01 · Kim S, Lee EK, Kim H 외 2
Increased Risk of Dementia after Transient Global Amnesia: A Nationwide Population-Based, Longitudinal Follow-Up Study in South Korea.
Neuroepidemiology · 2024-01 · Lee SJ, Lee TK, Bae YJ 외 1
Psychotic Disorders and the Risk of Type 2 Diabetes Mellitus, Atherosclerotic Cardiovascular Diseases, and All-Cause Mortality: A Population-Based Matched Cohort Study.
Diabetes & metabolism journal · 2024-01 · Lee YB, Kim H, Lee J 외 6
Impact of guideline-directed medical therapy on 5-year mortality in patients with newly diagnosed peripheral artery disease.
Journal of vascular surgery · 2023-12 · Lee JH, Jeon HS, Lee JW 외 7
Association Between Ambroxol at the Usual Dose and the Risk of Parkinson's Disease in Chronic Lung Disease.
Journal of clinical neurology (Seoul, Korea) · 2023-11 · Kim MS, Lee J, Kang D 외 2
Discovery of orally active sulfonylphenyl thieno[3,2-d]pyrimidine derivatives as GPR119 agonists.
European journal of medicinal chemistry · 2023-10 · Kim H, Kim M, Oh K 외 6
Longitudinal trends in direct costs and healthcare utilization ascribable to inflammatory bowel disease in the biologic era: a nationwide, population-based study.
Journal of gastroenterology and hepatology · 2023-09 · Park EY, Baek DH, Kim GH 외 4
Temporal Trend of the Incidence and Characteristics of Renal Infarction: Korean Nationwide Population Study.
Journal of Korean medical science · 2023-08 · Kim DE, Moon I, Park S 외 10
Risk of epilepsy in gonadal teratoma: a nationwide population-based study.
Scientific reports · 2023-07 · Kim S, Kim H, Lee J 외 4
Risk of Dementia in Newly Diagnosed Glaucoma: A Nationwide Cohort Study in Korea.
Ophthalmology · 2023-07 · Park DY, Kim M, Bae Y 외 2
Comparative analysis of mortality and progression to end-stage renal disease between surgically induced and medical chronic kidney disease: A study using the National Health Insurance customized database.
Investigative and clinical urology · 2023-07 · Jung G, Park S, Kim H 외 2
Comparison of efficacy and safety between third-dose triple and third-dose dual antihypertensive combination therapies in patients with hypertension.
Journal of clinical hypertension (Greenwich, Conn.) · 2023-05 · Sung KC, Hong SJ, Rhee MY 외 19
Association of body weight change with all-cause and cause-specific mortality: A nationwide population-based study.
Diabetes research and clinical practice · 2023-05 · Kwon SY, Kim G, Lee J 외 5
Cemented versus Cementless Total Hip Arthroplasty for Femoral Head Osteonecrosis: A Study Based on National Claim Data in South Korea.
Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews · 2023-05 · Park JW, Ko YS, Park S 외 3
Belvarafenib penetrates the BBB and shows potent antitumor activity in a murine melanoma brain metastasis model.
Clinical & experimental metastasis · 2023-04 · Kim YY, Park H, Song T 외 7
Participation and Prognostic Impact of Cardiac Rehabilitation After Acute Coronary Syndrome: Big-Data Study of the Korean National Health Insurance Service.
Journal of Korean medical science · 2023-04 · Choi HE, Kim C, Lee DJ 외 2
Oral anticoagulants and concurrent rifampin administration in tuberculosis patients with non-valvular atrial fibrillation.
BMC cardiovascular disorders · 2023-04 · Hwang KW, Choi JH, Lee SY 외 12
The Impact of BMI Changes on the Incidence of Glomerular Hematuria in Korean Adults: A Retrospective Study Based on the NHIS-HEALS Cohort.
Biomedicines · 2023-03 · Kwon YJ, Kim M, Kim H 외 1
Incidence of Retinal Artery Occlusion and Related Mortality in Korea, 2005 to 2018.
JAMA network open · 2023-03 · Hwang DD, Lee KE, Kim Y 외 6
Gemcitabine-cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study.
Scientific reports · 2023-03 · Lee YS, Ha MS, Tae JH 외 11
HM15912, a Novel Long-Acting Glucagon-Like Peptide-2 Analog, Improves Intestinal Growth and Absorption Capacity in a Male Rat Model of Short Bowel Syndrome.
The Journal of pharmacology and experimental therapeutics · 2023-02 · Choi J, Lee J, Park E 외 5
Prevalence of motor neuron diseases in gout patients: a nationwide population-based cohort study.
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2023-02 · Kwon HS, Park Y, Kim JH 외 5
Real-World Comparison of Transcatheter Versus Surgical Aortic Valve Replacement in the Era of Current-Generation Devices.
Journal of clinical medicine · 2023-01 · Sa YK, Hwang BH, Chung WB 외 16
Shifting role of cytoreductive nephrectomy according to type of systemic therapy: A nationwide cohort study.
Asian journal of surgery · 2023-01 · Choi SY, Ha MS, Lee JW 외 7
Direct oral anti-Xa anticoagulants versus warfarin in newly diagnosed atrial fibrillation and CKD: the Korean National Health Insurance Data.
Frontiers in medicine · 2023-01 · Kee YK, Jeon HJ, Oh J 외 4
Adherence and clinical outcomes for twice-daily versus once-daily dosing of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: Is dosing frequency important?
PloS one · 2023-01 · Hwang HJ, Sohn IS, Jin ES 외 1
10-year survival outcome after clinically suspected acute myocarditis in adults: A nationwide study in the pre-COVID-19 era.
PloS one · 2023-01 · Kim MJ, Jung HO, Kim H 외 3
Gout and the Prevalence of Dementia: A Nationwide Population-Based Study.
Journal of Alzheimer's disease : JAD · 2023-01 · Sung W, Kwon HS, Park Y 외 4
Depression, antidepressant use, and the risk of type 2 diabetes: a nationally representative cohort study.
Frontiers in psychiatry · 2023-01 · Kim H, Lee YB, Lee J 외 6
Seasonality in hip fracture among haemodialysis patients and kidney transplant recipients in South Korea.
Nephrology (Carlton, Vic.) · 2022-12 · Yoon HE, Lee YH, Lee JE 외 4
The associations between changes in hepatic steatosis and heart failure and mortality: a nationwide cohort study.
Cardiovascular diabetology · 2022-12 · Park J, Kim G, Kim H 외 3
Neoadjuvant versus adjuvant chemotherapy in upper tract urothelial carcinoma: A nationwide cohort study.
BMC urology · 2022-11 · Tae JH, Ha MS, Chi BH 외 11
Comparing the Characteristics of Patients With Newly Diagnosed Dementia Before and After 2008 in Seoul, South Korea: A Population-Based Study.
Journal of clinical neurology (Seoul, Korea) · 2022-11 · Kwon HS, Jeong YW, Park S 외 2
Nationwide Trends of Gatekeeper to Invasive Coronary Angiography in Suspected Coronary Artery Disease.
Korean circulation journal · 2022-11 · Cha MJ, Kim WD, Won H 외 6
The association between prostatitis and risk of prostate cancer: a National Health Insurance Database study.
World journal of urology · 2022-11 · Jung G, Kim JK, Kim H 외 2
Neoadjuvant versus adjuvant chemotherapy in bladder cancer: a nationwide cohort study.
Journal of cancer research and clinical oncology · 2022-11 · Choi SY, Ha MS, Chi BH 외 10
Increased incidence of dementia following herpesvirus infection in the Korean population.
Medicine · 2022-10 · Shim Y, Park M, Kim J
Gastrointestinal bleeding risk of non-vitamin K antagonist oral anticoagulants versus warfarin in general and after polypectomy: a population-based study with propensity score matching analysis.
Intestinal research · 2022-10 · Pae JY, Kim ES, Kim SK 외 4
Severe hypoglycemia and risk of hospitalization for heart failure in adults with diabetes treated with oral medications with or without insulin: A population-based study.
Diabetes research and clinical practice · 2022-10 · Lee YB, Bae YJ, Kim H 외 7
Effects of Sodium-Glucose Cotransporter-2 Inhibitors and Thiazolidinedione on New-Onset Atrial Fibrillation Risk to Patients with Type 2 Diabetes.
Reviews in cardiovascular medicine · 2022-09 · Song H, Kim YR, Lee SE 외 4
Analysis of treatment outcomes according to the cycles of adjuvant chemotherapy in gastric cancer: a retrospective nationwide cohort study.
BMC cancer · 2022-09 · Kim TH, Ahn MS, Choi YW 외 5
Novel Esomeprazole Magnesium-Loaded Dual-Release Mini-Tablet Polycap: Formulation, Optimization, Characterization, and In Vivo Evaluation in Beagle Dogs.
Pharmaceutics · 2022-07 · Kwon TK, Kang JH, Na SB 외 4
Comparative Effects of Sodium-Glucose Cotransporter 2 Inhibitor and Thiazolidinedione Treatment on Risk of Stroke among Patients with Type 2 Diabetes Mellitus.
Diabetes & metabolism journal · 2022-07 · Lee SE, Nam H, Choi HS 외 3
Trends in Mortality from Hemorrhagic Stroke in Korea from 2012 to 2020.
Neurointervention · 2022-07 · Cho KC, Kim H, Suh SH
Calcium Supplementation, Risk of Cardiovascular Diseases, and Mortality: A Real-World Study of the Korean National Health Insurance Service Data.
Nutrients · 2022-06 · Park JM, Lee B, Kim YS 외 9
Transfusion Trends of Knee Arthroplasty in Korea: A Nationwide Study Using the Korean National Health Insurance Service Sample Data.
International journal of environmental research and public health · 2022-05 · Suh YS, Choi HS, Lee JS 외 7
Increased Risk of Cardio-Cerebrovascular Diseases in Migraine Patients: A Nationwide Population-Based, Longitudinal Follow-Up Study in South Korea.
Journal of clinical neurology (Seoul, Korea) · 2022-05 · Lee SJ, Yoon S, Bae YJ 외 3
Understanding and Utilizing Claim Data from the Korean National Health Insurance Service (NHIS) and Health Insurance Review & Assessment (HIRA) Database for Research.
Journal of lipid and atherosclerosis · 2022-05 · Kyoung DS, Kim HS
Anaerobe coverage is important for the prognosis of pyogenic liver abscess: A population-based study in Korea.
Journal of infection and public health · 2022-04 · Myeong JH, Kyoung DS, Park MA 외 4
Risk of ischaemic stroke in patients with transient global amnesia: a propensity-matched cohort study.
Stroke and vascular neurology · 2022-04 · Lee SH, Kim KY, Lee JW 외 2
Novel dapagliflozin di-L-proline cocrystal-loaded tablet: preparation, physicochemical characterization, and pharmacokinetics in beagle dogs and mini-pigs.
Pharmaceutical development and technology · 2022-03 · Cho HJ, Woo MR, Cho JH 외 2
Status of Glucocorticoid-Induced Osteoporosis Preventive Care in Korea: A Retrospective Cohort Study on the Korean National Health Insurance Service Database.
Medicina (Kaunas, Lithuania) · 2022-02 · Song BW, Kim AR, Kim MA 외 2
Annual Incidence of Dementia from 2003 to 2018 in Metropolitan Seoul, Korea: A Population-Based Study.
Journal of clinical medicine · 2022-02 · Kwon HS, Jeong YW, Kim SH 외 10
Cardiovascular and renal protective effects of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation.
PloS one · 2022-01 · Choi SH, Kim M, Kim H 외 2
A population-based study of pyogenic liver abscess in Korea: Incidence, mortality and temporal trends during 2007-2017.
Liver international : official journal of the International Association for the Study of the Liver · 2021-11 · Yoo JJ, Lee TK, Kyoung DS 외 3
Vasodilator agents improve hemodialysis vascular access patency: A population-based study from Korea.
Medicine · 2021-10 · Kim DH, Han D, Kim J 외 7
Heart Failure Statistics in Korea, 2020: A Report from the Korean Society of Heart Failure.
International journal of heart failure · 2021-10 · Park JJ, Lee CJ, Park SJ 외 10
The association of hepatic steatosis and fibrosis with heart failure and mortality.
Cardiovascular diabetology · 2021-09 · Park J, Kim G, Kim H 외 5
Target modulation and pharmacokinetics/pharmacodynamics translation of the BTK inhibitor poseltinib for model-informed phase II dose selection.
Scientific reports · 2021-09 · Byun JY, Koh YT, Jang SY 외 8
Acetaminophen and tramadol hydrochloride-loaded soft gelatin capsule: preparation, dissolution and pharmacokinetics in beagle dogs.
Pharmaceutical development and technology · 2021-06 · Cho JH, Choi HG
Body mass index change and incident asthma in adults: A nationwide cohort study.
Allergy · 2021-06 · Lee H, Choi H, Nam H 외 12
Methotrexate use does not increase the prevalence of hepatic steatosis: a real-world retrospective nested case-control study.
Clinical rheumatology · 2021-05 · Choi Y, Lee CH, Kim IH 외 3
Association between alcohol consumption status and obesity-related comorbidities in men: data from the 2016 Korean community health survey.
BMC public health · 2021-04 · Kim BY, Nam H, Yoo JJ 외 5
Effects of a DPP-4 Inhibitor and RAS Blockade on Clinical Outcomes of Patients with Diabetes and COVID-19.
Diabetes & metabolism journal · 2021-03 · Rhee SY, Lee J, Nam H 외 3
Design, synthesis and biological evaluation of new bivalent quinazoline analogues as IAP antagonists.
Bioorganic & medicinal chemistry letters · 2021-02 · Bae I, Kim D, Choi J 외 7
Treatment Modality and Risk of Heart Failure in Patients With Long-Standing Graves' Disease: A Nationwide Population-Based Cohort Study.
Frontiers in endocrinology · 2021-01 · Song E, Kim M, Park S 외 11
Synergistic Effects of BTK Inhibitor HM71224 and Methotrexate in a Collagen-induced Arthritis Rat Model.
In vivo (Athens, Greece) · 2021-01 · Choi KJ, Kim YY, Jang SY 외 4
Adverse outcomes after surgeries in patients with liver cirrhosis among Korean population: A population-based study.
PloS one · 2021-01 · Jo HH, Min C, Kyoung DS 외 12
Preparation, characterization, and pharmacological study of a novel long-acting FGF21 with a potential therapeutic effect in obesity.
Biologicals : journal of the International Association of Biological Standardization · 2021-01 · Kim D, Lee J, Bae I 외 7
Chemosensitivity to HM90822, a novel synthetic IAP antagonist, is determined by p-AKT-inducible XIAP phosphorylation in human pancreatic cancer cells.
Investigational new drugs · 2020-12 · Hong SW, Shin JS, Moon JH 외 19
Synthesis and biological evaluation of novel thienopyrimidine derivatives as diacylglycerol acyltransferase 1 (DGAT-1) inhibitors.
Journal of enzyme inhibition and medicinal chemistry · 2020-12 · Hong DJ, Jung SH, Kim J 외 4
Synthesis and biological activity of 2-cyanoacrylamide derivatives tethered to imidazopyridine as TAK1 inhibitors.
Journal of enzyme inhibition and medicinal chemistry · 2020-12 · Kang SJ, Lee JW, Song J 외 4
Cardiovascular disease burden in adult patients with cancer: An 11-year nationwide population-based cohort study.
International journal of cardiology · 2020-10 · Youn JC, Chung WB, Ezekowitz JA 외 12
Single-and repeat-dose toxicity of HM10760A, a long-acting erythropoietin, in rats and monkeys.
Toxicology and applied pharmacology · 2020-09 · Lim HK, Choi J, Kim D 외 4
Development of novel tenofovir disoproxil phosphate salt with stability enhancement and bioequivalence to the commercial tenofovir disoproxil fumarate salt in rats and beagle dogs.
International journal of pharmaceutics · 2020-02 · Cho JH, Choi HG
Comparison of Pharmacokinetics of a Fixed-Dose Combination of Amlodipine/Losartan/Rosuvastatin with Concomitant Administration of Amlodipine/Losartan and Rosuvastatin in Healthy Volunteers.
Drug design, development and therapy · 2020-01 · Yoon DY, Park SI, Jung JA 외 3
Trends in the Diagnosis of Osteoporosis in Patients with Distal Radius Fractures Based on a National Claims Database.
Journal of bone metabolism · 2019-11 · Kim DG, Seo GW, Nam HW
Pharmacokinetic and haemodynamic interactions between amlodipine and losartan in human beings.
Basic & clinical pharmacology & toxicology · 2019-10 · Park JW, Kim KA, Il Kim Y 외 1
Population-based prevalence of bronchiectasis and associated comorbidities in South Korea.
The European respiratory journal · 2019-08 · Choi H, Yang B, Nam H 외 11
Synthesis and evaluation of thieno[3,2-d]pyrimidine derivatives as novel FMS inhibitors.
Bioorganic & medicinal chemistry letters · 2019-01 · Kim YY, Choi J, Choi K 외 7
WITHDRAWN: HM47118A, a novel insulinotropic GPR119 agonist and potential oral antidiabetic agent.
Diabetes research and clinical practice · 2019-01 · Song TH, Lee SD, Ha YE 외 5
Humanized Anti-hepatocyte Growth Factor Monoclonal Antibody (YYB-101) Inhibits Ovarian Cancer Progression.
Frontiers in oncology · 2019-01 · Kim HJ, Lee S, Oh YS 외 9
Phase 1 Studies of Poziotinib, an Irreversible Pan-HER Tyrosine Kinase Inhibitor in Patients with Advanced Solid Tumors.
Cancer research and treatment · 2018-07 · Kim TM, Lee KW, Oh DY 외 10
Formulation of novel dry powder inhalation for fluticasone propionate and salmeterol xinafoate with capsule-based device.
Pharmaceutical development and technology · 2018-02 · Kim KS, Kim JH, Jin SG 외 7
Transcriptomic features of primary prostate cancer and their prognostic relevance to castration-resistant prostate cancer.
Oncotarget · 2017-12 · Yun SJ, Kim SK, Kim J 외 14
HM71224, a selective Bruton's tyrosine kinase inhibitor, attenuates the development of murine lupus.
Arthritis research & therapy · 2017-09 · Kim YY, Park KT, Jang SY 외 6
Novel dabigatran etexilate hemisuccinate-loaded polycap: Physicochemical characterisation and in vivo evaluation in beagle dogs.
International journal of pharmaceutics · 2017-06 · Cho JH, Kim JC, Kim HS 외 9
Association of genetic variations with pharmacokinetics and lipid-lowering response to atorvastatin in healthy Korean subjects.
Drug design, development and therapy · 2017-01 · Woo HI, Kim SR, Huh W 외 2
Development of novel prasugrel base microsphere-loaded tablet with enhanced stability: Physicochemical characterization and in vivo evaluation in beagle dogs.
Colloids and surfaces. B, Biointerfaces · 2016-10 · Kim KS, Kim JC, Jin SG 외 8
(p40)2-Fc reduces immune-inflammatory response through the activation of T cells in collagen induced arthritis mice.
Immunology letters · 2016-08 · Lee SY, Lee SH, Park SJ 외 8
Effect of HM30181 mesylate salt-loaded microcapsules on the oral absorption of paclitaxel as a novel P-glycoprotein inhibitor.
International journal of pharmaceutics · 2016-06 · Kim JC, Kim KS, Kim DS 외 9
Novel montelukast sodium-loaded stable oral suspension bioequivalent to the commercial granules in rats.
Archives of pharmacal research · 2016-04 · Kim DW, Kim YH, Yousaf AM 외 13
HM71224, a novel Bruton's tyrosine kinase inhibitor, suppresses B cell and monocyte activation and ameliorates arthritis in a mouse model: a potential drug for rheumatoid arthritis.
Arthritis research & therapy · 2016-04 · Park JK, Byun JY, Park JA 외 10
Effect of magnesium carbonate on the solubility, dissolution and oral bioavailability of fenofibric acid powder as an alkalising solubilizer.
Archives of pharmacal research · 2016-04 · Kim KS, Kim JH, Jin SG 외 8
Preparation and evaluation of enteric-coated delayed-release pellets of duloxetine hydrochloride using a fluidized bed coater.
Archives of pharmacal research · 2015-12 · Kim YI, Pradhan R, Paudel BK 외 3
Development of a novel bi-coated combination capsule containing mosapride and probiotics for irritable bowel syndrome.
Pharmaceutical development and technology · 2015-12 · Kim YI, Poudel BK, Pradhan R 외 4
Novel fenofibric acid-loaded controlled release pellet bioequivalent to choline fenofibrate-loaded commercial product in beagle dogs.
International journal of pharmaceutics · 2015-07 · Kim KS, Jin SG, Mustapha O 외 7
Enhanced oral bioavailability of paclitaxel by solid dispersion granulation.
Drug development and industrial pharmacy · 2015-01 · Shanmugam S, Im HT, Sohn YT 외 4
Granulation techniques and technologies: recent progresses.
BioImpacts : BI · 2015-01 · Shanmugam S
A novel antagonist to the inhibitors of apoptosis (IAPs) potentiates cell death in EGFR-overexpressing non-small-cell lung cancer cells.
Cell death & disease · 2014-10 · Lee SH, Lee JY, Jung CL 외 7
Discovery of novel pyrimidine and malonamide derivatives as TGR5 agonists.
Bioorganic & medicinal chemistry letters · 2014-09 · Park EJ, Ahn YG, Jung SH 외 10
Sildenafil vaginal suppositories: preparation, characterization, in vitro and in vivo evaluation.
Drug development and industrial pharmacy · 2014-06 · Shanmugam S, Kim YH, Park JH 외 8
Development of novel fast-dissolving tacrolimus solid dispersion-loaded prolonged release tablet.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2014-04 · Cho JH, Kim YI, Kim DW 외 5
Purification and biocompatibility of fermented hyaluronic acid for its applications to biomaterials.
Biomaterials research · 2014-01 · Choi S, Choi W, Kim S 외 3
Zanamivir oral delivery: enhanced plasma and lung bioavailability in rats.
Biomolecules & therapeutics · 2013-03 · Shanmugam S, Im HT, Sohn YT 외 6
Preparation and evaluation of bicyclol microemulsions for enhanced oral bioavailability.
Drug development and industrial pharmacy · 2012-11 · Ryu JK, Yoo SD
Cobalt(III)-induced hexamerization of PEGylated insulin.
International journal of biological macromolecules · 2011-11 · Lim SI, Jang MH, Kim DJ 외 2
Enhanced bioavailability and retinal accumulation of lutein from self-emulsifying phospholipid suspension (SEPS).
International journal of pharmaceutics · 2011-06 · Shanmugam S, Park JH, Kim KS 외 4
Physicochemical stability, pharmacokinetic, and biodistribution evaluation of paclitaxel solid dispersion prepared using supercritical antisolvent process.
Drug development and industrial pharmacy · 2011-06 · Shanmugam S, Park JH, Chi SC 외 3
Preparation and evaluation of Cremophor-free paclitaxel solid dispersion by a supercritical antisolvent process.
The Journal of pharmacy and pharmacology · 2011-04 · Park JH, Yan YD, Chi SC 외 6
Antitumor efficacy of solid dispersion of paclitaxel prepared by supercritical antisolvent process in human mammary tumor xenografts.
International journal of pharmaceutics · 2011-01 · Shanmugam S, Park JH, Chi SC 외 3
Genotoxicity studies on HM10760A, recombinant human erythropoietin conjugated to globin fragment.
Drug and chemical toxicology · 2010-04 · Kwon SC, Lee GS, Han JY 외 4
Reduced food-effect and enhanced bioavailability of a self-microemulsifying formulation of itraconazole in healthy volunteers.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2008-02 · Woo JS, Song YK, Hong JY 외 2
Nasal absorption studies of granisetron in rats using a validated high-performance liquid chromatographic method with mass spectrometric detection.
Archives of pharmacal research · 2007-06 · Woo JS
Formulation and biopharmaceutical evaluation of silymarin using SMEDDS.
Archives of pharmacal research · 2007-01 · Woo JS, Kim TS, Park JH 외 1
Quantitative determination of voglibose in pharmaceutical tablets using high-performance liquid chromatography-fluorescence detection with post-column derivatization and mass spectrometric detection.
Journal of pharmaceutical and biomedical analysis · 2006-09 · Woo JS, Ryu JK

Patents

KIPRIS · applicant-matched

수불용성 중합체를 이용해 복용 편의성을 개선한 위식도 역류질환 치료제
Published · 2025-12 · Application 1020250208062
GLP-1 유사체를 포함하는 경구투여용 리포솜 조성물 및 이의 제조방법
Published · 2025-12 · Application 1020250202729
POSELTINIB COMBINATION THERAPY FOR PREVENTION OR TREATMENT OF LYMPHOMA
PCT · Published · 2025-11 · Application PCT/KR2025/019685
림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법
Published · 2025-11 · Application 1020250181306
암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 CTLA-4 길항제의 병용 요법
Published · 2025-10 · Application 1020250162148
YAP-TEAD 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
Registered · 2025-10 · Application 1020250158919
PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE
US · Published · 2025-10 · Application 19368909
GLP-1 receptor agonist and uses thereof
TW · Published · 2025-09 · Application 114134904
GLP-1 수용체 작용제 및 이의 용도
Published · 2025-09 · Application 1020250130180
PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING METFORMIN AND EMPAGLIFLOZIN WITH IMPROVED DISSOLUTION RATE AND PRODUCTIVITY
PCT · Published · 2025-07 · Application PCT/KR2025/011331

Show 817 more patents

신규한 이종이작용기 단백질 분해제 및 이의 용도
Published · 2025-06 · Application 1020250086286
Novel heterobifunctional protein degraders and pharmaceutical composition comprising the same
TW · Published · 2025-06 · Application 114124203
Triple GLP-1/GIP/glucagon receptor agonist and pharmaceutical composition comprising same for preventing or treating lipid metabolism diseases
TW · Published · 2025-06 · Application 114122309
Triple GLP-1/GIP/glucagon receptor agonist and pharmaceutical composition comprising same for preventing or treating kidney diseases
TW · Published · 2025-06 · Application 114122311
Triple GLP-1/GIP/glucagon receptor agonist and pharmaceutical composition comprising same for preventing or treating cardiovascular diseases
TW · Published · 2025-06 · Application 114122314
Triple GLP-1/GIP/glucagon receptor agonist and pharmaceutical composition comprising same for preventing or treating diabetes
TW · Published · 2025-06 · Application 114122313
ORALLY DISINTEGRATING TABLET COMPRISING PREGABALIN OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
PCT · Published · 2025-06 · Application PCT/KR2025/008123
TRIPLE ACTIVATOR HAVING ACTIVITY ON ALL OF GLP-1, GIP, AND GLUCAGON RECEPTORS, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LIPID METABOLIC DISEASES COMPRISING SAME
PCT · Published · 2025-06 · Application PCT/KR2025/008179
GLP-1, GIP, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 신장 질환의 예방 또는 치료용 약학적 조성물
Published · 2025-06 · Application 1020250077974
GLP-1, GIP, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 심혈관계 질환 예방 또는 치료용 약학적 조성물
Published · 2025-06 · Application 1020250077976
GLP-1, GIP, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 당뇨 예방 또는 치료용 약학적 조성물
Published · 2025-06 · Application 1020250077975
GLP-1, GIP, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 지질 대사 질환 예방 또는 치료용 약학적 조성물
Published · 2025-06 · Application 1020250077973
NOVEL METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
US · Published · 2025-06 · Application 19236607
림프종의 예방 또는 치료를 위한 포셀티닙의 병용투여 요법
Published · 2025-06 · Application 1020250072335
Novel sulfamide camptothecin derivatives with antitumor activity and pharmaceutical composition comprising the same
TW · Published · 2025-05 · Application 114120035
항종양 활성을 지니는 신규한 설파마이드 캄토테신 유도체
Published · 2025-05 · Application 1020250069698
Combination preparation containing ezetimibe, rosuvastatin and empagliflozin with improved medication adherence
TW · Published · 2025-05 · Application 114117249
METHODS OF TREATING NEUTORPENIA USING G-CSF PROTEIN COMPLEX
US · Published · 2025-05 · Application 19199879
Peptide, peptide-fatty acid conjugate, and pharmaceutical composition
TW · Published · 2025-04 · Application 114116094
USE OF CRF2 RECEPTOR AGONIST AND ACYLATED CONJUGATE THEREOF
PCT · Published · 2025-04 · Application PCT/KR2025/005692
CRF2 수용체 작용제와 그 아실화 결합체의 용도
Rejected · 2025-04 · Application 1020250055456
흡입제 조성물
Published · 2025-04 · Application 1020250049591
Inhalable composition
TW · Published · 2025-04 · Application 114114419
INHALATION COMPOSITION
PCT · Published · 2025-04 · Application PCT/KR2025/005186
Antigen peptide with multiple KRAS variant peptides linked, nucleic acid encoding the same, and use thereof
TW · Published · 2025-03 · Application 114111907
복수 KRAS 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
Published · 2025-03 · Application 1020250040213
퓨로피리미딘 화합물의 산 부가염의 결정형
Published · 2025-03 · Application 1020250038234
복약편의성이 개선된 두타스테리드 및 탐스로신을 포함하는 경구용 복합제제
Published · 2025-03 · Application 1020250027512
지속형 GLP-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도
Published · 2025-01 · Application 1020250011523
흡입제 조성물
Published · 2024-12 · Application 1020240197596
Composition for inhalation
TW · Published · 2024-12 · Application 113150975
EP300 단백질 분해제 및 이의 용도
Published · 2024-12 · Application 1020240192521
Pharmaceutical composition comprising efpeglenatide and its dosing regimens
TW · Published · 2024-12 · Application 113149689
리나글립틴, 엠파글리플로진 및 메트포르민을 포함하는 약제학적 복합제제
Published · 2024-12 · Application 1020240188090
사쿠비트릴-발사르탄 및 SGLT-2 억제제를 포함하는 복합제제
Published · 2024-12 · Application 1020240183802
빠른 흡수를 위한 입도가 관리된 바리시티닙을 포함하는 경구투여용 제제
Published · 2024-12 · Application 1020240180448
세마글루타이드 함유 마이크로니들 어레이 및 이의 제조방법
Published · 2024-11 · Application 1020240168446
단백질 및 펩타이드의 면역원성을 감소시키는 방법
Withdrawn · 2024-10 · Application 1020240148791
비천연 3'비번역 영역 및 그의 용도
Published · 2024-09 · Application 1020240132001
Nucleic acid molecules comprising modified polyadenylic acid sequences
CN · Published · 2024-09 · Application 202480061559.7
Non-natural 5apos; untranslated regions and applications thereof
CN · Published · 2024-09 · Application 202480060276.0
A non-natural 3apos; untranslated regions and applications thereof
CN · Published · 2024-09 · Application 202480060262.9
Pharmaceutical composition for preventing or treating cancer comprising nucleic acid construct-encoding p53 protein
CN · Published · 2024-09 · Application 202480060370.6
Messenger RNA including non-natural 5` untranslated region, DNA encoding the same, and composition including the same
TW · Published · 2024-09 · Application 113136817
Messenger RNA including non-natural 3` untranslated region, DNA encoding the same, and composition including the same
TW · Published · 2024-09 · Application 113136805
Messenger rna and pharmaceutical composition for preventing or treating cancer including the same, deoxyribonucleic acid construct encoding the same, and method for preventing or treating cancer
TW · Published · 2024-09 · Application 113136829
Subsidiary: 한미정밀화학MRNA cap analog and use thereof
TW · Published · 2024-09 · Application 113137110
NON-NATURAL 3` UNTRANSLATED REGION AND USE THEREOF
EP · Published · 2024-09 · Application 24873041.8
NON-NATURAL 5`UNTRANSLATED REGION AND USE THEREOF
EP · Published · 2024-09 · Application 24873040.0
Subsidiary: 한미정밀화학mRNA 캡 유사체 및 이의 용도
Published · 2024-09 · Application 1020240132004
Subsidiary: 한미정밀화학MRNA CAP ANALOG AND USE THEREOF
EP · Published · 2024-09 · Application 24873066.5
Subsidiary: 한미정밀화학MRNA CAP ANALOG AND USE THEREOF
PCT · Published · 2024-09 · Application PCT/KR2024/014788
비천연 5'비번역 영역 및 그의 용도
Published · 2024-09 · Application 1020240132000
p53 단백질을 코딩하는 핵산 구조체를 포함하는 암의 예방 또는 치료용 약학적 조성물
Published · 2024-09 · Application 1020240132003
Novel skeletal derivatives effective for HER2 mutations and pharmaceutical compositions comprising same
CN · Published · 2024-09 · Application 202480060472.8
Novel scaffold derivatives effective for HER2 alterations and pharmaceutical composition comprising the same
TW · Published · 2024-09 · Application 113135635
HER2 변이에 유효한 신규 골격 유도체와 이를 포함하는 약학적 조성물
Published · 2024-09 · Application 1020240127278
Novel lyophilized preparation containing alpha-galactosidase A fusion protein
CN · Published · 2024-09 · Application 202480057808.5
Novel lyophilized formulation containing [alpha]-galactosidase A fusion protein
TW · Published · 2024-09 · Application 113133924
α-갈락토시다제 A의 융합단백질을 포함하는 신규한 동결 건조 제제
Published · 2024-09 · Application 1020240121740
용출률 및 생산성이 개선된 메트포르민 및 엠파글리플로진을 포함하는 약제학적 복합 제제
Published · 2024-07 · Application 1020240100858
Novel phthalazine derivative compounds as SOS1 inhibitors and uses thereof
CN · Published · 2024-06 · Application 202480062103.2
SOS1 억제제로서의 신규한 프탈라진 유도체 화합물 및 이의 용도
Published · 2024-06 · Application 1020240085424
신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법
Published · 2024-06 · Application 1020240077657
프레가발린 또는 이의 약학적으로 허용가능한 염을 포함하는 구강붕해정
Published · 2024-06 · Application 1020240077587
엠파글리플로진 및 메트포르민을 포함하는 약제학적 복합제제
Published · 2024-05 · Application 1020240071412
골수성 키놈 억제제의 고체 분산물 및 그를 포함하는 제약 조성물
Published · 2024-05 · Application 1020257043684
지용성 서방화제를 이용해 생산성 개선과 용출률을 확보한 서방성 당뇨병 치료제
Published · 2024-05 · Application 1020240065451
서방성 고분자를 이용해 복용 편의성을 개선한 당뇨병 치료제
Published · 2024-05 · Application 1020240065464
복약순응도가 개선된 에제티미브, 로수바스타틴 및 엠파글리플로진을 포함하는 복합제제
Published · 2024-05 · Application 1020240060726
Combination formulation comprising sacubitril-valsartan and SGLT-2 inhibitor with improved stability and dissolution
CN · Published · 2024-04 · Application 202480024528.4
개선된 안정성과 용출률이 확보된 사쿠비트릴-발사르탄 및 SGLT-2 억제제를 포함하는 복합제제
Published · 2024-04 · Application 1020240046246
아비라테론 아세테이트 및 프레드니솔론을 포함하는 약제학적 제제 및 이의 제조방법
Published · 2024-03 · Application 1020240040799
인터루킨 2 아날로그 또는 이의 결합체를 포함하는 암의 예방 또는 치료용 약학적 조성물
Published · 2024-03 · Application 1020240032671
암의 예방 또는 치료를 위한 인터루킨 2 아날로그 또는 이의 결합체 및 면역관문 억제제의 병용 요법
Published · 2024-03 · Application 1020240032672
Combination therapy of interleukin-2 (IL-2) analogs or conjugates thereof with immune checkpoint inhibitors for prevention or treatment of cancer
CN · Published · 2024-03 · Application 202480017209.0
PHARMACEUTICAL COMPOSITION COMPRISING INTERLEUKIN-2 (IL-2) ANALOG OR CONJUGATE THEREOF FOR PREVENTING OR TREATING CANCER
CN · Published · 2024-03 · Application 202480017267.3
A combination therapy of IL-2 analog or conjugate thereof and immune checkpoint inhibitor for preventing or treating cancer
TW · Published · 2024-03 · Application 113108372
A pharmaceutical composition for preventing or treating cancer comprising IL-2 analog or conjugate thereof
TW · Published · 2024-03 · Application 113108370
COMBINATION THERAPY OF INTERLEUKIN-2 (IL-2) ANALOG OR CONJUGATE THEREOF AND IMMUNE CHECKPOINT INHIBITOR FOR PREVENTING OR TREATING CANCER
US · Published · 2024-03 · Application 19161476
COMBINATION THERAPY OF INTERLEUKIN-2 ANALOG OR CONJUGATE THEREOF AND IMMUNE CHECKPOINT INHIBITOR FOR PREVENTION OR TREATMENT OF CANCER
EP · Published · 2024-03 · Application 24767431.0
COMBINATION THERAPY OF INTERLEUKIN-2 ANALOG OR CONJUGATE THEREOF AND IMMUNE CHECKPOINT INHIBITOR FOR PREVENTION OR TREATMENT OF CANCER
PCT · Published · 2024-03 · Application PCT/KR2024/002946
신규한 함질소 헤테로고리 유도체 및 이의 용도
Published · 2024-02 · Application 1020240018246
글루카곤 유사 펩타이드-2(GLP-2) 유도체의 지속형 결합체
Registered · 2024-01 · Application 1020240009740
복수 KRAS 변이 펩티드가 연결된 항원 펩티드, 이를 코딩하는 핵산 및 이의 용도
Published · 2023-12 · Application 1020230190347
신규한 GLP-1, GIP, 및 글루카곤 수용체 모두에 활성을 갖는 삼중 활성체 및 이를 포함하는 비만의 예방 또는 치료용 약학적 조성물
Registered · 2023-12 · Application 1020230189789
Formulations comprising immunocompetent interleukin 2 analogue conjugates
CN · Published · 2023-12 · Application 202380088393.3
Antigen peptide formed by connecting multiple KRAS variant peptides, nucleic acid for coding antigen peptide and application of antigen peptide
CN · Published · 2023-12 · Application 202380088403.3
Novel triple GLP-1/GIP/glucagon receptor agonist and pharmaceutical composition for preventing or treating obesity comprising same
CN · Published · 2023-12 · Application 202380088014.0
Pharmaceutical composition for preventing or treating graft versus host disease containing GLP-2 derivative or long-acting conjugate thereof
CN · Published · 2023-12 · Application 202380088553.4
Novel triple GLP-1/GIP/glucagon receptor agonist and a pharmaceutical composition for preventing or treating obesity comprising the same
TW · Published · 2023-12 · Application 112150412
NOVEL TRIPLE GLP-1/GIP/GLUCAGON RECEPTOR AGONIST AND A PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING OBESITY COMPRISING THE SAME
US · Published · 2023-12 · Application 19141765
FORMULATIONS COMPRISING IMMUNE STIMULATING IL-2 ANALOG CONJUGATES
US · Published · 2023-12 · Application 19142326
ANTIGENIC PEPTIDE HAVING MULTIPLE KRAS VARIANT PEPTIDES LINKED THERETO, NUCLEIC ACID ENCODING THE SAME, AND USE THEREOF
PCT · Published · 2023-12 · Application PCT/KR2023/021488
GLP-2 유도체 또는 이의 지속형 결합체를 포함하는 이식편대숙주질환의 예방 또는 치료용 약학적 조성물
Published · 2023-12 · Application 1020230190239
면역 활성 인터루킨 2 아날로그 결합체를 포함하는 제제
Published · 2023-12 · Application 1020230189788
YAP-TEAD 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
Published · 2023-12 · Application 1020230188647
에페글레나타이드를 유효성분으로 포함하는 약학 조성물 및 이의 투여 요법
Rejected · 2023-12 · Application 1020230186003
Methods for treating patients with hematological malignancies
CN · Published · 2023-12 · Application 202380089213.3
혈액암 환자를 치료하기 위한 방법
Published · 2023-12 · Application 1020257023139
Novel crystalline forms of pyrimidine compounds and pharmaceutical compositions comprising same and methods of using same
CN · Published · 2023-11 · Application 202380083828.5
NOVEL CRYSTALLINE FORM OF A PYRIMIDINE COMPOUND AND PHARMACEUTICAL COMPOSITIONS COMPRISING THE SAME AND METHODS OF USE THEREOF
PCT · Published · 2023-11 · Application PCT/KR2023/017598
피리미딘 화합물의 신규한 결정질 형태 및 이를 포함하는 약학적 조성물 및 이의 사용 방법
Published · 2023-11 · Application 1020257015937
신규한 GLP-1 수용체 길항제 및 이를 포함하는 선천성 고인슐린증 또는 저혈당증의 예방 또는 치료용 약학적 조성물
Published · 2023-10 · Application 1020230137057
Novel pyrimidine derivatives as bruton's tyrosine kinase inhibitors
CN · Published · 2023-10 · Application 202380083102.1
NOVEL GLP-1 RECEPTOR ANTAGONIST AND PHARMACEUTICAL COMPOSITION COMPRISING SAME FOR PREVENTING OR TREATING CONGENERATIVE HIGH INSULINEmia OR
CN · Published · 2023-10 · Application 202380083807.3
Novel pyrimidine derivative as Bruton`s tyrosine kinase inhibitor
TW · Published · 2023-10 · Application 112139223
브루톤 티로신 키나제 저해 활성을 갖는 신규 피리미딘 유도체
Published · 2023-10 · Application 1020230136978
Novel hetero-bicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising same
CN · Published · 2023-10 · Application 202380072183.5
Novel tricyclic derivative compounds and uses thereof
CN · Published · 2023-10 · Application 202380071687.5
Novel heterobicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising same
TW · Published · 2023-10 · Application 112138969
Novel heterobicyclic compound for inhibiting YAP-TEAD interaction and pharmaceutical composition comprising same
TW · Published · 2023-10 · Application 112138968
Novel tricycle derivative compounds and uses thereof
TW · Published · 2023-10 · Application 112138856
NOVEL TRICYCLIC DERIVATIVE COMPOUND AND USES THEREOF
PCT · Published · 2023-10 · Application PCT/KR2023/015752
YAP-TEAD 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
Published · 2023-10 · Application 1020230135954
YAP-TEAD 상호작용 억제를 위한 신규한 헤테로비시클릭 화합물 및 이를 포함하는 약학적 조성물
Published · 2023-10 · Application 1020230135956
신규한 트리사이클 유도체 화합물 및 이의 용도
Published · 2023-10 · Application 1020230135955
신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
Registered · 2023-10 · Application 1020230131722
변형된 폴리아데닐 서열 및 OX40L 단백질 코딩서열을 포함하는 핵산 분자
Published · 2023-09 · Application 1020230130731
변형된 폴리아데닐 서열 및 p53 단백질 코딩서열을 포함하는 핵산 분자
Published · 2023-09 · Application 1020230130730
Novel tricyclic heterocyclic aldehyde compound and pharmaceutical composition for inhibiting IRE1 alpha comprising same
CN · Published · 2023-09 · Application 202380069973.8
변형된 폴리아데닐 서열을 포함하는 핵산 분자
Published · 2023-09 · Application 1020230130729
신규한 삼환식 헤테로고리 카바알데히드 화합물 및 이를 포함하는 IRE1α 저해를 위한 약학적 조성물
Published · 2023-09 · Application 1020230130734
아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
Published · 2023-09 · Application 1020230128006
아비라테론 아세테이트 및 프레드니솔론을 포함하는 경구용 복합정제
Registered · 2023-08 · Application 1020230114821
신규한 면역 활성 인터루킨 2 아날로그
Registered · 2023-06 · Application 1020230074093
지속형 GLP-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도
Registered · 2023-06 · Application 1020230072287
Methods of treating neutorpenia using G-CSF protein complex
US · Registered · 2023-05 · Application 18318492
Combination therapy of GLP-2 with insulinotropic peptide, TNF alpha inhibitor or both for preventing or treating bowel disease
CN · Published · 2023-04 · Application 202380045504.2
COMBINATION THERAPY COMPRISING GLP-2, AND INSULINOTROPIC PEPTIDE, TNFa INHIBITOR, OR BOTH FOR PREVENTING OR TREATING BOWEL DISEASE
US · Published · 2023-04 · Application 18857479
COMBINATION THERAPY OF GLP-2 WITH INSULINOTROPIC PEPTIDE, TNF? INHIBITOR OR BOTH FOR PREVENTING OR TREATING INTESTINAL DISEASES
EP · Published · 2023-04 · Application 23792132.5
장질환의 예방 또는 치료를 위한 GLP-2와, 인슐린 분비 펩타이드, TNFα 억제제, 또는 이 둘 모두의 병용 요법
Published · 2023-04 · Application 1020230050914
Liquid formulations comprising alpha-galactosidase A-containing fusion proteins
CN · Published · 2023-03 · Application 202380022935.7
Subsidiary: 한미정밀화학MRNA cap analogs and uses thereof
CN · Published · 2023-03 · Application 202380032262.3
Methods of treating neutorpenia using G-CSF protein complex
US · Registered · 2023-03 · Application 18181852
Subsidiary: 한미정밀화학MRNA cap analog and uses thereof
US · Registered · 2023-03 · Application 18852777
Subsidiary: 한미정밀화학mRNA 캡 유사체 및 이의 용도
Registered · 2023-03 · Application 1020230031991
Subsidiary: 한미정밀화학MRNA CAP ANALOG AND USES THEREOF
EP · Published · 2023-03 · Application 23781199.7
LIQUID FORMULATION COMPRISING A FUSION PROTEIN INCLUDING α-GALACTOSIDASE A
PCT · Published · 2023-03 · Application PCT/KR2023/003299
LYOPHILIZED FORMULATION COMPRISING A FUSION PROTEIN INCLUDING α-GALACTOSIDASE A
PCT · Published · 2023-03 · Application PCT/KR2023/003300
Subsidiary: 한미정밀화학MRNA CAP ANALOG AND USES THEREOF
PCT · Published · 2023-03 · Application PCT/KR2023/003327
단백질 및 펩타이드의 면역원성을 감소시키는 방법
Rejected · 2023-02 · Application 1020230014950
Pharmaceutical composition comprising acetylsalicylic acid and proton pump inhibitor
CN · Published · 2023-01 · Application 202380034892.4
마이크로니들 어레이 및 이의 제조방법
Published · 2022-12 · Application 1020220182573
쿠에티아핀을 포함하는 약제학적 조성물
Rejected · 2022-12 · Application 1020220178195
코로나바이러스 백신
Published · 2022-12 · Application 1020220174990
THERAPEUTICALLY EFFECTIVE COMBINATION OF A FLT3 INHIBITOR AND A BCL-2 INHIBITOR FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA
PCT · Published · 2022-10 · Application PCT/KR2022/016095
용해성 마이크로니들 어레이 및 이의 제조방법
Published · 2022-10 · Application 1020220128715
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
Registered · 2022-10 · Application 1020220128883
PIKfyve 키나아제 억제제
Published · 2022-09 · Application 1020220125748
Subsidiary: 한미정밀화학MRNA cap analogs and uses thereof
CN · Published · 2022-08 · Application 202280059081.5
Subsidiary: 한미정밀화학mRNA CAP ANALOGUE AND USE THEREOF
US · Published · 2022-08 · Application 18687771
Subsidiary: 한미정밀화학mRNA 캡 유사체와 및 이의 용도
Registered · 2022-08 · Application 1020220110267
Subsidiary: 한미정밀화학MRNA CAP ANALOGUE AND USE THEREOF
EP · Published · 2022-08 · Application 22865053.7
Subsidiary: 한미정밀화학MRNA CAP ANALOGUE AND USE THEREOF
PCT · Published · 2022-08 · Application PCT/KR2022/013062
IMMUNOGLOBULIN FC CONJUGATE WHICH MAINTAINS BINDING AFFINITY OF IMMUNOGLOBULIN FC FRAGMENT TO FCRN
US · Published · 2022-08 · Application 17880358
아세틸살리실산 및 프로톤 펌프 저해제를 포함하는 약학적 조성물
Registered · 2022-07 · Application 1020220088943
Subsidiary: 한미정밀화학캡 유사체 및 이의 용도
Withdrawn · 2022-07 · Application 1020220087527
아비라테론 아세테이트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 약제학적 조성물
Published · 2022-07 · Application 1020220087639
마이크로니들용 조성물, 마이크로니들 어레이 및 이를 포함하는 경피 패치
Registered · 2022-07 · Application 1020220083027
비천연 5'-비번역 영역 및 3'-비번역 영역 및 그의 용도
Published · 2022-06 · Application 1020220077707
신규 치료학적 효소 융합단백질 및 이의 용도
Registered · 2022-06 · Application 1020220076363
지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
Registered · 2022-04 · Application 1020220046925
글루카곤 유도체를 포함하는 만성 신장 질환 예방 또는 치료용 약학 조성물
Published · 2022-04 · Application 1020220044574
RAF 억제제와 PD-1 축 억제제를 사용한 병용 요법
Published · 2022-04 · Application 1020237038183
COMBINATION THERAPY WITH A RAF INHIBITOR AND A PD-1 AXIS INHIBITOR
PCT · Published · 2022-04 · Application PCT/US2022/023775
벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법
Published · 2022-04 · Application 1020237036682
신규한 면역 활성 인터루킨 2 아날로그 결합체 및 이의 제조 방법
Registered · 2022-03 · Application 1020220040626
Novel conjugate of immune stimulating il-2 analog and a preparation method thereof
TW · Registered · 2022-03 · Application 111112574
마이크로니들 어레이 및 이의 제조방법
Registered · 2022-03 · Application 1020220040642
저점도 점안 조성물의 제조방법
Registered · 2022-03 · Application 1020220039613
면역반응이 약화된 결합체
Rejected · 2022-03 · Application 1020220036034
면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
Rejected · 2022-03 · Application 1020220035314
α-갈락토시다제 A의 융합단백질을 포함하는 액상 제제
Published · 2022-03 · Application 1020220032090
α-갈락토시다제 A의 융합단백질을 포함하는 동결 건조 제제
Published · 2022-03 · Application 1020220032091
BELVARAFENIB FOR USE IN TREATMENT OF BRAIN CANCERS
PCT · Published · 2022-03 · Application PCT/US2022/019273
뇌암 치료에 이용하기 위한 벨바라페닙
Published · 2022-03 · Application 1020237033790
GIP 유도체 또는 이의 지속형 결합체를 포함하는 폐질환의 예방 또는 치료용 약학적 조성물
Withdrawn · 2022-01 · Application 1020220012583
Liquid formulations of protein and methods of preparing the same
TW · Registered · 2022-01 · Application 111103421
바레니클린 옥살산염을 포함하는 안정성이 개선된 약제학적 제제
Published · 2022-01 · Application 1020220002165
프로톤 펌프 저해제 및 제산제를 포함하는 경구용 복합정제의 제조방법 및 이에 의해 제조된 경구용 복합정제
Rejected · 2021-12 · Application 1020210186751
Novel trigonal glucagon/glp-1/gip receptor agonist and use thereof
TW · Registered · 2021-12 · Application 110148701
COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME
US · Published · 2021-12 · Application 18269134
COMBINATION THERAPY OF INSULINOTROPIC PEPTIDE AND GLP-2, FOR PREVENTING OR TREATING SHORT BOWEL SYNDROME
EP · Published · 2021-12 · Application 21911617.5
타크로리무스를 포함하는 안정성이 개선된 약제학적 조성물
Published · 2021-12 · Application 1020210187066
신규한 글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중활성체 및 이의 용도
Published · 2021-12 · Application 1020210187212
GLP-1 유사체를 함유하는 경구 투여 제형 조성물
Published · 2021-12 · Application 1020210187101
단장증후군의 예방 또는 치료를 위한 인슐린 분비 펩타이드 및 GLP-2의 병용 요법
Published · 2021-12 · Application 1020210187452
신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
Published · 2021-12 · Application 1020210185260
간 표적 물질 및 이의 용도
Rejected · 2021-12 · Application 1020210185351
간 표적 약물 및 이의 용도
Rejected · 2021-12 · Application 1020210185350
SOS1 억제제로서의 신규한 퀴나졸린 유도체 화합물 및 이의 용도
Published · 2021-12 · Application 1020210179103
신규한 아디포넥틴 아날로그 및 결합체
Published · 2021-12 · Application 1020210175141
Subsidiary: 한미정밀화학정제된 로사탄 칼륨의 제조방법
Withdrawn · 2021-11 · Application 1020210169514
치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신경병증 예방 및 치료 용도
Published · 2021-11 · Application 1020210156862
치료학적 효소 융합단백질의 파브리병에 기인하거나 동반되는 신장질환 예방 및 치료 용도
Published · 2021-11 · Application 1020210156861
Pharmaceutical composition comprising FLT3 inhibitor for the treatment of myeloid leukemia
TW · Published · 2021-11 · Application 110141175
FLT3 억제제를 포함하는 백혈병 치료용 약학적 조성물
Published · 2021-11 · Application 1020210149894
Pharmaceutical compositions comprising FLT3 inhibitors for treatment of myeloid leukemia
CN · Published · 2021-11 · Application 202180084028.6
급성 골수성 백혈병의 치료를 위한 FLT3 저해제와 Bcl-2 저해제의 치료 유효적 조합
Published · 2021-10 · Application 1020210140237
메트포르민, 리나글립틴 및 메글루민을 포함하는 약제학적 복합제제
Published · 2021-10 · Application 1020210139537
약물 방출 속도가 개선된 니세르골린을 함유하는 약제학적 조성물 및 이의 제조 방법
Published · 2021-10 · Application 1020210139580
Use of triangular agonist having activity on all glucagon, GLP-1 and GIP receptors for treating sequelae after respiratory infectious disease
CN · Published · 2021-10 · Application 202180077958.9
Trigonal glucagon/GLP-1/GIP receptor agonist for use in the treatment of sequelae of respiratory infection
TW · Published · 2021-10 · Application 110138562
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES COMPRISING GIP DERIVATIVE OR LONG-ACTING CONJUGATE THEREOF
US · Published · 2021-10 · Application 18031781
PHARMACEUTICAL COMPOSITION COMPRISING GLUCAGON/GLP-1/GIP TRIPLE AGONIST OR LONG-ACTING CONJUGATE THEREOF FOR PREVENTING OR TREATING LUPUS-RELATED DISEASES
EP · Registered · 2021-10 · Application 21880635.4
글루카곤/GLP-1/GIP 삼중작용제 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
Published · 2021-10 · Application 1020210138604
글루카곤/GLP-1/GIP 삼중작용제 또는 이의 지속형 결합체를 포함하는 혈관염 예방 또는 치료용 약학적 조성물
Published · 2021-10 · Application 1020210138603
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 호흡기 감염 질환의 후유증의 치료 용도
Published · 2021-10 · Application 1020210138700
GIP 유도체, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
Published · 2021-10 · Application 1020210138600
GLP-1/GIP 이중작용제, 이의 지속형 결합체, 및 이를 포함하는 약학적 조성물
Published · 2021-10 · Application 1020210138602
GIP 유도체 또는 이의 지속형 결합체를 포함하는 루푸스-관련 질환의 예방 또는 치료용 약학적 조성물
Withdrawn · 2021-10 · Application 1020210138601
옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
Registered · 2021-09 · Application 1020210129977
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 골 질환에 대한 예방 또는 치료용 약학적 조성물
Published · 2021-09 · Application 1020210126417
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 신경퇴행성 질환의 치료 용도
Published · 2021-09 · Application 1020210126416
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 다발성 경화증의 치료 용도
Published · 2021-09 · Application 1020210126418
Subsidiary: 한미정밀화학Polyethylene glycol derivative, composition comprising same, and method for preparing bioactive peptide conjugate using same
CN · Published · 2021-09 · Application 202180063303.6
Subsidiary: 한미정밀화학Polyethylene glycol derivatives, composition comprising the same and processes for preparing biologically active polypeptide conjugate using the same
TW · Registered · 2021-09 · Application 110134650
Polyethylene glycol derivative, composition comprising same, and method for preparing bioactive polypeptide conjugate by using same
US · Registered · 2021-09 · Application 18026481
POLYETHYLENE GLYCOL DERIVATIVE, COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING BIOACTIVE POLYPEPTIDE CONJUGATE BY USING SAME
EP · Published · 2021-09 · Application 21869753.0
Subsidiary: 한미정밀화학POLYETHYLENE GLYCOL DERIVATIVE, COMPOSITION COMPRISING SAME, AND METHOD FOR PREPARING BIOACTIVE POLYPEPTIDE CONJUGATE BY USING SAME
PCT · Published · 2021-09 · Application PCT/KR2021/012717
저점도 점안 조성물
Withdrawn · 2021-08 · Application 1020210113713
단백질 및 펩타이드의 면역원성을 감소시키는 방법
Rejected · 2021-08 · Application 1020210110349
新規なインスリンアナログ及びその用途
JP · Published · 2021-08 · Application 33133932
이리노테칸 함유 경구용 고형제제 및 그 제조방법
Registered · 2021-08 · Application 1020210109641
신규한 인슐린 아날로그 및 이의 용도
Registered · 2021-08 · Application 1020210109688
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 혈압 강하용 약학 조성물
Published · 2021-08 · Application 1020210108368
NOVEL METHODS OF TREATING NEUTROPENIA USING G-CSF PROTEIN COMPLEX
PCT · Published · 2021-08 · Application PCT/US2021/046108
PHARMACEUTICAL COMPOSITION COMPRISING LONG-ACTING CONJUGATE OF TRIPLE GLUCAGON/GLP-1/GIP RECEPTOR AGONIST
US · Published · 2021-08 · Application 18040869
삼중 활성체 지속형 결합체를 유효성분으로 포함하는 약학 조성물
Published · 2021-08 · Application 1020210107599
3중 작용성 지속형 결합체 또는 3중 작용제를 포함하는 조합물의 치료학적 용도
Published · 2021-07 · Application 1020210093709
글루카곤 유도체 또는 이의 결합체의 간질환에 대한 치료적 용도
Published · 2021-07 · Application 1020210093028
시타글립틴, 다파글리플로진 및 메트포르민을 포함하는 경구용 복합정제
Registered · 2021-07 · Application 1020210089566
ORAL SOLID FORMULATION CONTAINING IRINOTECAN AND METHOD OF PREPARING THE SAME
US · Published · 2021-07 · Application 17370709
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체를 포함하는 조합물의 치료학적 용도
Published · 2021-06 · Application 1020210086014
심혈관 질환 또는 신장 기능장애 발생의 위험을 감소시키기 위한 에페글레나타이드
Published · 2021-06 · Application 1020210083100
카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제
Registered · 2021-06 · Application 1020210077231
Liquid formulations of long-acting conjugates of glucagon, GLP-1 and GIP triple agonists
CN · Published · 2021-05 · Application 202180048037.X
Liquid formulations of long-acting conjugates of GLP-2
CN · Published · 2021-05 · Application 202180060215.0
LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLUCAGON, GLP-1, AND GIP TRIGONAL AGONIST
US · Published · 2021-05 · Application 17926912
LIQUID FORMULATION OF LONG-ACTING CONJUGATE OF GLP-2
US · Published · 2021-05 · Application 17927225
글루카곤 유도체의 지속형 결합체의 액상 제제
Published · 2021-05 · Application 1020210066282
GLP-2의 지속형 결합체의 액상 제제
Published · 2021-05 · Application 1020210066408
글루카곤, GLP-1 및 GIP 삼중 활성체의 지속형 결합체의 액상 제제
Published · 2021-05 · Application 1020210066452
액상 제제
Published · 2021-05 · Application 1020210066409
Novel dioxoisoquinolinone derivative and application thereof
CN · Published · 2021-05 · Application 202180055369.0
암로디핀, 로사르탄 및 클로르탈리돈을 단층정에 포함하는 심혈관계 질환의 예방 또는 치료용 약제학적 복합제제
Published · 2021-05 · Application 1020210064538
암 치료에 사용하기 위한 벨바라페닙
Published · 2021-05 · Application 1020227045396
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체를 포함하는 고지혈증 예방 또는 치료용 약학적 조성물 및 예방 또는 치료 방법
Published · 2021-04 · Application 1020210051337
Subsidiary: 한미정밀화학캡핑된 올리고뉴클레오티드 프라이머 및 이의 용도
Withdrawn · 2021-04 · Application 1020210046260
GLP-2 유도체 또는 이의 지속형 결합체를 포함하는 방사선요법, 화학요법, 또는 이들의 조합으로 유발된 점막염의 예방 또는 치료용 약학적 조성물
Published · 2021-04 · Application 1020210043372
신규한 면역 활성 인터루킨 2 아날로그
Registered · 2021-03 · Application 1020210042319
면역반응이 약화된 결합체
Rejected · 2021-01 · Application 1020210012321
단백질 액상 제제 및 이의 제조방법
Registered · 2021-01 · Application 1020210011802
프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제
Registered · 2021-01 · Application 1020210009234
착탈식 방음판넬
Rejected · 2020-12 · Application 2020200004895
Pharmaceutical composition for preventing or treating metabolic bone disease comprising GLP-2 or conjugate thereof
CN · Published · 2020-12 · Application 202080095573.0
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING METABOLIC BONE DISEASES, COMPRISING GLP-2 OR CONJUGATE THEREOF
US · Published · 2020-12 · Application 17788488
GLP-2 또는 이의 결합체를 포함하는 골 대사성 질환에 대한 예방 또는 치료용 약학적 조성물
Published · 2020-12 · Application 1020200183241
카라기난을 포함하는 구강 청결용 조성물
Withdrawn · 2020-12 · Application 1020200183861
카라기난을 포함하는 피부 외용 연고제 조성물
Withdrawn · 2020-12 · Application 1020200183596
카라기난을 포함하는 점안용 조성물
Withdrawn · 2020-12 · Application 1020200183593
카라기난을 포함하는 저 농도 알코올 손소독제 조성물
Withdrawn · 2020-12 · Application 1020200183586
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
Registered · 2020-12 · Application 1020200175636
Method for treating neutropenia caused by chemotherapy or radiotherapy
CN · Published · 2020-12 · Application 202080083791.2
METHODS OF TREATING CHEMOTHERAPY OR RADIOTHERAPY INDUCED NEUTROPENIA
PCT · Published · 2020-12 · Application PCT/KR2020/017798
화학 요법 또는 방사선 요법으로 유도된 호중구감소증을 치료하는 방법
Published · 2020-12 · Application 1020227018532
신규한 뇌 표적 지속형 단백질 결합체 및 이의 제조방법
Rejected · 2020-11 · Application 1020200161534
Therapeutic use of long-acting conjugates of triple agonists having activity for both glucagon/GLP-1/GIP receptors for lung diseases
CN · Published · 2020-11 · Application 202080098001.8
Therapeutic use of long-acting conjugate of triple agonist having activities to all of glucagon, GLP-1, and GIP receptors
TW · Published · 2020-11 · Application 109141074
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체의 폐질환의 치료 용도
Published · 2020-11 · Application 1020200157048
비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
Registered · 2020-11 · Application 1020200155786
신규한 글루코스 유도체
Withdrawn · 2020-11 · Application 1020200156001
수용체-매개 제거가 감소된, 생리활성 폴리펩타이드 단량체-면역글로불린 Fc 단편 결합체 및 이의 제조방법
Rejected · 2020-11 · Application 1020200154920
Subsidiary: 한미정밀화학3차 아민 함유 아릴 화합물
Withdrawn · 2020-11 · Application 1020200152905
A pharmaceutical preparation comprising an amide derivative inhibiting the growth of cancer cell and a pharmaceutical product containing the same
TW · Published · 2020-10 · Application 109136947
암세포의 성장을 억제하는 아마이드 유도체를 포함하는 약제학적 제제 및 이를 포함하는 약제학적 제품
Registered · 2020-10 · Application 1020200137829
프로톤 펌프 저해제 및 제산제를 포함하는 약학적 조성물
Registered · 2020-10 · Application 1020200134575
유전독성 안정성이 개선된 메트포르민 또는 약학적으로 허용 가능한 그의 염을 포함하는 약학적 조성물
Registered · 2020-10 · Application 1020200130560
사쿠비트릴 및 발사르탄 나트륨염을 포함하는 경구용 고형제제
Registered · 2020-10 · Application 1020200130568
카라기난을 유효성분으로 포함하는 항바이러스 조성물
Registered · 2020-10 · Application 1020200130536
Glucagon, composition comprising dual GLP-1 receptor and GIP receptor agonists, and therapeutic uses thereof
CN · Published · 2020-10 · Application 202080083888.3
COMPOSITION COMPRISING GLUCAGON AND GLP-1 AND GIP RECEPTOR DUAL AGONIST AND THERAPEUTIC USE OF SAME
US · Published · 2020-10 · Application 17766137
글루카곤, 및 GLP-1 수용체 및 GIP 수용체 이중 작용제를 포함하는 조성물 및 이의 치료학적 용도
Published · 2020-10 · Application 1020200128260
FLT3 저해제 및 MDM2 저해제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
Withdrawn · 2020-09 · Application 1020200125920
폴리에틸렌글리콜 유도체, 이를 포함하는 조성물 및 이를 이용한 생리활성 폴리펩타이드 결합체의 제조 방법
Registered · 2020-09 · Application 1020200119259
Methods of treating neutorpenia using G-CSF protein complex
US · Registered · 2020-08 · Application 16996635
신규한 디옥솔로이소퀴놀린온 유도체 화합물 및 이의 용도
Registered · 2020-08 · Application 1020200102034
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
Registered · 2020-07 · Application 1020200093190
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체
Registered · 2020-07 · Application 1020200093189
Subsidiary: 한미정밀화학링커-레진 화합물, 그 제조방법, 및 그 화합물을 이용한 펩타이드 제조방법
Registered · 2020-07 · Application 1020200087117
프로톤 펌프 저해제 및 제산제를 포함하는 약제학적 복합제제 및 그의 제조방법
Registered · 2020-07 · Application 1020200087143
시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
Registered · 2020-07 · Application 1020200085679
THERAPEUTIC USE, FOR LIVER DISEASE, OF TRIPLE AGONIST HAVING ACTIVITY WITH RESPECT TO ALL OF GLUCAGON, GLP-1, AND GIP RECEPTORS, OR CONJUGATE THEREOF
CN · Published · 2020-06 · Application 202080008168.0
Therapeutic use of trigonal glucagon/GLP-1/GIP receptor agonist or a conjugate thereof for liver disease
TW · Published · 2020-06 · Application 109121883
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 또는 이의 결합체의 간 질환에 대한 치료적 용도
Registered · 2020-06 · Application 1020200079585
아미노시아노피리딘 유도체 및 그의 용도
Withdrawn · 2020-06 · Application 1020200079523
FLT3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물
Rejected · 2020-06 · Application 1020200078053
항 종양 활성을 갖는 신규 퀴나졸린 유도체 및 이를 포함하는 약학 조성물
Withdrawn · 2020-06 · Application 1020200077953
에스오메프라졸 또는 이의 약학적으로 허용 가능한 염을 포함하고 이중방출 프로파일을 갖는 약학적 조성물
Registered · 2020-04 · Application 1020200039952
시타글립틴, 다파글리플로진, 및 메트포르민을 포함하는 경구용 복합정제
Registered · 2020-03 · Application 1020200038568
시타글립틴 및 다파글리플로진을 포함하는 복합제제 및 그 제조방법
Registered · 2020-03 · Application 1020200038569
Crystalline forms of acid addition salts of furopyrimidine compound, use thereof and pharmaceutical composition
TW · Registered · 2020-03 · Application 112147224
Crystalline forms of acid addition salts of furopyrimidine compound, its use and pharmaceutical composition
TW · Registered · 2020-03 · Application 109109900
FLT3 저해제 및 저메틸화제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조성물
Published · 2020-02 · Application 1020200021502
FLT3 저해제 및 IAP 길항제를 포함하는 급성 골수성 백혈병의 치료를 위한 약학적 조합물
Withdrawn · 2020-02 · Application 1020200021501
Subsidiary: 한미정밀화학Intermediate used for biologically active polypeptide and method for preparing same
US · Registered · 2020-02 · Application 17430864
Subsidiary: 한미정밀화학생리활성 폴리펩타이드에 사용되는 신규한 중간체 및 이의 제조방법
Registered · 2020-02 · Application 1020217025828
Subsidiary: 한미정밀화학NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME
EP · Published · 2020-02 · Application 20756094.7
Subsidiary: 한미정밀화학NOVEL INTERMEDIATE USED FOR BIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME
PCT · Published · 2020-02 · Application PCT/KR2020/002084
Imidazopyridine derivative compound and use thereof
TW · Published · 2020-02 · Application 109103208
이미다조피리딘 유도체 화합물 및 이의 용도
Registered · 2020-01 · Application 1020200011623
암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
Withdrawn · 2020-01 · Application 1020200004239
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체 및 인슐린을 포함하는 약학 조성물
Rejected · 2019-12 · Application 1020190173150
인슐린 및 글루카곤을 포함하는 약학 조성물
Rejected · 2019-12 · Application 1020190173205
탐수로신 및 타다라필을 포함하는 경구용 복합제제 및 그 제조방법
Registered · 2019-12 · Application 1020190173332
타크로리무스 연고제의 제조 방법 및 이에 의해 제조된 타크로리무스 연고제
Rejected · 2019-12 · Application 1020190169519
암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
Registered · 2019-12 · Application 1020190164354
히알루론산 가교물, 히알루론산 수화 겔 및 이들의 제조방법
Registered · 2019-12 · Application 1020190161388
생산성 및 용출성이 개선된 소라페닙 토실레이트염의 제제 및 그 제조 방법
Registered · 2019-10 · Application 1020190134056
에독사반 유리 염기 함유 제약 조성물
Withdrawn · 2019-10 · Application 1020190132109
흡입 제형용 건조 분말 및 이의 제조방법
Registered · 2019-10 · Application 1020190126757
글루카곤 및 이를 포함하는 조합물의 치료학적 용도
Rejected · 2019-10 · Application 1020190123214
상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 피리미디나다이벤젠아사이클로헵타판 유도체
Withdrawn · 2019-10 · Application 1020190121809
신규 면역 억제 인터루킨 2 (Interleukin 2) 아날로그
Rejected · 2019-09 · Application 1020190120725
NOVEL SULFONAMIDE DERIVATIVE WITH FUSED PYRIMIDINE SKELETON, HAVING EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION INHIBITORY EFFECT
PCT · Published · 2019-09 · Application PCT/KR2019/012207
퀴나졸린 화합물 및 이의 염산염의 결정 형태
Registered · 2019-09 · Application 1020217010957
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
Registered · 2019-08 · Application 1020190106691
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체
Registered · 2019-08 · Application 1020190106690
상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 융합 피리미딘 골격 설폰아마이드 유도체
Registered · 2019-08 · Application 1020190098931
글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
Registered · 2019-07 · Application 1020190089585
신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
Registered · 2019-07 · Application 1020190089584
Subsidiary: 한미정밀화학NOVEL INTERMEDIATE USED FOR PHYSIOLOGICALLY ACTIVE POLYPEPTIDE AND METHOD FOR PREPARING SAME
PCT · Published · 2019-07 · Application PCT/KR2019/008935
신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
Registered · 2019-07 · Application 1020207021823
신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
Registered · 2019-07 · Application 1020217038443
단백질 결합체의 신규 제조 방법
Published · 2019-07 · Application 1020190087240
몬테루카스트 또는 이의 약학적으로 허용가능한 염을 포함하는 액상 시럽제제 및 이의 제조방법
Registered · 2019-07 · Application 1020190085191
흡입용 캡슐제 및 이의 제조방법
Registered · 2019-07 · Application 1020190083163
Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same
TW · Published · 2019-07 · Application 108124118
新規なインスリンアナログ及びその用途
JP · Published · 2019-07 · Application 31124525
탐수로신 또는 이의 염산염 함유 제약 조성물 및 이의 제조방법
Registered · 2019-07 · Application 1020190078517
저장 안정성이 개선된 라타노프로스트 함유 점안제
Registered · 2019-06 · Application 1020190078055
제어 방출형 미라베그론 제제 및 이의 제조방법
Registered · 2019-06 · Application 1020190078189
이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
Registered · 2019-06 · Application 1020190076487
항-HER1, HER2 또는 HER4 항체와 포지오티닙의 조합물 및 이의 사용 방법
Rejected · 2019-06 · Application 1020217001979
Combination of cross-linked hyaluronic acids and method of preparing the same
US · Registered · 2019-06 · Application 16448180
FGFR 저해활성을 갖는 신규한 헤테로시클릭 유도체 화합물 및 이의 용도
Withdrawn · 2019-06 · Application 1020190073055
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
Registered · 2019-05 · Application 1020190061853
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체
Registered · 2019-05 · Application 1020190061852
에제티미브 및 로사르탄을 포함하는 약제학적 복합제제
Registered · 2019-04 · Application 1020190045295
빌다글립틴 염산염 함유 복합 제제의 안정성 개선을 위한 포장재
Registered · 2019-04 · Application 1020190044076
탐스로신 및 솔리페나신을 포함하는 복합제제 및 그 제조방법
Withdrawn · 2019-04 · Application 1020190043927
퓨로피리미딘 화합물의 산 부가염의 결정형
Registered · 2019-03 · Application 1020190037060
뇌 표적 지속형 치료학적 효소 결합체
Withdrawn · 2019-03 · Application 1020190037321
뇌 표적 지속성 단백질 결합체, 이의 제조 방법, 및 이를 포함하는 조성물
Rejected · 2019-03 · Application 1020190037281
상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체
Withdrawn · 2019-03 · Application 1020190037310
카운터기용 정전기 제거 장치
Registered · 2019-03 · Application 2020190001216
Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin Fc region
US · Registered · 2019-03 · Application 16356319
아데노신 수용체 길항제로서 신규 화합물 및 이를 포함하는 약학 조성물
Rejected · 2019-02 · Application 1020190024151
신규한 헤테로트리시클릭 유도체 화합물 및 이의 용도
Registered · 2019-02 · Application 1020190019544
Pyrimidine compound and pharmaceutical composition for preventing or treating cancer comprising same
CN · Published · 2019-02 · Application 202310204523.7
PYRIMIDINE COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR PREVENTING OR TREATING CANCERS INCLUDING THE SAME
CN · Published · 2019-02 · Application 201980049569.8
N−末端の電荷が改変されたインスリン分泌ペプチド誘導体
JP · Published · 2019-02 · Application 31016968
1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
Registered · 2019-01 · Application 1020190010242
1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)プロパ−2−エン−1−オンの製造方法
JP · Registered · 2018-12 · Application 30241276
Therapeutic enzyme fusion protein having a novel structure and use thereof
TW · Registered · 2018-12 · Application 107146641
내산성이 우수한 탐수로신 염산염 함유 제약 조성물 및 이의 제조방법
Rejected · 2018-12 · Application 1020180167767
THERAPEUTIC ENZYME FUSION PROTEIN HAVING NOVEL STRUCTURE AND USE THEREOF
PCT · Published · 2018-12 · Application PCT/KR2018/016487
신규한 구조를 갖는 치료학적 효소 융합단백질 및 이의 용도
Registered · 2018-12 · Application 1020180167795
흡입 제형용 건조 분말 및 이의 제조방법
Registered · 2018-12 · Application 1020180167794
탐수로신 및 솔리페나신을 포함하는 경구용 복합제제 및 그 제조방법
Withdrawn · 2018-12 · Application 1020180167725
목시플록사신 고형 제제 및 이의 제조방법
Withdrawn · 2018-12 · Application 1020180166838
다파글리플로진 L-프롤린을 포함하는 우수한 안정성을 갖는 약제학적 제제
Rejected · 2018-12 · Application 1020180166423
Subsidiary: 북경한미약품유한공사천연 항체 구조-유사 헤테로다이머 형태의 항 PD-L1/항 CD47 이중특이성 항체 및 이의 제조
Withdrawn · 2018-12 · Application 1020207019202
Thieno[3,2-d]pyrimidine derivative compound having inhibitory activity for protein kinase
US · Registered · 2018-11 · Application 16768538
단백질 키나제에 대한 억제 활성을 갖는 티에노[3,2-d]피리미딘 화합물
Abandoned · 2018-11 · Application 1020207018364
4-아미노-N-(1-((3-클로로-2-플루오로페닐)아미노)-6-메틸이소퀴놀린-5-일)티에노[3,2-d]피리미딘-7-카르복사미드의 염, 및 그의 결정질 형태
Registered · 2018-11 · Application 1020207018365
Subsidiary: 한미정밀화학POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF
CN · Published · 2018-11 · Application 201880070863.2
Subsidiary: 한미정밀화학Polyethylene glycol derivative and preparation method thereof
US · Registered · 2018-11 · Application 16648443
Subsidiary: 한미정밀화학폴리에틸렌글리콜 유도체 및 이의 제조방법
Registered · 2018-11 · Application 1020180134964
Subsidiary: 한미정밀화학POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF
EP · Registered · 2018-11 · Application 18872534.5
Subsidiary: 한미정밀화학POLYETHYLENE GLYCOL DERIVATIVE AND PREPARATION METHOD THEREOF
PCT · Published · 2018-11 · Application PCT/KR2018/013381
생리활성폴리펩타이드 결합체의 제조방법
Registered · 2018-10 · Application 1020180129197
미라베그론이 함유된 방출 제어 약제학적 조성물
Registered · 2018-10 · Application 1020180124442
링커로서 비펩타이드성 중합체 결합 지방산 유도체 화합물을 포함하는 단백질 결합체 및 이의 제조방법
Registered · 2018-10 · Application 1020180117071
효력이 향상된 지속성 단백질 결합체
Rejected · 2018-10 · Application 1020180116837
생산성 및 균일성이 개선된 타다라필을 함유하는 고형제제 및 그 제조방법
Registered · 2018-09 · Application 1020180116348
글루카곤 유사 펩타이드-2(GLP-2) 유도체의 지속형 결합체
Registered · 2018-09 · Application 1020180116327
에스오메프라졸 및 그의 약학적으로 허용가능한 염을 함유하는 다중 투여 단위 정제를 포함한 약제학적 조성물 및 그의 제조 방법
Rejected · 2018-09 · Application 1020180116349
제어 방출용 바레니클린 제제
Withdrawn · 2018-09 · Application 1020180113906
암로디핀, 로자탄 및 로수바스타틴을 포함하는 당뇨병을 동반한 심혈관계 질환의 예방 또는 치료용 약학 조성물 및 이를 포함하는 복합제제
Rejected · 2018-09 · Application 1020180112376
피라졸 유도체 화합물 및 이의 용도
Registered · 2018-09 · Application 1020180109856
카라기난을 유효성분으로 포함하는 항-바이러스 조성물
Registered · 2018-08 · Application 1020180096704
Subsidiary: 북경한미약품유한공사화합물, 이의 약제학적 조성물, 및 이의 용도 및 응용
Withdrawn · 2018-08 · Application 1020207007715
디펩티딜 펩티다아제-4 억제제 및 메트포르민을 포함하는 경구용 고형 복합제제 및 이의 제조방법
Registered · 2018-07 · Application 1020180089385
이두로네이트 2-설파타제 결합체
Withdrawn · 2018-07 · Application 1020180087997
몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
Registered · 2018-07 · Application 1020180088162
피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물
Registered · 2018-07 · Application 1020180086768
케토프로펜 함유 반고형 제제 및 그 제조방법
Registered · 2018-07 · Application 1020180085836
신규 치료학적 효소 융합단백질 및 이의 용도
Registered · 2018-07 · Application 1020180079409
다파글리플로진 L-프롤린과 메트포르민을 포함하는 약제학적 복합제제
Registered · 2018-07 · Application 1020180079614
무정형의 다파글리플로진 L-프롤린을 포함하는 약학적 제제 및 이의 제조방법
Registered · 2018-07 · Application 1020180078899
FcRn 결합력이 유지되는 면역글로불린 Fc 결합체
Registered · 2018-06 · Application 1020180070435
반제품 깨짐 방지 장치
Registered · 2018-06 · Application 1020180070218
의약 분석 서비스를 제공하기 위한 장치 및 방법
Rejected · 2018-06 · Application 1020180065654
암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
Rejected · 2018-04 · Application 1020180047999
암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합제제
Rejected · 2018-04 · Application 1020180047987
레보세티리진 및 몬테루카스트를 포함하는 안정성 및 복약순응도가 향상된 복합 츄어블정 및 그 제조방법
Registered · 2018-04 · Application 1020180047553
카라기난을 유효성분으로 포함하는 보존성이 개선된 액상 제제
Registered · 2018-04 · Application 1020180046301
오셀타미비어 함유 경구용 고형제제 및 그 제조방법
Registered · 2018-04 · Application 1020180042964
미라베그론이 함유된 방출 제어 약학적 조성물
Registered · 2018-04 · Application 1020180040139
다파글리플로진 L-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
Rejected · 2018-04 · Application 1020180039254
빌다글립틴을 함유하는 경구용 고형제제 및 그의 제조 방법
Registered · 2018-03 · Application 1020180037671
플루르비프로펜 함유 스프레이 조성물 및 그 제조방법
Registered · 2018-03 · Application 1020180037670
바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 우수한 안정성 및 용출률을 갖는 복합제제
Withdrawn · 2018-03 · Application 1020180034403
인슐린 수용체와의 결합력이 감소된 인슐린 아날로그의 결합체 및 이의 용도
Registered · 2018-03 · Application 1020180034032
에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제
Registered · 2018-03 · Application 1020180031536
유산균 배양물 혼합액을 함유하는 피부 미백용 화장료 조성물
Registered · 2018-03 · Application 1020180027957
비펩티드성 중합체 링커 화합물, 그 링커 화합물을 포함하는 결합체, 및 이들의 제조방법
Rejected · 2018-02 · Application 1020180015184
지속성이 증가된 생리활성 물질의 결합체 및 이의 용도
Registered · 2018-02 · Application 1020180013528
LONG-ACTING CONJUGATE OF A PHYSIOLOGICALLY ACTIVE MATERIAL AND USE THEREOF
US · Published · 2018-02 · Application 16483169
CONJUGATE OF BIOACTIVE MATERIAL HAVING ENHANCED SUSTAINABILITY AND USE THEREOF
EP · Published · 2018-02 · Application 18748653.5
피리미딘 화합물 및 그의 의약 용도
Registered · 2018-01 · Application 1020180010226
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
Registered · 2018-01 · Application 1020180007825
도네페질 및 메만틴의 동시 분석방법
Withdrawn · 2018-01 · Application 1020180006278
메만틴을 포함하는 속방성 및 서방성을 동시에 가지는 경질캡슐 제제 및 그 제조방법
Withdrawn · 2017-12 · Application 1020170178743
신규한 2,6-나프티리딘 2-옥시드 유도체 화합물 및 이의 용도
Withdrawn · 2017-12 · Application 1020170178061
뇌 표적 지속성 단백질 결합체
Withdrawn · 2017-12 · Application 1020170175550
바제독시펜 아세테이트를 함유하는 안정화된 약제학적 조성물
Published · 2017-12 · Application 1020170169991
테르비나핀을 포함하는 외용제 조성물 및 그 제조방법
Withdrawn · 2017-12 · Application 1020170167525
재조합 단백질의 개선된 정제 방법
Withdrawn · 2017-12 · Application 1020170165901
면역반응이 약화된 결합체
Rejected · 2017-12 · Application 1020170166105
다파글리플로진 L-프롤린과 항당뇨병제를 포함하는 약제학적 복합 제제
Registered · 2017-12 · Application 1020170163882
Subsidiary: 북경한미약품유한공사항 PD-1/항 HER2 천연항체 구조 형태의 헤테로다이머 계의 이중특이성 항체 및 그 제조방법
Registered · 2017-11 · Application 1020197013134
암의 포지오티닙 치료에 대한 반응을 나타내는 바이오마커 및 그의 용도
Rejected · 2017-11 · Application 1020170151831
바제독시펜 또는 그의 약제학적으로 허용가능한 염 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는, 습식과립법을 이용하여 제조되는 복합제제
Withdrawn · 2017-10 · Application 1020170140880
리나글립틴 및 메트포르민을 포함하는 복합제제 및 그의 제조방법
Registered · 2017-10 · Application 1020170138662
라이신 특이적 데메틸라제-1 억제제로서의 피라졸 유도체
Withdrawn · 2017-10 · Application 1020170131426
피라졸로피리딘 유도체 화합물 및 이의 용도
Withdrawn · 2017-10 · Application 1020170131023
용출율이 향상된 라록시펜, 및 비타민 D 또는 그 유도체를 포함하는 복합 캡슐제 및 이의 제조방법
Registered · 2017-09 · Application 1020170128329
아세트아미노펜, 및 트라마돌 또는 이의 약학적 허용 가능한 염을 포함하는 연질캡슐 조성물
Withdrawn · 2017-09 · Application 1020170127980
Subsidiary: 북경한미약품유한공사헤테로다이머 면역글로불린 구조체 및 이의 제조 방법
Registered · 2017-09 · Application 1020197009091
지속형 단쇄 인슐린 아날로그 및 이의 결합체
Rejected · 2017-09 · Application 1020170126476
다비가트란 이텍실레이트를 포함하는 복합 캡슐제
Withdrawn · 2017-09 · Application 1020170126264
(2R)-2-(2-메톡시페닐)-2-(옥산-4-일옥시)에탄-1-올 화합물의 신규 제조방법 및 이에 사용되는 중간체
Rejected · 2017-09 · Application 1020170125928
Liquid formulation of long acting insulinotropic peptide conjugate
US · Registered · 2017-09 · Application 15714556
인슐린 수용체와의 결합력이 감소된, 인슐린 아날로그 및 이의 용도
Registered · 2017-09 · Application 1020170122759
PHARMACEUTICAL PREPARATION FOR ORAL ADMINISTRATION WITH CONTROLLED DISSOLUTION RATE, THE PREPARATION COMPRISING TAMSULOSIN HYDROCHLORIDE-CONTAINING SUSTAINED-RELEASE PELLETS
EP · Registered · 2017-08 · Application 17839879.8
탐수로신 염산염 함유 서방성 펠렛을 포함하는 용출률이 제어된 경구투여용 약제학적 제제
Registered · 2017-08 · Application 1020170102553
Subsidiary: 한미정밀화학IMPROVED METHOD FOR PRODUCING HIGH-PURITY CRYSTALLINE FEBUXOSTAT
PCT · Published · 2017-07 · Application PCT/KR2017/008042
함량 균일성이 개선된 탐수로신 염산염 함유 서방성 펠렛을 포함하는 경구용 약제학적 제제
Registered · 2017-07 · Application 1020170089677
리나글립틴, 메트포르민 및 항산화제를 포함하는, 안정성이 개선된 약제학적 조성물
Registered · 2017-06 · Application 1020170083831
함량 균일성 및 안정성이 향상된 바레니클린 옥살산염이 포함된 약제학적 조성물
Registered · 2017-06 · Application 1020170083834
아세클로페낙을 포함하는 안정성 및 용출률이 개선된 약제학적 조성물
Rejected · 2017-06 · Application 1020170083725
Liquid formulation of long-lasting protein conjugate comprising the oxyntomodulin and an immunoglobulin fragment
US · Registered · 2017-06 · Application 15637583
ALK5 억제제로서의 신규 피라졸 유도체 및 이의 용도
Registered · 2017-06 · Application 1020170082868
글루카곤 유도체, 이의 결합체, 및 이를 포함하는 조성물, 및 이의 치료적 용도
Registered · 2017-06 · Application 1020170082862
신규한 헤테로시클릭 유도체 화합물 및 이의 용도
Withdrawn · 2017-06 · Application 1020170081047
탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
Registered · 2017-06 · Application 1020170078677
시클로프로필아민 유도체 화합물 및 이의 용도
Withdrawn · 2017-06 · Application 1020170072728
두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
Rejected · 2017-05 · Application 1020170065231
암 세포 성장을 저해하는 아민 유도체 또는 이의 약학적으로 허용가능한 염 및 저융점을 갖는 안정화제를 포함하는 약학적 조성물
Withdrawn · 2017-05 · Application 1020187037359
Subsidiary: 한미정밀화학사쿠비트릴 결합체, 이의 제조방법 및 이를 포함하는 약학 조성물
Withdrawn · 2017-05 · Application 1020170058844
Subsidiary: 한미정밀화학결정형 사쿠비트릴 헤미나트륨염, 이의 제조방법 및 이를 포함하는 약학 조성물
Withdrawn · 2017-05 · Application 1020170058913
오셀타미비어 함유 경구용 고형제제 및 그 제조방법
Rejected · 2017-05 · Application 1020170056473
오셀타미비어 함유 경구용 고형제제 및 그 제조방법
Registered · 2017-04 · Application 1020170042842
안정성 및 용출율이 개선된 타다라필 및 탐수로신 함유 캡슐 복합제제
Registered · 2017-03 · Application 1020170042259
타다라필 및 암로디핀 함유 고형 복합제제
Rejected · 2017-03 · Application 1020170042200
이부프로펜 및 아세트아미노펜을 포함하는 약제학적 조성물 및 이의 제조방법
Registered · 2017-03 · Application 1020170040642
바제독시펜 또는 그의 약제학적으로 허용가능한 염, 및 콜레칼시페롤 또는 그의 약제학적으로 허용가능한 염을 포함하는 복합제제
Withdrawn · 2017-03 · Application 1020170040509
오메가-3 지방산 또는 이의 에스테르, 및 하이드록시메틸글루타릴 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
Rejected · 2017-03 · Application 1020170040635
두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
Registered · 2017-03 · Application 1020170033369
POLYETHYLENE GLYCOL DERIVATIVE AND USE THEREOF
PCT · Published · 2017-03 · Application PCT/KR2017/002469
폴리에틸렌 글리콜 유도체 및 이의 용도
Registered · 2017-03 · Application 1020170029139
5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
Expired · 2017-02 · Application 1020170025042
Subsidiary: 한미정밀화학METHOD FOR PREPARING POLYETHYLENE GLYCOL DIALDEHYDE DERIVATIVE
CN · Published · 2017-02 · Application 201780012402.5
Subsidiary: 한미정밀화학Method for preparing polyethylene glycol dialdehyde derivative
US · Registered · 2017-02 · Application 16074592
Subsidiary: 한미정밀화학METHOD FOR PREPARING POLYETHYLENE GLYCOL DIALDEHYDE DERIVATIVE
EP · Registered · 2017-02 · Application 17756781.5
Subsidiary: 한미정밀화학METHOD FOR PREPARING POLYETHYLENE GLYCOL DIALDEHYDE DERIVATIVE
PCT · Published · 2017-02 · Application PCT/KR2017/001906
Subsidiary: 한미정밀화학ポリエチレングリコールジアルデヒド誘導体の製造方法
JP · Registered · 2017-02 · Application 30545151
치료학적 효소류의 결합체
Registered · 2017-01 · Application 1020170014052
이미다조피리다진 화합물
Registered · 2017-01 · Application 1020170012767
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체의 지속형 결합체
Rejected · 2016-12 · Application 1020160183500
TRIPLE ACTIVATOR ACTIVATING GLUCAGON, GLP-1 AND GIP RECEPTOR
EP · Registered · 2016-12 · Application 16882156.9
싸이에노피리미딘 화합물의 결정형
Withdrawn · 2016-12 · Application 1020187018171
싸이에노피리미딘 화합물의 하이드로클로라이드 염의 결정형
Withdrawn · 2016-12 · Application 1020187018170
글루카곤, GLP-1 및 GIP 수용체 모두에 활성을 갖는 삼중 활성체
Rejected · 2016-12 · Application 1020160183499
FGF21 아날로그, FGF21 결합체, 및 이의 용도
Rejected · 2016-12 · Application 1020160183620
다파글리플로진 L-프롤린을 포함하는 당뇨병 질환의 예방 또는 치료용 약제학적 조성물
Withdrawn · 2016-12 · Application 1020160183853
싸이에노피리미딘 화합물의 신규 제조방법 및 중간체
Withdrawn · 2016-12 · Application 1020160179320
오셀타미비어 유리염기를 포함하는 약학 조성물
Registered · 2016-12 · Application 1020160163173
지방산 유도체를 이용한 단백질 결합체 및 이의 제조방법
Rejected · 2016-12 · Application 1020160163932
에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제
Registered · 2016-11 · Application 1020160160513
다파글리플로진 L-프롤린을 포함하는 약제학적 제제
Rejected · 2016-11 · Application 1020160157550
암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제
Registered · 2016-11 · Application 1020160145518
에스오메프라졸 함유 복합 캡슐제 및 그 제조방법
Registered · 2016-10 · Application 1020160142156
테노포비어 디소프록실 인산염과, 비금속염 붕해제 및 비금속염 활택제를 포함하는 약학 조성물
Expired · 2016-10 · Application 1020160137685
고미 및 이물감이 개선된 에르도스테인 과립제제
Registered · 2016-10 · Application 1020160130851
복합 활성성분의 개선된 함량 균일성 및 높은 단위전달량을 갖는 흡입용 캡슐제 및 이의 제조방법
Rejected · 2016-09 · Application 1020160127148
PROTEIN COMPLEX BY USE OF A SPECIFIC SITE OF AN IMMUNOGLOBULIN FRAGMENT FOR LINKAGE
PCT · Published · 2016-09 · Application PCT/KR2016/010762
면역글로불린 단편의 특정 위치를 연결 부위로 이용한 단백질 결합체
Registered · 2016-09 · Application 1020160123300
다수의 생리활성 폴리펩타이드 및 면역글로불린 Fc 영역을 포함하는, 단백질 결합체
Withdrawn · 2016-09 · Application 1020160123109
METHOD OF INSULIN PRODUCTION
US · Published · 2016-09 · Application 15762613
인슐린의 제조 방법
Withdrawn · 2016-09 · Application 1020160122485
Subsidiary: 한미정밀화학LINAGLIPTIN CRYSTAL FORM, AND PREPARATION METHOD THEREFOR
CN · Published · 2016-09 · Application 201680054246.4
Subsidiary: 한미정밀화학LINAGLIPTIN CRYSTAL FORM, AND PREPARATION METHOD THEREFOR
PCT · Published · 2016-09 · Application PCT/KR2016/010001
신규한 인슐린 아날로그 및 이의 용도
Registered · 2016-08 · Application 1020160110301
Subsidiary: 한미정밀화학고순도 결정형 페북소스타트의 개선된 제조 방법
Withdrawn · 2016-07 · Application 1020160097444
에스오메프라졸, 또는 약학적으로 허용 가능한 그의 염을 포함하는, pH-의존성 약물 방출 특성이 개선된 제형
Registered · 2016-07 · Application 1020160094238
Method of preparing physiologically active polypeptide conjugate
US · Registered · 2016-07 · Application 15747141
METHOD OF PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE
EP · Registered · 2016-07 · Application 16830775.9
METHOD OF PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE
PCT · Published · 2016-07 · Application PCT/KR2016/008050
생리활성폴리펩타이드 결합체의 제조방법
Rejected · 2016-07 · Application 1020160093714
비타민 D 또는 그 유도체를 함유하는 과립 및 상기 과립과 라록시펜을 포함하는 복합 캡슐제
Registered · 2016-06 · Application 1020160083025
무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
Withdrawn · 2016-06 · Application 1020160083030
방출특성 및 생체이용률이 개선된 소라페닙 토실레이트를 포함하는 경구투여용 약제학적 조성물
Rejected · 2016-06 · Application 1020160082171
독실아민 및 피리독신을 포함하는 약제학적 복합 제제
Withdrawn · 2016-06 · Application 1020160081954
신규 글루카곤 유도체 및 이의 지속형 결합체를 포함하는 조성물
Registered · 2016-06 · Application 1020160081976
암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
Rejected · 2016-06 · Application 1020160081848
COMBINATION OF CROSS-LINKED HYALURONIC ACIDS AND METHOD OF PREPARING THE SAME
US · Published · 2016-06 · Application 15322326
COMBINATION OF CROSS-LINKED HYALURONIC ACIDS AND METHOD OF PREPARING THE SAME
PCT · Published · 2016-06 · Application PCT/KR2016/005819
테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
Expired · 2016-03 · Application 1020160039649
멜라토닌 함유 경구용 고형제제 및 그 제조방법
Withdrawn · 2016-03 · Application 1020160039632
Subsidiary: 한미정밀화학폴리에틸렌글리콜 디알데히드 유도체의 제조방법
Registered · 2016-02 · Application 1020160023217
지속형 FGF21 수용체 아고니스트 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 대사증후군 치료용 조성물
Withdrawn · 2016-02 · Application 1020160023377
G 단백질 연결 수용체 폴리펩타이드 리간드의 지속형 결합체 및 이의 제조방법
Withdrawn · 2016-02 · Application 1020160023450
지속형 인슐린 또는 이의 아날로그 결합체
Withdrawn · 2016-02 · Application 1020160018668
복합 히알루론산 가교물 및 그 제조방법
Rejected · 2016-02 · Application 1020160012519
라록시펜, 및 비타민 D 또는 그 유도체를 포함하는 복합 캡슐제
Registered · 2016-01 · Application 1020160010981
GLUCAGON DERIVATIVES
EP · Registered · 2015-12 · Application 15875711.2
안정성이 증가된 글루카곤 유도체
Registered · 2015-12 · Application 1020150189532
지속형 인간 성장 호르몬 결합체의 신규 액상 제제
Withdrawn · 2015-12 · Application 1020150189919
싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
Expired · 2015-12 · Application 1020150189343
두타스테라이드를 포함하는 경구용 연질 캡슐 제형용 포장재
Registered · 2015-12 · Application 1020150184221
다비가트란 이텍실레이트를 함유하는 복합 캡슐제
Withdrawn · 2015-12 · Application 1020150178411
복합 유산균 배양물을 함유하는 피부장벽 강화용 화장료 조성물
Registered · 2015-11 · Application 1020150164712
무정형 솔리페나신 함유 경구용 고형제제 및 그 제조방법
Withdrawn · 2015-11 · Application 1020150158108
CAPSULE FORMULATION COMPRISING MONTELUKAST AND LEVOCETIRIZINE
US · Published · 2015-11 · Application 14934348
티오트로피움 또는 이의 약학적으로 허용가능한 염을 함유하는 흡입용 건조분말 조성물
Registered · 2015-11 · Application 1020150154084
싸이에노피리미딘 화합물의 신규 제조방법 및 이에 사용되는 중간체
Withdrawn · 2015-10 · Application 1020150151993
활성성분의 전달량이 향상된 흡입용 캡슐제
Registered · 2015-09 · Application 1020150138140
오셀타미비어 함유 과립, 그 과립을 포함하는 캡슐제, 및 이들의 제조방법
Withdrawn · 2015-09 · Application 1020150137083
개시 메티오닌 잔기를 포함하는 면역글로불린 Fc 영역의 생산방법
Withdrawn · 2015-09 · Application 1020150136553
Subsidiary: 한미정밀화학Method for preparing high-purity (r)-9-[2-(phosphonomethoxy)propyl]adenine
CN · Published · 2015-09 · Application 201580047014.1
Subsidiary: 한미정밀화학METHOD FOR PREPARING HIGH-PURITY (R)-9-[2-(PHOSPHONOMETHOXY)PROPYL]ADENINE
PCT · Published · 2015-09 · Application PCT/KR2015/010114
Subsidiary: 한미정밀화학高純度の(R)−9−[2−(ホスホノメトキシ)プロピル]アデニンの製造方法
JP · Published · 2015-09 · Application 29516154
수용성 아줄렌 및 알킬피리디늄 할라이드를 포함하는 구강 스프레이 조성물
Rejected · 2015-09 · Application 1020150134922
복합 활성성분의 안정성이 개선된 흡입 제형용 건조분말
Rejected · 2015-09 · Application 1020150133883
로플루밀라스트 함유 경구용 고형제제 및 그 제조방법
Rejected · 2015-09 · Application 1020150133358
Subsidiary: 한미정밀화학리나글립틴 결정형 및 이의 제조방법
Registered · 2015-09 · Application 1020150131749
지속형 GLP-1/글루카곤 수용체 듀얼 아고니스트의 비알콜성 지방간질환에 대한 용도
Registered · 2015-09 · Application 1020150131004
암로디핀 및 로잘탄을 포함하는 고형 약제학적 조성물
Registered · 2015-08 · Application 1020150123167
병마개
Expired · 2015-08 · Application 2020150005689
Subsidiary: 한미정밀화학CRYSTALLINE COMPOSITE COMPRISING DAPAGLIFLOZIN AND METHOD FOR PREPARING SAME
PCT · Published · 2015-07 · Application PCT/KR2015/007821
TENOFOVIR DISOPROXIL PHOSPHATE, AND PHARMACEUTICAL COMPOSITION THEREOF COMPRISING NON-METALLIC SALT DISINTEGRANT AND NON-METALLIC SALT LUBRICANT
PCT · Published · 2015-07 · Application PCT/KR2015/006766
COMPOSITE PREPARATION COMPRISING 5- -REDUCTASE INHIBITOR-CONTAINING FILM COATING LAYER, AND METHOD FOR PRODUCING THE COMPOSITE PREPARATION
EP · Registered · 2015-06 · Application 15815459.1
COMPOSITE PREPARATION COMPRISING ACTIVE INGREDIENT-CONTAINING FILM COATING LAYER
EP · Registered · 2015-06 · Application 15816054.9
이리노테칸 함유 경구용 고형제제 및 그 제조방법
Registered · 2015-06 · Application 1020150093413
5-α-환원효소 억제제-함유 필름 코팅층을 포함하는 복합제제 및 그 제조방법
Rejected · 2015-06 · Application 1020150093777
활성성분-함유 필름 코팅층을 포함하는 복합제제
Expired · 2015-06 · Application 1020150093778
테노포비어 디소프록실 함유 경구용 고형제제 및 그 제조방법
Rejected · 2015-06 · Application 1020150093233
Subsidiary: 한미정밀화학솔리페나신 또는 그의 약학적으로 허용되는 염과 락토즈를 포함하는 안정한 무정형 솔리페나신 약학 조성물 및 그의 제조방법
Withdrawn · 2015-06 · Application 1020150083722
비강 분무용 약학 조성물 및 그 제조방법
Withdrawn · 2015-06 · Application 1020150081984
METHOD FOR DECREASING IMMUNOGENICITY OF PROTEIN AND PEPTIDE
US · Published · 2015-06 · Application 15315992
Subsidiary: 한미정밀화학신규한 바레니클린 뮤케이트 염, 이의 결정형 및 이의 제조방법
Withdrawn · 2015-06 · Application 1020150080089
COMPOSITION FOR TREATING DIABETES MELLITUS COMPRISING INSULIN AND A GLP-1/GLUCAGON DUAL AGONIST
EP · Registered · 2015-06 · Application 15799077.1
인슐린 및 GLP-1/글루카곤 이중작용제를 포함하는 당뇨병 치료용 조성물
Registered · 2015-06 · Application 1020150077271
Composition for treating diabetes and containing long-acting insulin analog conjugate and long-acting insulin secretion peptide conjugate
CN · Published · 2015-05 · Application 201580041340.1
Compositions comprising long-acting insulin analogue conjugates and long-acting insulinotropic peptide conjugates for treatment of diabetes
CN · Published · 2015-05 · Application 202411307269.4
COMPOSITION FOR TREATING DIABETES, CONTAINING LONG-ACTING INSULIN ANALOG CONJUGATE AND LONG-ACTING INSULIN SECRETION PEPTIDE CONJUGATE
PCT · Published · 2015-05 · Application PCT/KR2015/005424
지속형 인슐린 아날로그 결합체 및 지속형 인슐린 분비 펩타이드 결합체를 포함하는 당뇨병 치료용 조성물
Rejected · 2015-05 · Application 1020150076311
스프레이 용기
Expired · 2015-05 · Application 2020150003289
Subsidiary: 한미정밀화학PHARMACEUTICAL COMPOSITION COMPRISING P-GLYCOPROTEIN INHIBITOR AND P-GLYCOPROTEIN SUBSTRATE DRUG
PCT · Published · 2015-05 · Application PCT/KR2015/005053
Subsidiary: 한미정밀화학p-당단백질의 저해제 및 p-당단백질의 기질 약물을 포함하는 약제학적 조성물
Withdrawn · 2015-05 · Application 1020150069859
Subsidiary: 한미정밀화학신규 결정형의 바레니클린 옥살산 염 수화물, 이의 제조방법, 및 이를 포함하는 약학 조성물
Rejected · 2015-04 · Application 1020150058108
Subsidiary: 한미정밀화학METHOD FOR PRODUCING GAMMA-FORM CRYSTAL OF SILODOSIN
PCT · Published · 2015-04 · Application PCT/KR2015/003252
암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합 제제
Registered · 2015-03 · Application 1020150045645
METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOBULIN FC FRAGMENT LINKAGE
EP · Registered · 2015-03 · Application 15772562.3
METHOD FOR IMPROVING SOLUBILITY OF PROTEIN AND PEPTIDE BY USING IMMUNOGLOBULIN FC FRAGMENT LINKAGE
PCT · Published · 2015-03 · Application PCT/KR2015/003195
면역글로불린 Fc 단편 결합을 이용한 단백질 및 펩타이드의 용해도를 개선시키는 방법
Registered · 2015-03 · Application 1020150045621
복합 활성성분의 안정성이 개선된 흡입용 캡슐제
Rejected · 2015-03 · Application 1020150045686
오셀타미비어 함유 경구용 고형제제 및 그 제조방법
Rejected · 2015-03 · Application 1020150045687
탁산을 포함하는 무정형 고체 분산체, 그를 포함하는 정제 및 그를 제조하는 방법
Registered · 2015-03 · Application 1020167027373
메트포르민 및 시타글립틴을 포함하는 경구용 복합제제
Rejected · 2015-03 · Application 1020150036124
에제티미브 및 로수바스타틴을 포함하는 경구용 고형 복합제제
Registered · 2015-02 · Application 1020150028195
탐수로신 염산염 함유 서방성 과립을 포함하는 경구용 약제학적 제제
Rejected · 2015-02 · Application 1020150023152
Subsidiary: 한미정밀화학NOVEL INTERMEDIATE USED IN PREPARATION OF SILODOSIN, PREPARATION METHOD THEREFOR, AND SILODOSIN PREPARATION METHOD USING SAME
PCT · Published · 2015-01 · Application PCT/KR2015/001030
Subsidiary: 한미정밀화학실로도신 제조에 사용되는 신규 중간체, 이의 제조방법 및 이를 이용한 실로도신의 제조방법
Rejected · 2015-01 · Application 1020150014442
지속형 인슐린 및 그 용도
Registered · 2015-01 · Application 1020150009433
티아졸리딘 유도체 화합물 및 이의 용도
Withdrawn · 2014-12 · Application 1020140195390
비스테로이드성 항염증제 및 프로톤 펌프 저해제를 포함하는 경구용 서방성 복합제제
Registered · 2014-12 · Application 1020140195661
리바록사반 함유 경구용 고형제제
Registered · 2014-12 · Application 1020140195662
피리미딘 유도체 화합물 및 이의 용도
Withdrawn · 2014-12 · Application 1020140194888
Subsidiary: 한미정밀화학고순도의 (R)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
Expired · 2014-12 · Application 1020140194296
글루카곤 유도체
Registered · 2014-12 · Application 1020140193691
싸이옥소 퓨로피리미디논 유도체의 제조방법 및 이에 사용되는 중간체
Withdrawn · 2014-12 · Application 1020140193987
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
Rejected · 2014-12 · Application 1020140192374
푸마르산 에스테르를 함유하는 미니-정제 형태의 약제학적 제제
Expired · 2014-12 · Application 1020140187570
두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물
Registered · 2014-12 · Application 1020140187571
타다라필 및 암로디핀을 포함하는 복합제제
Expired · 2014-11 · Application 1020140151219
신규 하이드록사메이트 유도체 및 이를 포함하는 암의 예방 또는 치료용 약제학적 조성물
Withdrawn · 2014-09 · Application 1020140131887
신규한 싸이옥소 퓨로피리미디논 유도체의 신규 제조방법 및 이에 사용되는 중간체
Withdrawn · 2014-09 · Application 1020140131954
Subsidiary: 한미정밀화학고순도의 (R)-9-[2-(포스포노메톡시)프로필]아데닌의 제조방법
Expired · 2014-09 · Application 1020140131973
TAK1 저해 활성을 갖는 피라진 접합고리 유도체
Withdrawn · 2014-09 · Application 1020140131917
신규한 싸이옥소 싸이에노피리미디논 유도체의 신규 제조방법 및 이에 사용되는 중간체
Withdrawn · 2014-09 · Application 1020140131943
지속형 인간 성장 호르몬 제제
Registered · 2014-09 · Application 1020140129476
Subsidiary: 한미정밀화학다파글리프로진 및 피페라진의 신규 복합체 및 이의 제조방법
Withdrawn · 2014-09 · Application 1020140121290
Subsidiary: 한미정밀화학신규한 다비가트란 에텍실레이트 헤미숙시네이트 및 이의 제조방법
Withdrawn · 2014-09 · Application 1020140115423
METHOD FOR MASS PRODUCING HUMAN BLOOD COAGULATION FACTOR VII DERIVATIVE
EP · Registered · 2014-08 · Application 14839952.0
임펠러형 피더를 갖는 정제형 제품 타정기
Registered · 2014-08 · Application 1020140111200
Subsidiary: 한미정밀화학다파글리프로진의 신규 수화물 복합체 및 이의 제조방법
Withdrawn · 2014-08 · Application 1020140099158
타다라필 및 암로디핀을 포함하는 복합제제
Withdrawn · 2014-07 · Application 1020140096022
Subsidiary: 한미정밀화학다파글리프로진의 신규 결정질 복합체 및 이의 제조방법
Withdrawn · 2014-07 · Application 1020140096039
타다라필 및 암로디핀을 포함하는 복합 고형 제제
Expired · 2014-07 · Application 1020140096023
CONJUGATE OF BIOLOGICALLY ACTIVE POLYPEPTIDE MONOMER AND IMMUNOGLOBULIN FC FRAGMENT WITH REDUCED RECEPTOR-MEDIATED CLEARANCE, AND THE METHOD FOR PREPARING THE SAME
EP · Registered · 2014-07 · Application 14823791.0
수용체-매개 제거가 감소된, 생리활성 폴리펩타이드 단량체-면역글로불린 Fc 단편 결합체 및 이의 제조방법
Registered · 2014-07 · Application 1020140088535
FcRn 결합력이 유지되는 면역글로불린 Fc 결합체
Registered · 2014-07 · Application 1020140088530
인슐린 아날로그
Rejected · 2014-07 · Application 1020140087793
리바록사반을 포함하는 경구 투여용 약학 조성물 및 이의 제조방법
Registered · 2014-07 · Application 1020140082656
몬테루카스트 또는 이의 약제학적으로 허용가능한 염의 경구투여용 액상제제
Expired · 2014-07 · Application 1020140082633
테노포비어 디소프록실 인산염과, 비금속염 붕해제 및 비금속염 활택제를 포함하는 약학 조성물
Withdrawn · 2014-07 · Application 1020140082137
카라기난을 유효성분으로 포함하는 항-바이러스 조성물
Rejected · 2014-07 · Application 1020140081882
오셀타미비어 유리염기를 포함하는 약학 조성물
Withdrawn · 2014-06 · Application 1020140081137
타다라필 및 탐수로신을 함유하는 약학적 캡슐 복합 제제
Registered · 2014-06 · Application 1020140081242
SGLT 저해제로서 인단 유도체 및 이를 포함하는 약학적 조성물
Withdrawn · 2014-06 · Application 1020140081343
신규한 지속형 인슐린 아날로그 결합체 및 이의 용도
Rejected · 2014-06 · Application 1020140079848
카나비노이드 CB1 수용체 길항제로서의 1,5-디아릴-4,5-디하이드로-1H-피라졸-3-카복스아미딘 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
Expired · 2014-06 · Application 1020140079229
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 및 그 제조방법
Registered · 2014-06 · Application 1020140078388
에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제
Withdrawn · 2014-06 · Application 1020140071081
단백질 및 펩타이드의 면역원성을 감소시키는 방법
Rejected · 2014-06 · Application 1020140068660
Subsidiary: 한미정밀화학(R)-9-[2-(포스포노메톡시)프로필]아데닌의 개선된 제조 방법
Rejected · 2014-05 · Application 1020140066537
IGG4 FC FRAGMENT COMPRISING MODIFIED HINGE REGION
EP · Registered · 2014-05 · Application 14804503.2
IGG4 FC FRAGMENT COMPRISING MODIFIED HINGE REGION
EP · Registered · 2014-05 · Application 18168489.5
타다라필 또는 이의 약학적으로 허용가능한 염을 포함하는 저작정 제제
Registered · 2014-05 · Application 1020140064385
SGLT 저해제로서 2,3-다이하이드로벤조퓨란 유도체 및 이를 포함하는 약학적 조성물
Withdrawn · 2014-05 · Application 1020140057428
Subsidiary: 한미정밀화학실로도신 감마형 결정의 제조방법
Rejected · 2014-05 · Application 1020140054634
몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법
Registered · 2014-05 · Application 1020140054401
레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
Registered · 2014-05 · Application 1020140053473
COMPOSITE FORMULATION COMPRISING A FILM COATING LAYER CONTAINING ROSUVASTATIN OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
US · Published · 2014-04 · Application 14778678
실로도신을 포함하는 과립물, 및 이를 포함하는 약학적 조성물 및 제형
Registered · 2014-04 · Application 1020140040182
두타스테라이드를 포함하는 경구용 연질 캡슐 제형
Registered · 2014-03 · Application 1020140038291
레보세티리진 및 몬테루카스트를 포함하는 안정성이 개선된 복합 과립 제형
Registered · 2014-03 · Application 1020140037540
황 작용기를 포함하는 4,5-다이하이드로-1H-피라졸-3-카복스이미드아마이드 유도체, 이의 제조방법 및 이를 포함하는 약학 조성물
Withdrawn · 2014-03 · Application 1020140038258
로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형
Registered · 2014-03 · Application 1020140031675
IMPROVED PREPARATION METHOD FOR HIGH-YIELD PRODUCTION OF PHYSIOLOGICALLY ACTIVE POLYPEPTIDE CONJUGATE
EP · Registered · 2014-03 · Application 14760968.9
生理活性ポリペプチド結合体の高収率生産のための改善された製造方法
JP · Registered · 2014-03 · Application 27561270
생리활성 폴리펩타이드 결합체의 고수율 생산을 위한 개선된 제조 방법
Registered · 2014-03 · Application 1020140026256
INSULIN ANALOG CONJUGATES AND USE THEREOF
EP · Registered · 2014-02 · Application 19197388.2
INSULIN ANALOG AND USE THEREOF
EP · Registered · 2014-02 · Application 14757629.2
新規なインスリンアナログ及びその用途
JP · Registered · 2014-02 · Application 27559199
インスリン位置特異的結合体
JP · Registered · 2014-02 · Application 27559200
인슐린 위치 특이적 결합체
Registered · 2014-02 · Application 1020140022948
신규한 인슐린 아날로그 및 이의 용도
Rejected · 2014-02 · Application 1020140022909
RECOMBINANT YEAST TRANSFORMANT AND PROCESS FOR PREPARING IMMUNOGLOBULIN FC FRAGMENT EMPLOYING THE SAME
EP · Registered · 2014-02 · Application 14746164.4
A METHOD OF VIRUS INACTIVATION IN COMPOSITION COMPRISING FACTOR VII
EP · Registered · 2014-02 · Application 14746007.5
혈액응고인자 Ⅶ를 포함하는 조성물에서 바이러스의 불활성화 방법
Rejected · 2014-02 · Application 1020140012122
1−(4−(4−(3,4−ジクロロ−2−フルオロフェニルアミノ)−7−メトキシキナゾリン−6−イルオキシ)ピペリジン−1−イル)プロパ−2−エン−1−オンの製造方法
JP · Registered · 2014-01 · Application 27555109
Subsidiary: 한미정밀화학신규한 다비가트란 이텍실레이트 뮤케이트 및 이의 제조방법
Rejected · 2014-01 · Application 1020140002597
N−末端の電荷が改変されたインスリン分泌ペプチド誘導体
JP · Published · 2014-01 · Application 27551600
N-말단 전하가 변형된 인슐린 분비 펩티드 유도체
Rejected · 2014-01 · Application 1020140000031
암 치료 효과를 갖는 신규한 퀴나졸린 화합물
Withdrawn · 2013-12 · Application 1020130167067
암 치료 효과를 갖는 신규한 이속사졸 화합물
Withdrawn · 2013-12 · Application 1020130167048
암 치료 효과를 갖는 신규 락탐 유도체
Withdrawn · 2013-12 · Application 1020130166978
몬테루카스트 또는 이의 약제학적으로 허용 가능한 염을 포함하는 액상 제제 및 이의 제조방법
Expired · 2013-12 · Application 1020130159636
1회용 스틱제품의 포장지 및 이를 이용한 1회용 스틱제품의 제조방법
Registered · 2013-12 · Application 1020130155262
메트포르민 및 로자탄을 포함하는 이층정 복합 제제
Registered · 2013-12 · Application 1020130154742
Subsidiary: 한미정밀화학신규한 테노포비어 디소프록실 쿠말레이트 및 이의 제조방법
Withdrawn · 2013-12 · Application 1020130153483
암로디핀, 로자탄 및 로수바스타틴을 포함하는 약제학적 복합 제제
Registered · 2013-11 · Application 1020130147883
Liquid formulation of protein conjugate comprising an oxyntomodulin derivative covalently linked to a non-peptidyl polymer to an immunoglobulin FC region
US · Registered · 2013-11 · Application 14440422
LIQUID FORMULATION OF PROTEIN CONJUGATE COMPRISING THE OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT
EP · Registered · 2013-11 · Application 19180160.4
LIQUID FORMULATION OF PROTEIN CONJUGATE COMPRISING THE OXYNTOMODULIN AND AN IMMUNOGLOBULIN FRAGMENT
EP · Registered · 2013-11 · Application 13853118.1
A COMPOSITION FOR TREATING DIABETES COMPRISING OXYNTOMODULIN ANALOG
EP · Registered · 2013-11 · Application 20151111.0
옥신토모듈린과 면역글로불린 단편을 포함하는 단백질 결합체의 액상 제제
Registered · 2013-11 · Application 1020130134412
단백질 카이네이즈 억제 효과를 갖는 2-사이아노-아크릴아마이드 유도체
Withdrawn · 2013-10 · Application 1020130127851
Subsidiary: 한미정밀화학METHOD FOR PREPARING LOXOPROFEN (2S, 1`R, 2`S) TRANS-ALCOHOL
PCT · Published · 2013-10 · Application PCT/KR2013/009451
향상된 생체이용률을 나타내는 아토바스타틴 정제 및 페노피브릭산 펠렛을 포함하는 경질캡슐 복합제제
Withdrawn · 2013-09 · Application 1020130115898
FMS 키나아제 저해 활성을 갖는 피리미딘 화합물
Withdrawn · 2013-09 · Application 1020130116609
멜리사엽 추출물을 포함하는 정제의 제조방법
Withdrawn · 2013-09 · Application 1020130115571
몬테루카스트 또는 그의 약제학적으로 허용 가능한 염을 포함하는 광 안정성이 개선된 시럽 제제 및 그의 제조 방법
Rejected · 2013-09 · Application 1020130115650
몬테루카스트 또는 그의 약제학적으로 허용 가능한 염, 및 산성 안정화제를 포함하는 안정성이 개선된 시럽 제제 및 그의 제조 방법
Expired · 2013-09 · Application 1020130115624
숙취해소용 식품 조성물
Registered · 2013-09 · Application 1020130107591
PHARMACEUTICAL COMPOSITE CAPSULE FORMULATION COMPRISING IRBESARTAN AND HMG-COA REDUCTASE INHIBITOR
US · Published · 2013-08 · Application 14420953
인간 혈액응고 7인자 유도체의 대량 생산 방법
Rejected · 2013-08 · Application 1020130104308
지속형 인슐린 결합체의 액상 제제
Registered · 2013-07 · Application 1020130087909
Liquid formulation of long acting insulinotropic peptide conjugate
US · Registered · 2013-07 · Application 14416223
COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE
EP · Registered · 2013-07 · Application 18169490.2
A LIQUID FORMULATION OF LONG-ACTING INSULIN AND INSULINOTROPIC PEPTIDE
EP · Registered · 2013-07 · Application 13822545.3
A LIQUID FORMULATION OF LONG-ACTING INSULIN CONJUGATE
EP · Registered · 2013-07 · Application 13822348.2
A LIQUID FORMULATION OF LONG ACTING INSULINOTROPIC PEPTIDE CONJUGATE
EP · Registered · 2013-07 · Application 13823275.6
COMPOSITION FOR TREATING HYPERLIPIDEMIA COMPRISING OXYNTOMODULIN DERIVATIVE
EP · Registered · 2013-07 · Application 20188520.9
지속형 인슐린분비 펩타이드 결합체 액상 제제
Registered · 2013-07 · Application 1020130087896
지속형 인슐린 및 인슐린분비 펩타이드의 복합체 액상 제제
Registered · 2013-07 · Application 1020130087917
Subsidiary: 한미정밀화학신규한 테노포비어 디소프록실 오로테이트 및 이의 제조방법
Withdrawn · 2013-07 · Application 1020130079050
발라시클로버를 포함하는 소아용 과립 제형
Withdrawn · 2013-06 · Application 1020130075251
몬테루카스트 및 그의 약제학적으로 허용 가능한 염을 포함하는 안정성이 개선된 시럽 제제 및 그의 제조 방법
Expired · 2013-06 · Application 1020130075977
빠른 용출률을 나타내는 아토목세틴을 포함하는 경구용 약학 제제 및 이의 제조방법
Expired · 2013-06 · Application 1020130075806
용해도가 개선된 무정형의 드로네다론 염산염의 제조 방법
Withdrawn · 2013-06 · Application 1020130074708
FMS 키나아제 저해 활성을 갖는 피리미딘 유도체
Withdrawn · 2013-06 · Application 1020130074446
암브록솔 및 레보드로프로피진을 포함하는 안정성이 개선된 경구용 액상 제제
Expired · 2013-06 · Application 1020130068043
변이된 힌지 영역을 포함하는 IgG4 Fc 단편
Registered · 2013-05 · Application 1020130063029
비시클릭 헤테로아릴 유도체 및 이를 포함하는 약학 조성물
Withdrawn · 2013-04 · Application 1020130040860
신규한 하이드록사메이트 유도체
Withdrawn · 2013-03 · Application 1020130034751
FMS 키나아제 저해 활성을 갖는 티에노피리미딘 유도체
Withdrawn · 2013-03 · Application 1020130034509
FMS 키나아제 저해 활성을 갖는 피리미딘 접합고리 유도체
Withdrawn · 2013-03 · Application 1020130034467
티에노피리미딘 화합물의 제조방법
Withdrawn · 2013-03 · Application 1020130034436
Subsidiary: 한미정밀화학입체선택적인 록소프로펜 (2S, 1'R, 2'S) 트랜스-알코올의 제조방법
Expired · 2013-02 · Application 1020130021353
둘록세틴 염산염 및 히프로멜로스 프탈레이트를 포함하는 장용성 펠렛 제제 및 이의 제조방법
Withdrawn · 2013-02 · Application 1020130021478
포스포다이에스터라제-5 억제제 또는 이의 약학적으로 허용가능한 염을 포함하는 질내 투여용 약학적 조성물
Withdrawn · 2013-02 · Application 1020130016473
재조합 효모 형질전환체 및 이를 이용하여 면역글로불린 단편을 생산하는 방법
Registered · 2013-01 · Application 1020130011471
1-(4-(4-(3,4-디클로로-2-플루오로페닐아미노)-7-메톡시퀴나졸린-6-일옥시)피페리딘-1-일)프로프-2-엔-1-온의 제조방법
Withdrawn · 2013-01 · Application 1020130009282
TRIAZOLOPYRIDINE DERIVATIVES AS A TYROSINE KINASE INHIBITOR
US · Published · 2013-01 · Application 14376562
두타스테라이드 함유 자가 유화 약물전달 시스템용 조성물 및 이의 제조 방법
Registered · 2013-01 · Application 1020130002490
개봉 흔적이 표시되는 마개와 용기의 결합 구조
Expired · 2013-01 · Application 2020130000180
FMS 키나아제 저해 활성을 갖는 피리다진 접합고리 유도체
Withdrawn · 2012-12 · Application 1020120155972
단백질 키나아제 저해활성을 갖는 티에노[3,2-d]피리미딘 유도체
Registered · 2012-12 · Application 1020120154061
포스포다이에스터라제-5 억제제를 포함하는 츄정
Registered · 2012-12 · Application 1020120146705
에스오메프라졸 유리염기 또는 그의 알칼리염을 포함하는 고미가 차폐된 약학 제제 및 이의 제조방법
Registered · 2012-12 · Application 1020120145650
테트라졸 유도체를 활성 성분으로 포함하는 용해도가 개선된 고체 분산체
Registered · 2012-12 · Application 1020120145603
코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
Withdrawn · 2012-12 · Application 1020120144524
오메가-3 지방산 및 HMG-CoA 환원효소 억제제를 포함하는 안정성이 증가된 경구용 복합 제제
Registered · 2012-11 · Application 1020120128926
옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
Registered · 2012-11 · Application 1020120124724
Subsidiary: 한미정밀화학록소프로펜 (2S, 1'R, 2'S) 트랜스-알코올의 제조방법
Expired · 2012-10 · Application 1020120119272
건조분말 흡입장치
Registered · 2012-10 · Application 1020120113174
카베딜롤 및 주석산을 포함하는 약학 조성물 및 방출 조절형 약학 제제
Rejected · 2012-09 · Application 1020120104052
아토바스타틴, 이르베살탄 및 탄산마그네슘을 포함하는 이층정 복합제제
Rejected · 2012-08 · Application 1020120096477
이베살탄 및 HMG-CoA 환원효소 억제제를 포함하는 약제학적 캡슐 복합제제
Rejected · 2012-08 · Application 1020120096036
옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
Registered · 2012-07 · Application 1020120081475
메트포르민 및 로수바스타틴을 포함하는 경구용 복합 제제
Withdrawn · 2012-07 · Application 1020120080347
항바이러스성 뉴라미니다제 저해제 및 투과 증진제를 포함하는 경구 생체이용률이 향상된 약학 조성물
Withdrawn · 2012-07 · Application 1020157004160
단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
Withdrawn · 2012-07 · Application 1020120078904
이중 저해 활성을 갖는 헤테로고리 유도체
Withdrawn · 2012-07 · Application 1020120078862
멜리사엽 추출물을 포함하는 혈관신생 또는 MMP 활성 매개 질환의 예방 또는 치료용 정제
Withdrawn · 2012-07 · Application 1020120078349
고무전보울
Expired · 2012-07 · Application 1020120076404
살메테롤 지나포산염, 플루티카손 프로피오네이트 및 티오트로피움 브로마이드를 포함하는 흡입 제형용 건조 분말 및 이의 제조방법
Rejected · 2012-06 · Application 1020120063665
메트포르민 서방성 장용제제 및 이의 제조방법
Rejected · 2012-06 · Application 1020120060340
Subsidiary: 한미정밀화학MANUFACTURING METHOD OF HETEROCYCLIC COMPOUND
PCT · Published · 2012-05 · Application PCT/KR2012/003902
Subsidiary: 한미정밀화학MANUFACTURING METHOD OF AZILSARTAN
PCT · Published · 2012-05 · Application PCT/KR2012/003905
구형에 가까운 형태의 다중 투여 단위 정제를 포함하는 경질 캡슐 복합 제형 및 이의 제조방법
Registered · 2012-04 · Application 1020120038594
비스테로이드성 항염증약물 및 프로톤 펌프 저해제를 포함하는 약제학적 복합제제 및 이의 제조방법
Registered · 2012-04 · Application 1020120038030
암브록솔, 레보드로프로피진 및 완충제를 포함하는 경구용 액상 제제 및 이의 제조방법
Registered · 2012-04 · Application 1020120037409
암세포 성장 억제 효과를 갖는 신규 설포네이트 유도체
Withdrawn · 2012-03 · Application 1020120029304
타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
Withdrawn · 2012-02 · Application 1020120012758
안정성이 향상된 에페리손 또는 이의 약학적으로 허용 가능한 염 및 특정 산성화제를 포함하는 약학 조성물
Expired · 2012-01 · Application 1020120004432
레보세티리진 또는 이의 약학적으로 허용가능한 염 및 몬테루카스트 또는 이의 약학적으로 허용가능한 염을 함유하는 안정한 경구투여용 약학 제제
Registered · 2012-01 · Application 1020120001954
로자탄, 암로디핀 및 히드로클로로티아자이드를 포함하는 고정 용량 조합 제형
Registered · 2011-12 · Application 1020110146867
에페리손 또는 이의 약학적으로 허용 가능한 염을 함유하는 안정한 약학 조성물의 제조방법
Rejected · 2011-12 · Application 1020110146897
일정한 입도를 갖는 4,5―디아릴―3(2H)―퓨라논 유도체를 포함하는 약학 조성물
Withdrawn · 2011-12 · Application 1020110146934
G 단백질-커플링된 수용체의 조절을 위한 신규한 비사이클릭 화합물
Withdrawn · 2011-12 · Application 1020110146537
타이로신 카이네이즈 억제 활성을 갖는 신규 이미다조피리딘 유도체
Withdrawn · 2011-12 · Application 1020110144450
신규 페닐 옥사디아졸 유도체 및 이를 포함하는 약학 조성물
Withdrawn · 2011-12 · Application 1020110142617
고농축 락토바실러스균을 함유하는 장용성 캡슐 제제 및 그의 제조방법
Registered · 2011-12 · Application 1020110137268
용기병 설명서 부착기
Registered · 2011-11 · Application 1020110117617
몬테루카스트 또는 이의 약학적으로 허용가능한 염 및 레보세티리진 또는 이의 약학적으로 허용가능한 염을 함유하는 캡슐 제제
Rejected · 2011-10 · Application 1020110111132
정제를 포함하는 경질 캡슐 복합 제형
Registered · 2011-10 · Application 1020110104374
코르티코스테로이드, 항히스타민제 및 β-사이클로덱스트린을 포함하는, 안정성이 개선된 약학 조성물
Expired · 2011-09 · Application 1020110094198
실데나필 유리 염기를 포함하는 구강 붕해정
Registered · 2011-08 · Application 1020110084426
신규 피리미딘 유도체 및 이를 활성성분으로 포함하는 약학 조성물
Withdrawn · 2011-07 · Application 1020110074706
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
Registered · 2011-06 · Application 1020110064907
오메가-3 지방산 또는 이의 에스테르 및 하이드록시메틸글루타닐 코엔자임에이 환원효소 억제제를 포함하는 경구용 복합 제제
Rejected · 2011-06 · Application 1020110064906
일회용 안과 조성물
Rejected · 2011-06 · Application 1020110055556
암세포의 성장을 억제하는 아마이드 유도체 및 비금속염 활택제를 포함하는 약학 조성물
Expired · 2011-06 · Application 1020110054685
Subsidiary: 한미정밀화학헤테로고리 화합물의 제조방법
Expired · 2011-05 · Application 1020110047489
Subsidiary: 한미정밀화학아질사르탄의 개선된 제조방법
Expired · 2011-05 · Application 1020110047490
오메가-3 지방산 에스테르 및 HMG-CoA 환원효소 억제제를 포함하는 경구용 복합 조성물
Registered · 2011-04 · Application 1020110041168
루테인의 용출률 및 체내 생체이용률이 개선된 약학 조성물 및 이의 제조방법
Rejected · 2011-03 · Application 1020110025770
정제 식별용 라벨.
Expired · 2011-03 · Application 2020110001787
정제 타정기
Expired · 2011-02 · Application 1020110015552
플랩을 구비한 봉함 케이스.
Rejected · 2010-12 · Application 2020100013099
흡습제 용기 부착 병마개
Expired · 2010-12 · Application 2020100012866
이중라벨러와 이중라벨 부착방법
Rejected · 2010-12 · Application 1020100124909
피타바스타틴류 및 500 ㎚ 초과 600 ㎚ 이하에서 극대 흡수 파장을 갖는 착색제를 포함하는 광안정성이 우수한 의약 제제
Expired · 2010-10 · Application 1020100097892
올란자핀을 포함하는 경구용 약제학적 조성물
Rejected · 2010-08 · Application 1020100082467
형질전환 조류를 이용한 단백질의 생산방법
Rejected · 2010-08 · Application 1020100076439
정제공급기
Rejected · 2010-07 · Application 1020100069349
Subsidiary: 한미정밀화학비화재보 방지 커버 및 화재 감지기
Expired · 2010-05 · Application 1020100045953
테르비나핀 염산염의 안정성을 향상시키는 방법
Rejected · 2010-04 · Application 1020100030513
신규 결정형의 자나미비어 수화물 및 이의 제조방법
Rejected · 2010-03 · Application 1020100022905
자나미비어의 제조방법
Expired · 2010-02 · Application 1020100014789
단백질 키나아제 저해활성을 갖는 비시클릭 헤테로아릴 유도체
Registered · 2010-01 · Application 1020100008720
에제티밉의 제조방법 및 이에 사용되는 중간체
Registered · 2009-12 · Application 1020090125646
β-펜에틸아민계 화합물 및 피브레이트계 화합물을 포함하는, 비만 또는 비만 관련 질환의 예방 또는 치료용 약제학적 조성물
Withdrawn · 2009-08 · Application 1020090077247
전립선암 치료 효과를 갖는 비칼루타미드의 인산 에스테르
Rejected · 2009-06 · Application 1020090058891
비결정형의 (+)-란소프라졸 제조방법 및 이에 사용되는 (+)-란소프라졸 알코올레이트
Rejected · 2009-03 · Application 1020090019877
L-아스코르빈산-2-인산 삼나트륨염을 포함하는 탈모 치료 및 발모 촉진용 외용제 조성물
Withdrawn · 2009-01 · Application 1020090005843
에제티밉 중간체의 제조방법
Expired · 2008-12 · Application 1020080127900
(R)-(+)-란소프라졸의 제조방법 및 이에 사용되는 중간체
Expired · 2008-12 · Application 1020080126478
HMG-CoA 환원효소 억제제와 아스피린을 함유하는복합제제
Rejected · 2007-09 · Application 1020070095771
다중저해제로서의 퀴나졸린 유도체
Expired · 2007-04 · Application 1020070041100
PHARMACEUTICAL COMPOSITION CONTAINING CLOPIDOGREL CAMPHORSULFONATE OR POLYMORPHIC FORMS THEREOF
PCT · Published · 2007-03 · Application PCT/KR2007/001278
바데나필의 경구용 속효제형
Rejected · 2006-04 · Application 1020060033715
Complex Formulation Of 3-Hydroxy-3-Methyl Glutaryl Coa Reductace Inhibitor And Antihypertensive Agent, And Process For Preparing Same
US · Published · 2005-12 · Application 11722393
COMPLEX FORMULATION OF 3-HYDROXY-3-METHYL GLUTARYL COA REDUCTASE INHIBITOR AND ANTIHYPERTENSIVE AGENT, AND PROCESS FOR PREPARING SAME
PCT · Published · 2005-12 · Application PCT/KR2005/004607
휴대용 의약품 저장장치
Abandoned · 2005-10 · Application 1020050098496
온도표시 기능을 갖는 점안액 용기
Rejected · 2005-10 · Application 1020050096817
약물 적하 노즐
Expired · 2005-09 · Application 1020050091325
COMPOSITION FOR ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE AND CONTROLLED RELEASE GRANULE FORMULATION COMPRISING SAME
EP · Registered · 2005-02 · Application 05721856.2
COMPOSITION FOR ORAL ADMINISTRATION OF TAMSULOSIN HYDROCHLORIDE AND CONTROLLED RELEASE GRANULE FORMULATION COMPRISING SAME
PCT · Published · 2005-02 · Application PCT/KR2005/000422
CEFUROXIME AXETIL GRANULE AND PROCESS FOR THE PREPARATION THEREOF
PCT · Published · 2005-01 · Application PCT/KR2005/000066
CRYSTALLINE CLOPIDOGREL NAPHTHALENESULFONATE OR HYDRATE THEREOF, METHOD FOR PREPARING SAME AND PHARMACEUTICAL COMPOSITION CONTAINING SAME
PCT · Published · 2004-10 · Application PCT/KR2004/002665
EXPRESSION VECTOR FOR SECRETING ANTIBODY FRAGMENT USING E. COLI SIGNAL SEQUENCE AND METHOD FOR MASS-PRODUCING ANTIBODY FRAGMENT
EP · Registered · 2004-10 · Application 04793487.2
HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR CONJUGATE HAVING ENHANCED STABILITY IN BLOOD AND PROCESS FOR THE PREPARATION THEREOF
PCT · Published · 2004-03 · Application PCT/KR2004/000569
STABLE AMORPHOUS AMLODIPINE CAMSYLATE, PROCESS FOR PREPARING SAME AND COMPOSITION FOR ORAL ADMINISTRATION THEREOF
PCT · Published · 2004-01 · Application PCT/KR2004/000136
MICROEMULSION COMPOSITION FOR ORAL ADMINISTRATION OF BIPHENYLDIMETHYLDICARBOXYLATE
PCT · Published · 2003-11 · Application PCT/KR2003/002610
Method for the preparatin of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby
US · Published · 2003-11 · Application 10534353
METHOD FOR THE PREPARATION OF PACLITAXEL SOLID DISPERSION BY USING THE SUPERCRITICAL FLUID PROCESS AND PACLITAXEL SOLID DISPERSION PREPARED THEREBY
PCT · Published · 2003-11 · Application PCT/KR2003/002441
MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR PREPARING SAME
EP · Registered · 2003-11 · Application 03810716.5
MICROEMULSION CONCENTRATE FOR ORAL ADMINISTRATION OF WATER-INSOLUBLE ANTI-COLD DRUG AND METHOD FOR PREPARING SAME
PCT · Published · 2003-11 · Application PCT/KR2003/002388
SUSTAINED RELEASE COMPOSITION FOR ORAL ADMINISTRATION OF DRUGS
PCT · Published · 2003-10 · Application PCT/KR2003/002241
Sustained release composition for oral administration of drugs
EP · Registered · 2003-07 · Application 03014596.5
NOVEL AMLODIPINE CAMSYLATE AND METHOD FOR PREPARING THEREOF
PCT · Published · 2002-03 · Application PCT/KR2002/000543
Subsidiary: 한미정밀화학다중 인터넷 접속 서비스를 제공하는 장치
Expired · 2001-08 · Application 1020010048918
EXPRESSION AND SECRETION VECTOR FOR HUMAN INTERFERON ALPHA AND PROCESS FOR PRODUCING HUMAN INTERFERON ALPHA BY EMPLOYING SAME
EP · Registered · 2001-01 · Application 01949005.1
MODIFIED HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR AND PROCESS FOR PRODUCING SAME
EP · Registered · 2000-07 · Application 00942494.6
MODIFIED HUMAN GRANULOCYTE-COLONY STIMULATING FACTOR AND PROCESS FOR PRODUCING SAME
PCT · Published · 2000-07 · Application PCT/KR2000/000733
Subsidiary: 한미정밀화학신규한 티아졸 화합물을 이용한 세팔로스포린계항생물질의 제조 방법
Expired · 2000-03 · Application 1020000014076
Subsidiary: 한미정밀화학신규한 티아졸 화합물 및 그의 제조 방법
Expired · 2000-03 · Application 1020000011127
MODIFIED E. COLI ENTEROTOXIN II SIGNAL PEPTIDE AND A MICROORGANISM EXPRESSING A FUSION PROTEIN OF SAID PEPTIDE AND A HETEROLOGOUS PROTEIN
PCT · Published · 1999-09 · Application PCT/KR1999/000547

AI reads

MAA server logs · IP-verified

115

Times AI engines pulled Hanmi Pharm. Co., Ltd.'s records

Pulled records become part of each AI's index and keep feeding its answers. When an AI cites from that index, nothing reaches our server — so actual citations are uncounted here and exceed this number.

Fetched fresh mid-answer

Times an AI needed something not yet in its index and fetched this page fresh while answering. Citations served from the index leave no trace here.

112

Index crawls

Collected as raw material for future answers.

Direct AI-tool queries (MCP)

Queries from users who connected this index to their own AI.

live 0

Last 7 days

live 1

Last 30 days

115

live 3

All time

OpenAIChatGPT-Userlive3
OpenAIOAI-SearchBot100
GoogleGoogleOther5
PerplexityPerplexityBot4
AnthropicClaudeBot2
MicrosoftBingbot1

Measured since Aug 26, 2026 · 5 AI engines · last read Oct 8, 2026

User-agent strings can be forged, so we do not count them at face value. We count only requests matched against vendor-published IP ranges, or confirmed by forward-verified reverse DNS. MCP queries are actual calls to this index's tool endpoint.

Connect this index to your AI tool →

Connect this company index directly to your AI

Connect it to ChatGPT or Claude, and your AI queries the full record — profiles, financials, stock data, regulatory approvals, clinical trials, publications and patents — for Hanmi Pharm. Co., Ltd. and every listed Korean medical, bio and AI company.

How to connect (MCP)

Not yet compiled: business overview · R&D. Send us materials and we will add them

Company facts

Founded: 2010
Listed: 2010
Market: KOSPI 128940
CEO: 황상연
Location: Gyeonggi
Category: Pharma & CDMO

Performance

Consolidated · DART

Year	Revenue	Op. profit
2025	₩1547.5B	₩257.8B
2024	₩1495.5B	₩216.2B
2023	₩1490.9B	₩220.7B

Keywords

combination-drugantihypertensiveapi-manufacturingchina-subsidiarykospipharmaceuticalcgmp

Companies approved for the same productsPharma & CDMO

Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.

DAE HWA PHARM CO., LTD2 shared

KOSDAQ-listed pharmaceutical company behind the world's first oral paclitaxel Liporaxel (DHP107) and the Amalian dermal filler.

IL DONG PHARMACEUTICAL CO., LTD.2 shared

Founded and listed on the KOSPI in 2016, Il Dong Pharmaceutical manufactures products including the Aronamin vitamin line.

NUON CO., LTD.1 shared

KOSDAQ-listed healthcare company selling the Cissus weight-management ingredient and Sallimbaekseo household products.

Hanmi Science Co.,Ltd1 shared

KOSPI-listed operating holding company of the Hanmi Pharm group, also running healthcare and pharmaceutical wholesale businesses.

JW SHINYAK CORPORATION1 shared

A pharmaceutical company supplying antifungal and urology drugs to clinics, co-marketing original drugs together with JW Pharmaceutical.

KYUNG NAM PHARM.CO.,LTD.1 shared

Founded in 1998, Kyungnam Pharm is a pharmaceutical and health-food company known for the vitamin brand Lemona and placenta drink Jahasaengryeok.

Samyang Biopharm Corporation1 shared

Founded and KOSPI-listed in 2025, Samyang Biopharm develops medical devices, pharmaceuticals, and new drug candidates.

Sugentech, Inc.1 shared

Founded in 2011 and KOSDAQ-listed in 2019, Sugentech develops multiplex immunoblot, point-of-care, and digital healthcare diagnostics.

ChoA Pharmaceutical Co., LTD.1 shared

Founded in 1996 and listed on KOSDAQ in 1999, ChoA Pharmaceutical is an OTC-focused drugmaker exporting to 23 countries worldwide.

Wonbiogen Co.,Ltd.1 shared

Wonbiogen Co.,Ltd., established September 2018, listed on KOSDAQ in December 2018, manufactures wound dressings and moist wound dressings.

BNC KOREA, Inc.1 shared

Founded and listed on the KOSDAQ in 2016, BNC Korea is a biohealthcare company specializing in HA fillers, botulinum toxin, and dermo-cosmetics.

DongKookPharmaceuticalCo.,Ltd.1 shared

KOSDAQ-listed comprehensive healthcare and pharmaceutical company behind the gum treatment Insadol and the wound-care ointment Madecassol.

Sources and updates

Counts on this page are not company-reported figures. MAA matched records from DART, the Korean MFDS, the US FDA, ClinicalTrials.gov, PubMed and KIPRIS to this company itself, by business registration number or registered name, never by name similarity. They may differ from figures the company publishes.

Company basics: Korea Exchange · DART
Business content: Compiled from disclosure filings
Approvals & clinical trials: Korean MFDS (data.go.kr) · US FDA openFDA — updated weekly
Key disclosures: KRX KIND via OpenDART exchange filings — updated daily
Global clinical trials: ClinicalTrials.gov (US NIH) — sponsor-matched, updated weekly
Financials: DART corporate disclosure filings — annual
Publications: PubMed (US National Library of Medicine) — affiliation-matched, updated daily
Patents: KIPRIS (Korea Institute of Patent Information) — applicant-matched, updated monthly
AI reads: Our server logs, IP-verified every 6 hours
AI visibility: Measured 2026-10-01

This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.

Request a correction or addition